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ABSTRACT 
USE OF PHOTOBIOMODULATION IN OSTEOCLAST FORMATION:  POSSIBLE 
INTERVENTION FOR THE TREATMENT OF OSTEOPOROSIS 
 
by 
 Lisa Anderson-Antle  
The University of Wisconsin-Milwaukee, 2014 
Under the Supervision of Dr. Karen H. Morin 
 
After critically examining the literature to gain a robust understanding for the 
pathogenesis of bone loss, specifically osteoporosis, the development of a possible new 
intervention to prevent or treat osteoporosis was explored.  The purpose of this 
dissertation was to pilot test a new protocol designed to answer the broad research 
question:  Does Near-Infrared Light Emitting Diode (NIR-LED) treatment affect 
Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL) induced 
osteoclastogenesis in a cell culture model?   
Osteoporosis is defined as a disease characterized by low bone mass and 
structural deterioration of bone tissue, leading to bone fragility and an increased 
susceptibility to fractures, especially of the hip, spine, and wrist. Specifically, 
osteoporosis has been shown to increase the risk for fracture resulting from a fall. The 
World Health Organization reported in 2003 that osteoporosis-induced fractures burden 
society due to the great health care costs for treatment and rehabilitation.  Experts have 
estimated that, between 2005-2025, the incidence and economic burden to treat 
osteoporotic related fractures will increase 50% annually (Burge et al., 2007).  The 
development of additional interventions meant to slow the progression of osteoporosis 
may contribute to decreasing this burden.  Near-Infrared Light Emitting Diode (NIR-
LED) photobiomodulation has been found to be effective in improving wound healing, 
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bone regeneration, mitochondrial function, and attenuating cellular oxidative stress. Little 
is known regarding the use of NIR-LED and the formation of osteoclasts, which break 
down bone.  
This pilot study included two experiments using the WARP™ 75 light source. 
RAW264.7 cells were cultured for 24 hours and induced to differentiate into osteoclasts, 
using the cytokine Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL). 
Cultures were divided into groups according to RANKL dose (0, 2.5, 10, 25, 50 ng/ml) 
and different energy densities (2.25, 4.5, 45 J/cm²), treated with light either once or on 
four consecutive days using the WARP™ 75 (Quantum Devices, Barneveld, WI). 
Osteoclast-like cells were stained for Tartrate-Resistant Acid Phosphatase (TRAP). 
Multinucleated, TRAP+ cells were scored as osteoclasts, counted manually by 
microcopy. Results were expressed as means and standard deviations, and groups were 
compared by one-way ANOVA with posthoc Tukey. RANKL-induced osteoclast 
formation by RAW264.7 cells occurred as expected in all experiments. Light-treatment 
alone had no observable effect. A single light-treatment at 4.5 J/cm
2
 with RANKL added 
(10 - 50ng/ml) suggested a biostimulatory effect upon osteoclastogenesis compared to 
controls, as multiple light-treatments compared to single light-treatment were less 
stimulatory in the energy density 4.5 J/cm
2 and RANKL dose 25ng/ml group. In 
conclusion, effects of NIR-LED treatment on osteoclastogenesis are RANKL dose and 
light-intensity specific. NIR-LED light-treatment affects RANKL-induced osteoclast 
formation suggestive of a biostimulatory effect, and multiple light treatments compared 
to single light treatment may biostimulate osteoclastogenesis less.  
These experiments provide the foundation to further investigate possible NIR-
  
iv 
 
LED effects upon bone formation and include alternative bone formation quantification 
utilizing alternative cellular assays.  Contributing to this body of knowledge provides 
insight for nurses’ application of new therapies to prevent and treat bone loss.  
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CHAPTER ONE 
Introduction 
This chapter sets the context for the study.  The following will be presented in this 
chapter:  the significance, statement of the problem, followed by the study method and 
purpose, research questions and concluding with the implications for nursing practice, 
research and policy.  Within the statement of the problem, briefly, the definition, 
diagnosis, and incidence of osteoporosis are reviewed, and the consequences of the 
pathology significantly related to the older adult population are explored.  Further, an 
overview of osteoclast differentiation and the cellular-level effects of Near Infrared Light 
Emitting Diode (NIR-LED) treatment (i.e., oxidative stress and mitochondrial function) 
on osteoclast cells (bone-resorbing cells) are presented to familiarize the reader with this 
study’s intervention.   
The purpose of this dissertation was to pilot test a new protocol designed to 
answer the broad research question:  Does Near-Infrared Light Emitting Diode (NIR-
LED) treatment affect Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL) 
induced osteoclastogenesis in a cell culture model?  Osteoporosis is defined as “a disease 
characterized by low bone mass and structural deterioration of bone tissue, leading to 
bone fragility and an increased susceptibility to fractures, especially of the hip, spine, and 
wrist” (World Health Organization scientific Group, [WHOSG], 2003, p. 4) and is the 
most common bone disorder (National Institutes of Health Consensus Development Panel 
on Osteoporosis [NIH-CDPO] 2001) Specifically, osteoporosis has been shown to 
increase the risk for fracture resulting from a fall, especially of the hip (Rizzoli, 2010; 
Schwartz, Nevitt, Brown, & Kelsey, 2005).  The incidence of non-vertebral osteoporotic 
2 
 
 
 
fractures has been associated with increased chronological age, increased number of fall 
risk factors, and reduced bone density and strength (Crepaldi & Maggi, 2005; Cummings 
et al., 1995).  The World Health Organization (WHO) reported in 2003 that osteoporosis-
induced fractures burden society due to the great health care costs for treatment and 
rehabilitation.   Reported in 2005, the yearly fracture rate for those individuals in the 
United States 50 years and old was greater than 20 million, with an estimated cost of $17 
billion which 72% of the expenditures were spent to treat hip fracture (Burge et al., 
2007),  In 2008, estimates of cost to treat osteoporosis and fractures were reported as $22 
billion (Blume & Curtis, 2011).  These experts have estimated that, between 2005-2025, 
the incidence and economic burden to treat osteoporotic related fractures will increase 
50% annually.  Due to the current societal demographic growth and rising healthcare 
costs, it will become imperative to identify individuals at risk for falls and screen for 
bone loss.  The development of additional interventions meant to slow the progression of 
osteoporosis may contribute to decreasing the burden of osteoporosis-induced fractures in 
the aging population. 
One unique multidisciplinary approach to study skeletal health in the aging 
population involves teaming with researchers investigating skeletal health in a 
microgravity environment.  Microgravity during space flight simulates complications of 
muscle (Trappe et al., 2001), and bone loss (Rodionova & Oganov, 2001) often 
experienced by older adults from prolonged bed rest during hospitalization (Trappe, 
2009) which may result in self-limiting behaviors due to the fear of falling (Fletcher & 
Hirdes, 2004; Van Doorn et al., 2003),  
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A model for simulating conditions of micro-gravity uses a human bedrest model 
(Clement & Slenzka, 2006) Research in musculoskeletal health that develops and 
validates countermeasures taken during long duration space flights involves interventions 
and procedures designed to mitigate health and performance hazards present in a space 
environment (Clement, Bukley, & Paloski, 2007).  Some researchers investigating bone 
loss in microgravity environments believe that there is the potential for translational 
research that could impact the pathology of bone loss in the aging population (Rittweger, 
2007).  Therefore, continued collaborative interdisciplinary research with the National 
Aeronautics and Space Administration (NASA) may assist researchers in using new 
technologies to mitigate bone loss for the older adult population to prevent fracture 
(Rittweger, 2007). 
Statement of the Problem 
 The following section presents the essence and rationale for investigating osteoporosis.  
Briefly, an overview of osteoporosis is provided relative to its incidence within the aging 
population and its contribution to fall induced fractures.  The proposed use of NIR-LED 
as a possible future treatment for the management of osteoporosis, a brief review of bone 
physiology and pathology, diagnosis as it relates to falls, fractures and frailty and finishes 
with an overview of the cellular mechanisms of NIR-LED are discussed.    
Aging Population 
It is projected that by the year 2030, the United States population of older adults 
will double to 71.5 million 8.9 million of these, will be over the age of 85 (U.S. 
Department of Health and Human Services Administration on Aging [USDHHS-AOA], 
2006)  and represent the fastest-growing sector of the U.S. population. Similar 
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projections apply globally with a world population of individuals over 60 years reaching 
approximately two billion by the year 2050 (United Nations, 2010).  In fact, the number 
of Americans 65 and older has tripled between 1900-2005 (Friedland & Summer, 2005).  
According to the Alliance for Aging Research (1999), 6,000 Americans turn 65 each day.  
Further, it is projected that over the next 19 years, 10,000 Americans will turn 65 each 
day (Cohn & Taylor, 2010). Over time, this sub-set of the American population overtime 
will become vulnerable for disability, morbidity, and mortality (Ostir, Ottenbacher, & 
Markides, 2004). 
Incidence of Osteoporosis 
In the US, osteoporosis affects approximately 10 million people over the age of 
50 years and, of those, 8 million are women.  In addition, 34 million Americans are at 
risk for developing osteoporosis due to low bone mass (osteopenia) (Harvey, Dennison, 
& Cooper, 2013; A. C.  Looker, Melton, Harris, Borrud, & Shepherd, 2010).  Due to 
ethnic differences in bone and mineral metabolism (Norris, Micklesfield, & Pettifor, 
2013), osteoporosis is present more often in Caucasian than Hispanic and African 
American women.  Few data exist that report ethnic patterns in men; however trends are 
similar to women.  Bone loss is present more often in Caucasian than Hispanic and 
African American women.    
There has been only a modest decline in the rate of osteoporosis over the past 
years, despite the development and use of medications and weight-bearing exercise (A. 
C.  Looker et al., 2010).  Based upon this fact, current interventions and treatments of 
osteoporosis have not been effective enough to impact and decrease the prevalence of 
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osteoporosis.  Therefore, research investigating new interventions and treatments needs to 
be considered. 
Osteoporotic-Fall Induced Fractures.   
Due to the bone loss and strength, experts have associated the presence of 
osteoporosis with fall-induced fractures (Schwartz et al., 2005; WHOSG, 2003). Falls are 
the leading cause of death by unintentional injury for individual 65 (Avdic, Pecar, & 
Mujic-Skikic, 2004; Centers for Disease Control and Prevention National Center for 
Injury Prevention and Control [CDCP-NCIPC], 2003; 2005; 2010a) 
As individuals age they become susceptible to falling.  Falls have been an 
independent indicator for functional decline and are identified as the causal event for 
40% of nursing home admission (Bischoff-Ferrari, 2009; Tinetti & Williams, 1997). 
Further, a little over a half a million (1.4% of community dwelling older adults) 
experience a low-impact fall resulting in fracture annually (Morrison, Fan, Sen, & 
Weisenfluh, 2013).  Hip fractures are the most serious osteoporosis-associated fracture 
resulting in permanent disability (Harvey et al., 2013; WHOSG, 2003; Ziden, Wenestam, 
& Hansson-Scherman, 2008).  In fact, the mortality rate is estimated to be 20%-35% 
within the first year after suffering a hip fracture (Goldacre, Griffith, Gill, & Mackintosh, 
2002; Goldacre, Roberts, & Yeates, 2002).   
Further,  a hip fracture may be considered the “triggering event” contributing to 
functional decline, possibly transitioning the individual into a frail state of health 
(Morley, 2002; Runge & Hunter, 2006; Suh & Lyles, 2003).  Half of the people who are 
ambulatory prior to hip fracture cannot walk independently after the fall (Harvey et al., 
2013) and suffer from fear, anxiety and depression, dramatically impacting their quality 
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of life (Ziden et al., 2008).  However, it is unclear if a fall is an antecedent to frailty, or 
conversely, whether frailty is an antecedent to falls (J.E. Morley, 2002).  Therefore, it is 
important to explore possible interventions to alter the development of osteoporosis with 
the intent to preserve or rebuild the bone architecture to withstand the impact of a fall, 
thus avoiding fracture.   
Proposed use of NIR-LED 
One area to investigate when exploring potential new interventions could be 
cellular-level mechanisms involved with the pathology of osteoporosis.  The intervention 
employed in this study—near infrared light—already has a large body of research 
supporting the idea that near infrared light has advantageous effects at the cellular level 
(Brondon, Stadler, & Lanzafame, 2005; Karu, Piatibrat, & Kalendo, 1987; Karu, 1988; 
1999; 2003; Lubart, Wollman, Friedmann, Rochkind, & Laulicht, 1992; Tim et al., 2014; 
Whelan et al., 2008).  However, the literature offers only a limited amount of research 
studying the effects of near infrared light on bone.   
The initial literature search yielded six NIR-LED in vitro studies (cell culture 
model) (Pinheiro et al., 2002; Pinheiro & Gerbi, 2006; Renno, McDonnell, Parizotto, & 
Laakso, 2007; Stein, Benayahu, Maltz, & Oron, 2005; Yamada, 1991) that investigated 
osteoblast cells (bone-forming cells) and four  in vivo studies (animal model) (Blaya, 
Guimaraes, Pozza, Weber, & de Oliveira, 2008; Pinheiro et al., 2008; Pinheiro et al., 
2009; Torres, dos Santos, Monteiro, Amorim, & Pinheiro, 2008). Predominately, these 
investigations explored bone remodeling which would more specifically measure 
osteoclast and osteoblast interaction.  Because we found one in vitro study that 
investigated osteoclast cells (bone-resorbing cells) (Aihara et al., 2006), the decision was 
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made to investigate the effects of NIR-LED on osteoclastogenesis due to this gap in the 
literature.   
Background 
Presented below is a brief overview to introduce the literature’s main tenets that 
provided foundational evidence for identifying gaps in the literature.  This presentation 
will allow the reader to understand the dissertation’s structure and introduce the main 
content related to the following subjects:  bone physiology, diagnosis of osteoporosis, 
followed the discussion of osteoporosis as it relates to the incidence of frailty, falls, and 
fractures in the older adult population. This section will conclude with a more in-depth 
explanation for the study’s intervention, NIR-LED treatment.   
Bone Physiology 
Bone formation is central to growth and development during childhood and 
adolescence (Bonjour, Theintz, Law, Slosman, & Rizzoli, 1994).  Peak bone mass is 
complete by early adulthood ((WHOSG, 2003).   After the age of 20, bone resorption in 
males becomes a central process that demineralizes bone at about 4% per decade.  
Females maintain bone mineral content until menopause, then experience declines of 
15% per decade (NIH-CDPO, 2001); WHOSG, World Health Organization Scientific 
Group (2003). 
There are four types of bone cells that contribute to the formation and 
maintenance of bone:  osteoprogenitor cells, osteocytes, osteoclasts, and osteoblasts 
(Porth, 2009). Osteoprogenitor cells are undifferentiated cells that are the source of all 
bone cells except osteoclasts which originate from monocyte/macrophages within the 
hemopoietic lineage.  Osteocytes are mature bone cells that maintain the bony matrix.  In 
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addition, they may respond to bone tissue strain and recruit osteoclasts to areas of bone 
requiring bone repair/remodeling (Lanyon, 1993).  There are interconnected passageways 
called canaliculi that are found throughout the calcified matrix and contain extracellular 
fluid (Hadjidakis & Androulakis, 2006).  These passageways provide a communication 
network between the neighboring osteocytes and blood system for the exchange of 
nutrients and metabolites because diffusion does not occur is calcified bone (Porth, 
2009).      
Osteoclasts and osteoblasts are two types of cells within mineralized bone that 
contribute to mineral homeostasis (Lemaire, Tobin, Greller, Cho, & Suva, 2004). They 
are responsible for building and maintaining bone structure.  Osteoclasts are bone-
resorbing cells that originate from monocyte/macrophages within the hemopoietic 
lineage, and their activity is regulated by osteoblasts, bone-forming cells, and numerous 
hormones and other growth factors:  macrophage colony-stimulating factor (M-CSF), 
interleukin-1 (IL-1), and tumor necrosis factor (TNF) (Hock et al., 2001).  Osteoblasts are 
differentiated mesenchymal stem cells, responsible for lying down the new bone matrix 
that becomes mineralized, thus replacing old bone previously reabsorbed by osteoclasts 
(Hadjidakis & Androulakis, 2006; Hock et al., 2001). 
There are two pathways that induce osteoclastogenesis.   On the osteoblast 
stromal cell membrane, Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL) 
receptor, binds to the osteoclast precursor cell (macrophage) RANK receptor. When this 
occurs, RANK signaling activates the transcription factor Kappa-B to differentiate into 
osteoclasts (Kumar, 2010).  The other pathway occurs with the osteoblast secretion of M-
CSF and the osteoclast precursor cell (macrophage) M-CSF receptor.  When joined, 
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tyrosine kinase activity is stimulated, also important to osteoclast formation. This 
signaling occurs in tandem with the RANKL/RANK pathway.  Further bone marrow 
stromal/osteoblast cells secrete osteoprotegerin (OPG), a decoy receptor for RANKL, 
preventing RANKL from binding with the osteoclast precursor cell’s RANK receptor, 
preventing bone absorption and attenuating osteoclast differentiation (Kumar, 2010). 
Diagnosis of Osteoporosis 
Osteoporosis arises from the out-of-balance osteoclast/osteoblast activity in 
remodeling bone (Manolagas & Jilka, 1995).  In healthy remodeling tissue of the adult, 
osteoblasts lay down a new matrix that becomes mineralized, thus replacing old bone 
previously reabsorbed by osteoclasts (Hock et al., 2001).  This occurs in both spongy 
(cancellous) tissue and cortical (dense) bone, which together comprise intact bone; the 
relative contribution of cancellous and cortical tissues to a given bone varies.   
The diagnosis of osteoporosis is made by identification of reduced bone density of 
vertebral and/or femur cortical and cancellous bone.  Using dual energy x-ray 
absorptiometry (DEXA) scanning, a bone mineral density (BMD) that exceeds 2.5 
standard deviations (SD) below the mean BMD found in 30 year old women confirms a 
diagnosis of osteoporosis.  Osteopenia is identified by 1 to 2.5 SD below that same mean. 
From 2005-2006, for older adult women in the U.S., the incidence of osteopenia 
and osteoporosis was 49% and 10%, respectively (A. C.  Looker et al., 2010).  Among 
older adult men, 36% had osteopenia, and 2% had osteoporosis (A. C.  Looker et al., 
2010) estimating that 5.3 million older men and women had osteoporosis at the femur 
neck and an additional 34.5 million had osteopenia.  In data gathered by NHANES in 
2005-2006, femur neck osteoporosis prevalence was lower by three percentage units in 
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men and by seven percentage units among women compared to the 1988-1994 data 
(Looker et al., 2010). Decreased prevalence in the 2005-2006 data may be attributed to 
differences in DEXA technology even though the same manufacture scanner was utilized.  
The 1988-1994 study, a first-generation pencil-beam scanner was used while the 2005-
2006 study a third-generation scanner was employed.  The authors attempted to adjust the 
data to control for the scanner change, but the first generation scanner had few published 
studies with direct comparison to the third generation scanner, and reported mixed results 
of significant differences.  Further, correlations for the decline in femoral osteoporosis 
were not strongly associated with changes in body mass index or the use of osteoporosis 
medication. When combining the incidence of osteoporosis and osteopenia from the 
2005-2006 data compared to the 1988-1994 data, more older adults had low femur neck 
BMD in 2005-2006, possibly due to the increased aged population (Looker et al., 2010). 
Regardless of the decline in prevalence, the estimates of how many older adults 
experience these conditions remain high.   
Falls, Fractures, and Frailty 
Because falls are the leading cause of death by unintentional injury for individuals 
65 and older (Avdic (Avdic et al., 2004), Pecar, & Mujic-Skikic, 2004; Centers for 
Disease Control and Prevention (Centers for Disease Control and Prevention National 
Center For Injury Prevention and Control [CDCP-NCIPC], 2005; 2010a; 2010b; Centers 
for Disease Control National Center for Injury Prevention and Control Office of Statistics 
and Programming, 2003) mortality rate has also increased over the past decade (Stevens, 
2006). Bone loss (osteoporosis) has been associated with falls and fractures (Sinaki et al., 
2002; Suh & Lyles, 2003; WHOSG, 2003) and a little over a half a million low impact 
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falls result in osteoporotic fractures (Morrison et al., 2013).  In 1999, in the European 
Union, the Osteoporosis Foundation reported that every 30 seconds an individual has a 
fracture resulting from osteoporosis (World Health Organization, 1999).  
Vertebrae are particularly rich in cancellous tissue (spongy), and the hip and wrist 
are rich with cortical bone (dense) (Wyngaarden, Smith, & Bennett, 1992).  Vertebral 
compression fractures are the most common osteoporotic bone injury often experienced 
by women 45-60 years of age occurring in the early stages of the bone loss disease 
process.  They occur asymptomatically while performing normal activities of daily living 
such as lifting, and occur three times more often than hip fractures (Harvey et al., 2013).   
As the bone loss disease process progresses, cortical composite weakening occurs 
and the prevalence of wrist and hip fractures become apparent (Wyngaarden et al., 1992).   
A wrist fracture most commonly occurs when a women falls sideways or backwards and 
uses her arm to break the fall, thus breaking their wrist (Melton & Cooper, 2001). A fall 
induced hip fracture is the most serious osteoporosis-associated incidental fracture 
resulting in permanent disability (Harvey et al., 2013; WHOSG, 2003).  Hip fractures 
most commonly occur at the femoral neck resulting from landing directly on the hip 
during a fall (falling sideways) rather than falling forward (NIH-CDPO, 2001). As early 
as 1990, the WHO declared that hip fracture may become a worldwide epidemic by the 
middle of the 21
st
 century, increasing from an incidence of 1.7 million in 1990 to a 
projected 6.3 million by 2050 (C. Cooper, Campion, & Melton, 1992).  Therefore, 
impaired bone strength predisposes older adults to fracture when they fall and may lead 
to the development of frailty (Runge & Hunter, 2006; Suh & Lyles, 2003). This transition 
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may be acute if it stems from a “triggering event,” such as a hip fracture (Hamerman, 
1999). 
Frailty is often described as a decline in the functioning of the neuromuscular 
system, abnormal aging, vulnerability to adverse health outcomes, and loss of 
physiological reserve to handle minor stresses (Abate et al., 2007; Hamerman, 1999; 
Kinney, 2004; Morley, 2002) and is most frequently identified in older adults over 85 
years of age (Suzman, Willis, & Manton, 1992).  The current prevalence of frailty in 
persons aged 65 and older ranges from 4.0% to 17% (Collard, Boter, Schoevers, & Oude 
Voshaar, 2012).    
As the number of older adults increases, fall-risk will increase, as well as the 
incidence of fall induced osteoporotic fractures. There is an extensive body of literature 
concerning the study of bone loss and interventions to prevent bone loss over that past 15 
years; however the incidence of osteoporosis remains relatively unchanged.  Thus, 
investigating innovative technologies that may improve bone cell function and overall 
skeletal health in this population remains critical to preserve an older adult’s quality of 
life is important.   
Near-Infrared Light Emitting Diodes  
Presented are a brief overview of the use of Near-Infrared Light Emitting Diodes 
(NIR-LED) and rational for the proposed method of experimentation in a cell culture 
model.  A short review of associated tenets of aging affecting bone health, oxidative 
stress, mitochondrial dysfunction and increased apoptosis is presented broadly and then 
related to the aging skeleton.  This section will end with the research questions 
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formulated to begin a program of research investigating a potential intervention for the 
treatment and management of osteoporosis.  
The spectrum of electromagnetic radiation (ER) includes light and ranges from 
radio waves to gamma rays.  Light has amplitude (brightness), and wavelength defines 
the color and angle of wave vibration.  According to quantum theory, ER contains 
particles called photons, packets of energy that move at the speed of light (Chung et al., 
2012).  Typically a laser output is a narrow beam of light often named a “pencil beam” 
(Chung et al., 2012).  The peak irradiance is greatest at the center of the beam and 
dissipates outward.  
Light Emitting Diodes (LED) are semiconductors of light and emit low-intensity 
red light in ultraviolet and infrared wavelengths (Chung et al., 2012).  The mechanism 
that occurs within the diode releases energy in the form of photons (electroluminescence 
and color of light).  An LED is less than 1mm
2
 in diameter, thus, LED devices are made 
with numerous LED lights.  The optical window of low level laser light treatment 
(LLLT) is in the red and near-infrared wavelengths (600–1070 nm).  Wavelengths that 
effectively treat superficial tissues range between 600 and 700 nm and deeper tissues 
require longer wavelength ranges between 780–950 nm.  Wavelengths that are longer 
range, that is, between 700–770 nm, have little biological effect (Chung et al., 2012). 
Initial research used a Helium Neon (HeNe) laser at a wavelength of 632.8-nm.  Most 
recently semi-conductor diode lasers such as gallium arsenide lasers (GaAs) are used.  It 
is unknown if there really is a difference between lasers and LEDs. 
In search of innovative technologies for interventions that may improve bone cell 
function and skeletal health, particularly those that would inform the understanding of 
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osteoclast differentiation (bone-resorbing cells), the pilot use of Near Infrared Light-
Emitting Diodes (NIR-LEDs) photobiomodulation was proposed as a possible future 
intervention to treat bone loss and/or preserve bone health.  Although the focus of this 
study was to determine the effects of photobiomodulation upon osteoclastogenesis, it is 
important to understand the cellular effects noted in the NIR-LED literature for future 
research questions that may be appropriate to determine cellular effects in osteoclasts.  
The theory of biological aging related to human aging has been associated with 
cellular oxidative stress (OS) and mitochondrial dysfunction (Melov, 2000), and these 
may induce bone loss (Srinivasan & Avadhani, 2007).  Thirty years ago, somatic genetic 
errors, mutations of the nuclear genome, were postulated as a basis for aging (Hayflick, 
1985b; Shock, 1985) by negatively altering cell metabolism, resulting in free radical 
oxidative stress (ROS) (Hayflick, 1985a). Research about mitochondrial DNA (mtDNA) 
indicates that mutations of the mitochondrial genome are vulnerable to oxidative damage 
(Linnane, Marzuki, Ozawa, & Tanaka, 1989) and may cause degenerative diseases and 
aging.  
Cell mitochondria, which are producers of cell energy, regulators of apoptosis—a 
naturally occurring process of programmed cell death—and cell function, are vulnerable 
to OS and have an essential role in accelerating cell death (Dirks & Leeuwenburgh, 2005; 
Joza et al., 2005). Oxidative stress can result from the generation of excess free radicals  
(Beckman & Ames, 1998) which causes an imbalance with cellular antioxidants that, in 
turn, damages cellular components and function.    Specifically, free radicals are highly 
unstable and reactive with other molecules, and can instigate oxidative cell destruction. 
The oxygen molecule has an atypical placement of electrons within electron orbitals and 
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oxygen prefers to accept one electron at a time during chemical reactions, rather than two 
electrons. Accepting two elections at a time would keep the oxygen molecule in a stable 
state. When electrons are accepted one at a time, the oxygen molecule becomes unstable; 
and superoxide (O2-) and hydrogen peroxide (H2O2) are generated. These reactive oxygen 
species undergo further biochemical cellular reactions, and results the production of 
extremely reactive molecules such as hydroxyl radicals (OH-) (Beckman & Ames, 1998) 
affecting mitochondrial function, and cellular energy production.   
The aging skeleton is associated histologically by bone wall thinning due to a 
decreased bone matrix depositing (Almeida & O'Brien, 2013).  This is thought to be due 
to an insufficient number of functioning osteoblasts available for mineral deposit related 
to decreased bone marrow mesenchymal stem cells  (MSC) (precursor osteoblast and 
adipocyte cells), poor differentiation of osteoblast progenitor cells or more progenitor 
cells utilized for adipocyte formation rather than osteoblastogenesis, as well as apoptosis 
(cell death) (Almeida & O'Brien, 2013; Muruganandan, Roman, & Sinal, 2009).  The loss 
of the ability for MCS cells to regenerate due to aging leads to a diminished 
compensation to stress and increase reactive oxidative species. The use of NIR-LED may 
decrease oxidative stress and improve mitochondrial function by affecting COX-IV, a 
specific segment of the cell’s energy production system, thus enhancing cell function 
(Karu, 2008).   
The use of NIR-LED (630-1000nm) photobiomodulation—an FDA-approved 
treatment—has been found to be effective in improving wound healing (Whelan et al., 
2003), bone regeneration (Pinheiro et al., 2009), mitochondrial function (J. T. Eells et al., 
2004; Wong-Riley, Bai, Buchmann, & Whelan, 2001), attenuating cellular oxidative 
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stress (Desmet et al., 2006; Karu et al., 1987), decreasing inflammation and pain, aiding 
in recovery of ischemic cardiac injury (Oron, 2006; Oron et al., 2001), and attenuating 
retinal/optic nerve degeneration (Eells et al., 2007; Eells et al.,  2004; Eells et al.,  2003; 
Liang et al., 2006).  Reducing oxidative stress delays the activation of the apoptotic 
signaling pathways, thus preventing bone loss and mitochondrial dysfunction (Banfi, 
Iorio, & Corsi, 2008).  Mitochondrial dysfunction has been reported in several slow-
dividing tissue types such as central nervous system, cardiac, skeletal muscle, and liver 
tissues (Nagley et al., 1992; Varanasi, Francis, Berger, Papiha, & Datta, 1999).  
Investigators have suggested that mitochondrial dysfunction and sarcoplasmic reticulum 
stress may stimulate apoptosis and alter the mechanical signaling in bone (Booth & 
Criswell, 1997; Hock et al., 2001). 
Photobiomodulation, also referred to in the literature as low-level laser therapy, 
cold-laser therapy, or laser biostimulation, was introduced in the 1980’s. Laser light-
treatment uses light in the infrared to near-infrared region of the absorption spectrum 
(630-1000nm), as this range is known to affect numerous cell functions that are 
dependent on the energy production in the mitochondria (Desmet et al., 2006; Karu et al., 
1987).  (Karu (1988) ) postulated that the mechanism of the effect of a low-power laser is 
at the cellular level due to changes in components of the electron transport chain system 
within the mitochondria.. The electron transport system of the cell is directly related to 
the production of Adenosine triphosphate (ATP), the primary energy compound for the 
cell. 
The role of the electron transport chain oxidation reaction pathway (redox) 
transfers electrons and signals synthesis of apoptotic proteins activating the caspase-3 
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pathway (Hock et al., 2001; Karu, 1999). This cascade is responsible for signaling 
apoptosis (programmed cell death).  It occurs when the signal leaves the mitochondria, 
fueling cytoplasmic transcription factors, which upregulates cytoprotective and 
antioxidant genes that are thought to prevent free radical damage from oxidative stress. 
This increased transcription preserves cell survival (Eells et al., 2007; Karu, 2003; Squier, 
2001). The mechanism of action may be through release of nitrous oxide or initiating 
superoxide signaling.  Further, transcription factor nuclear factor B (NF-κ-B), regulated 
by changes in cellular redox state, is activated with low level light treatment producing 
protective and stimulatory gene products (Huang, Sharma, Carroll, & Hamblin, 2011).  
Light treatment may improve oxidative metabolism and mitochondrial function, and 
preserve cell life.  It still remains unknown if the activation of macrophage nuclear factor 
B (NF-κ-B) is helpful in attenuating osteoclastogenesis.     
In order to study light treatment, researcher must understand how to calculate the 
correct irradiation parameters.  To define LLLT according to the “medicine” (irradiation 
parameters) and “dose” (irradiation time) standards, delivery is a key to understanding 
and developing interventions using light treatment.  Energy Density J/cm
2
 often reflect 
the dose of treatment, however, energy has two components, power and time.  Energy (J) 
= Power (W) x Time (s).  There is reciprocity between the variables meaning that if the 
power was doubled and the time is cut in half the same energy is delivered but a different 
biological effect would be seen (Huang et al., 2009).  It is best to describe the parameters 
separate, irradiation parameters and dose.  This study used a continuous wave NIR-LED 
with a wavelength of 670nm, power intensity of 60mw/cm
2
 delivering and energy density 
of 4.5 J/cm
2
 and 45J/cm
2
 in 80 and 800 seconds, respectively. 
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Methods 
Cell Culture Model 
A cell culture model was chosen because a proposal to test any kind of 
intervention in a vulnerable population of older adults gives rise to many ethical 
considerations. For example, directly extracting bone cells in a human model by a 
researcher would be an invasive and painful procedure (WHOSG, 2003).  Interventions 
that alter the cellular function of bone cells require a careful progression of research.  
Thus, to gain an understanding of the efficacy and safety of a technology that is 
known to alter cellular functioning, an appropriate place to begin would be in a cell 
culture model because an in vitro method is economical compared to animal and human 
models, easily implemented for experimental replication to interpret data for protocol 
development determining dose response curves, and is exempt from Institutional Review 
Board submission.  This research was undertaken using a cell culture model with RAW 
264.7 animal cell line derived from mouse leukemia monocyte macrophages.  These cells 
are precursor osteoblastic cells (macrophages).  This particular cell line requires the 
induction of Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL) in order to 
promote osteoclast formation.  The induction method occurs when osteoblast stromal cell 
membrane RANKL receptors, bind to the osteoclast precursor cell (macrophage) RANK 
receptors. When this occurs, RANK signaling activates the transcription nuclear factor 
Kappa-B to differentiate into osteoclasts (Kumar, 2010).   
Two manufactures of RANKL (Sigma
TM
 & PeproTech
TM
) were tested to 
determine the best ligand to induce osteoclastogenesis because of poor osteoclast cell 
counts in preliminary experiments. In order to determine if cellular response occurred 
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during RANKL suspension, a vehicle control of Bovine Serum Albumin (BSA) was 
tested and was found to be negative and the stability of the RANKL was preserved.    
Based upon results of robust cell culture experiments, progressing the research 
into an animal may be advantageous to begin using primary cells obtained directly from 
experimental animals and, ultimately, if the intervention were deemed safe and beneficial 
at the cellular level—a human model may be appropriate to further bridge research from 
bench to bedside using non-invasive measurements of bone-mineral density.  In other 
words, if the outcomes from the cell culture model warrant positive effects, the research 
could progress to experimentation in animals.  In an animal model, the researcher is able 
to use skeletal remains, thus enabling direct maceration of a whole bone in order to flush 
and extract bone cells which are closer to human cells for study (Rittweger, 2007).  If the 
experimental treatment is deemed efficacious and safe in animals, then it may be 
undertaken in human model.  
In order to understand maximal does for RANKL and energy density dose 
response curves were conducted in the experiments.  Biphasic response has occurred in 
low level light treatment (LLLT) research (Huang et al., 2009) however, a biphasic dose 
response curve for RANKL is lacking in the literature. The “Arndt-Schultz Law”, the 
model to describe dose dependence, states a weak stimuli will induce slight activity, 
while a stronger stimuli will induce activity higher, but once a peak is reached (minimal 
threshold) an even stronger stimuli will suppress the activity until it has a negative 
response (Huang et al, 2009).  Therefore, the biphasic curve, described as insufficient 
energy, is applied there will be no response, if more is provided then the minimal 
threshold is crossed, but if too much energy is given, the response will disappear.   Huang 
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and colleagues (2009) report that energy density (J/cm
2
) is used to describe the light 
treatment dose, however, the energy density has two components, power and time.  They 
recommend describing the light treatment as two variables, the medicine (irradiation) and 
the time (dose).   
Purpose 
Our primary goal in this study was to determine the effects of NIR-LED 
treatment on osteoclast cell differentiation (osteoclastogenesis) in cell-cultured 
RAW264.7 cells using the WARP 75 ™ NIR-LED light. Our specific research questions 
and hypotheses were as follows.   
Question 1. Is there a difference in osteoclast cell count between single light-
treated Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL)-induced cell 
cultures as compared to non-light-treated controls?  Hypothesis. Single light-treatment 
of RANKL-induced cell cultures will impair osteoclastogenesis.  
Question 2.  Is there a difference in osteoclast cell count between light-treated 
RANKL-induced cell cultures treated at different energy densities of light-treatment 
(2.25, 4.5 and 45 J/cm
2
) compared to non-light-treated controls?  Hypothesis. Light-
treatment of RANKL-induced cell cultures at a higher energy density (45 J/cm
2
) will 
stimulate less osteoclastogenesis compared to lower energy densities (2.25 and 4.5 
J/cm
2
). 
Question 3. Is there a difference in osteoclast cell count between single light-
treated RANKL-induced cell cultures compared to multiple light-treated RANKL-
induced cell cultures?  Hypothesis. Multiple light-treatments of RANKL-induced cell 
cultures will stimulate osteoclastogenesis less compared to single light-treated RANKL-
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induced cell cultures. 
Experimental Control Research Question- Dose Response Curve:  Is there an 
expected biphasic dose dependent response curve in RANKL induced (0ng/ml, 2.5ng/ml, 
10ng/ml, 25ng/ml and 50ng/ml) cell cultures? Hypothesis: Lower dose RANKL-induced 
cell cultures will have lower osteoclast cell counts than higher dosed RANKL cell 
cultures until the minimum dose threshold is reached then osteoclast cell counts then will 
decrease inversely.  
Implications 
Conducting research brings a strong commitment and responsibility to 
disseminate results to impact public policy, nursing practice, and research.  Nursing 
historically is rich with political activism.  From the beginning of  nursing’s evolution 
pioneers such as  Florence Nightingale and Lillian Wald began over a century ago to 
improve deplorable hospital conditions and public health for all (Backer, 1993; 
Nightingale, 1989).  Nursing in the past has also been dominated by the political 
influences of medicine.  Due to subsequent professional conflicts, advocacy for 
vulnerable populations at times was challenging (Mechanic & Reinhard, 2002). As 
nursing has become more autonomous and has experienced professional growth, progress 
is made working collaboratively with medicine and other bench scientists through 
multidisciplinary professional organizations, advanced practice nursing, clinical practice 
settings and public policy to bridge new partnerships.     
Nursing Practice and Research 
Nurses are interested in investigating new interventions to prevent or treat 
osteoporosis because of its primary commitment to the patient, as nurses advocate and 
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protect the health and safety of patients, as well as improve the quality of care (American 
Nurses Association, 2001).  Nurses recognize evidence based practice (EBP) as the gold 
standard for providing safe and compassionate care (Brown, Wickline, Ecoff, & Glaser, 
2009).  Evidenced based pracice is recognized by the American Nurses Credentialing 
Center’s Magnet programme as key component for quality care (McClure & Hinshaw, 
2002).  Nurses many times are the most prevalent and consistent health care provider that 
older adults encounter throughout their health care service delivery.  Nursing has the 
opportunity to identify individuals at risk and implement timely interventions to prevent 
disease or implement the most beneficial appropriate intervention for the patient.  This 
type of interventional research is the first step in moving bench science to the bedside.   
Per the National Institutes of Health, translational research can be defined as a 
two stage process: the application of innovative laboratory research into preclinical 
studies to design human clinical trials and translation with implementation of best 
practices into the community objectives to achieve cost-effectiveness in prevention and 
treatment (National Institutes of Health, 2007).  Research is transferred from the 
laboratory’s bench (basic research) to the patient’s bedside (clinical research) then 
clinical study and trial findings transferred into the community and practice settings to 
improve health outcomes (Rubio et al., 2010).       
Public Policy 
As stated previously, the older adult population is aging in great numbers every 
day. In fact, fracture totals in 2005 were estimated to be 20 million with a cost to treat 
$17 billon, and estimated by 2025, fracture rate and costs will increase 50% (Burge et al., 
2007).    This program of research has one main public policy implication to discover 
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interventions to treat and manage osteoporosis in an effort to preserve, re-build and 
strengthen bone architecture.  This in turn may ultimately decrease the incidence of 
fracture rate and impact cost containment to treat osteoporotic-induced fractures. 
Once significant benefit is established, the medical device must be approved by the 
Federal Drug Association (FDA).  Choosing the use of an FDA approved device avoids 
the arduous process of establishing efficacy and safety. NIR-LED light used in this study 
is an FDA approved device invented by Quantum Devices Incorporated (Barneveld, WI) 
and was developed as a NASA technology entitled High Emissivity Aluminiferous 
Lighting Substrate 
TM
 (HEALS),   to grow plants for long-term space flight.   Receiving 
FDA approval, they successfully developed a commercial device; the Warfighter’s 
Accelerated Recovery by Photobiomodulation (WARP 10), a portable Near Infrared 
Light Emitting Diode (NIR-LED), used in combat to provide first aid for minor injuries 
and pain and received FDA approval.  In 2000, they received a Space Technology Hall 
Of Fame Award for their Innovation of Light Emitting Diodes for Medical Applications 
(National Astronautical Space Agency, 2008; Quantum Devices Incorporated, 2004). 
Nursing and NASA technology have common goals, the care of astronauts and 
patients.  Since 1976, 1,300 space related technologies have been applied to industry, 
daily life, and patient care (Plush & O’Rangers, 2004).  Such examples include:  cellular 
phones and personal data assistants (PDAs), CT scanners/MRI, as well as the ventricular 
assist device, a miniature heart pump based upon a NASA fuel pump which was 
developed by Michael DeBakjey, MD (Plush & O’Rangers, 2004).  Further, the 
translation of technology has been made in this current study, as the NIR-LED was 
developed for NASA to grow plants during space flight (National Astronautical Space 
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Agency, 2008). Given time and funding, this proposed new intervention to either prevent 
or treat osteoporosis has promise.   
Future Chapters 
The subsequent chapters of this dissertation are comprised of three manuscripts 
on the topics of osteoporosis and current interventions as well as a summary chapter.  
Chapter Two, the review of the literature, is divided into two sections; thus, two review 
manuscripts were written according to submission guidelines for MEDSURG NURSING:  
Official Journal of the Academy of Medical-Surgical Nurses.  Manuscript One, New 
Insights-Understanding the Etiology and Consequences of Osteoporosis, provides an 
overview of the definition, significance, incidence and pathophysiology for osteoporosis. 
This is followed by a discussion regarding outcomes of this pathology, osteoporotic 
induced fractures and frailty.  Manuscript two Nursing Implications for Osteoporosis 
Management, reviews current nursing implications for the generalist nurse and 
recommendations for nursing process, as well as pertinent osteoporosis medical 
management to inform the nurse’s knowledge base.  
The experimental bench research protocol development at the NASA Ames Bone 
and Signaling Laboratory that was consequently used for the experiments in the final 
manuscript is described in chapter III.  The specific protocols are found in Appendix A-
G, tables Appendix H and letters of permission Appendix I.   Further, the preliminary 
data that were collected during the piloting of the experimental protocols are presented in 
this chapter.  
In Chapter IV, the third manuscript, experiment pilot data, considered the 
dissertation study as described. This manuscript was presented at the 62
nd
 International 
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Astronautical Congress:  African Astronaissance, Cape Town, South Africa, on October 
3-7, 2011.   Lastly in, the relationship between manuscripts is reviewed.  Findings are 
discussed, conclusions and limitations highlighted, and directions for future research 
offered. 
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CHAPTER TWO:  REVIEW OF THE LITERATURE 
This chapter is divided into two sections comprised of two manuscripts prepared 
for submission to MEDSURG NURSING:  Official Journal of the Academy of Medical-
Surgical Nurses.  These manuscripts comprise a two-part series.  The first manuscript, 
entitled New Insights-Understanding the Etiology and Consequences of Osteoporosis and 
the second, entitled Nursing Implications:  Osteoporosis Management set the stage for 
the dissertation reported in Chapter Four.  The first manuscript provides the context by 
clarifying definitions, highlighting the prevalence, reviewing normal physiology and 
pathology of bone, factors to consider for making the diagnosis of osteoporosis, and 
osteoporosis health outcomes.  Manuscript two is a review of current nursing 
implications for the generalist nurse with recommendations for nursing interventions, 
new insights in osteoporosis management. 
Manuscript One 
New Insights-Understanding the Etiology and Consequences of Osteoporosis 
Abstract 
Osteoporosis is a growing worldwide public health problem given the increasing 
numbers of individuals over the age of 65, affecting 75 million people in Europe, Japan 
and the United States.  Osteoporosis, described as compromised bone strength, is a silent 
epidemic occurring virtually unnoticed, associated with staggering consequences of 
osteoporotic induced fractures, specifically, hip fracture.  In the near future, due to 
primary care provider shortages, generalist clinicians will be responsible to provide the 
majority of health care to those at risk for this condition.   It is important that generalist 
nurses become familiar with the basic underpinnings associated with this disease process. 
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The purpose of this review is to provide the generalist nurse with the most current 
definition, an overview of bone physiology and pathology, including its causes, and 
summarizes the negative health outcomes, including the societal financial burden.  
Further, new insights in osteoporosis management for evaluation of bone architecture and 
strength, new medications, and new therapies; Near-Infrared Light Emitting Diodes 
(NIR-LED) treatment and whole body vibration (WBV) therapy are introduced. 
Introduction 
Osteoporosis, the most common bone disorder (National Institutes of Health 
Consensus Development Panel on Osteoporosis [NIH-CDPO], 2001) is quickly becoming 
a worldwide public health problem (International Osteoporosis Foundation, 2013).  Given 
the increasing numbers of individuals over the age of 65 and that it affects 200 million 
people (Burge et al., 2007; Colón-Emeric, 2013). Older adults with low bone mineral 
densities (BMD) are at risk for fracture when they fall.  Therefore, the risk of 
osteoporotic-induced fractures, specifically those of the hip, increases as persons age 
(Rizzoli, 2010).  Hip fractures experienced by the older adult population are one of the 
most serious sentinel events that are associated with overall morbidity and mortality, and 
are associated with high treatment costs to the health care system.  It is projected that by 
the year 2030, the US older adult population will double to 71.5 million, 8.9 million of 
whom will be over the age of 85 (U.S. Department of Health and Human Services 
Administration on Aging, 2006), thus being the fastest-growing sector of the U.S. 
population. Similar projections apply globally with a world population of individuals 
over 60 years reaching approximately two billion by the year 2050 (United Nations, 
2010).  Over time, this older adult population will become vulnerable for disability, 
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morbidity, and mortality due to aging (Ostir, Ottenbacher, & Markides, 2004).  The focus 
of this manuscript is on individuals over aged 50 years.  
Osteoporosis-induced fractures burden society by over-use of available medical 
resources (Burge et al., 2007).  In 2008, estimated US costs to treat osteoporosis and 
fractures was reported as $22 billion (Blume & Curtis, 2011).  Within a year of fracture, 
one third of cases are admitted to long-term care; of these, 20% are found to be frail 
(Orsini et al., 2005).  In 2005, the cost associated with two million fractures was 
estimated to be $17 billion, of which 72% of the expenditures were spent to treat hip 
fractures.  Costs are projected to increase approximately by 50% (Blume & Curtis, 2011; 
Burge et al., 2007).  However, these figures do not take into account indirect costs such 
as lost wages or the decrease productivity of caregivers or the post-fracture medical 
management expenditures (NIH-CDPO, 2001).  Kilgore et al. (2009) reported the average 
cost to treat a wrist fracture was $7788 and an open hip fracture $31,310 (Iowa 
Foundation for Medical Care, 2008).  Given current societal demographic growth and 
rising healthcare cost it will become imperative to identify individuals at risk for falls, 
screen for bone loss and implement appropriate tailored interventions to improve bone 
loss and prevent falls. This in turn will ultimately impact morbidity and mortality 
outcomes and conserve medical resources.  In order to achieve these objectives, nurses 
must build a foundation of knowledge stemming from the basic physiological and 
pathological tenants associated with bone loss.  
Osteoporosis is a silent epidemic because it occurs without symptoms or pain.     
While considerable literature exists on this topic (European Foundation for Osteoporosis 
and Bone Disease & National Osteoporosis Foundation, USA [EFOBD & NOFUSA], 
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1997; National Guideline Clearinghouse [NGC], 2006 [Revised 2010]; North American 
Menopause Society [NAMS], 2010; World Health Organizaiton Scientific Group 
[WHOSG], 2003), synthesizing the literature can be time consuming.  Therefore, the 
purpose of this critical review of the literature is to provide the generalist nurse with the 
most current definition, an overview of bone physiology and pathology, causes, and 
health outcomes.   Fall-induced fractures, especially hip fractures, are highlighted given 
their association with osteoporosis, in terms of their health, social, and financial toll.  
Lastly future proposed cellular level physiological research utilizing near-infrared light 
emitting diode treatment (NIR-LED) that may impact reversing, preventing, or slowing 
bone loss is discussed. Nursing implications are discussed in another manuscript.  
Method 
An extensive search of the literature published between 2000 – 2013 was 
conducted focusing on osteoporosis, its etiology, and societal and health outcomes.  
Databases searched included PubMed, CINAHL, Academic Search Complete/EBSCO, 
Medline, National Guideline Clearinghouse, Google Scholar, Primo Central/Ex-Libris, as 
well as references from articles and books.  Moreover, a Google web search was 
employed to gather full text copies of standards and guidelines.  Seminal articles prior to 
1999 were subsequently authenticated from the extrapolated literature.  Expert identified 
literature also was reviewed. Of note, the Primer on the Metabolic Bone Diseases and 
Disorders of Mineral Metabolism, eighth edition which is distributed to the entire 
membership of The American Society for Bone and Mineral Research, was utilized to as 
the source of leading expert bone health researcher opinions (Rosen, 2013).  
30 
 
 
 
The following key words were used:  bone, in combination with physiology, 
pathology, remodeling, architecture, apoptosis, osteoblasts, osteoclasts, bone turnover, 
NIR-LED, low level light laser therapy, and whole body vibration treatment.  The term 
osteoporosis was searched in combination with epidemiology, definition, guidelines, 
position statement, primary and secondary causes, risk factors, cost analysis, fall induced 
fractures, hip fracture/risk, falls and frailty and was limited to English.  However, the 
main focus of the search was on the age group of 50+ years.   
The search, when feasible, was limited to meta-analyses (2), systematic reviews 
(4), clinical cohort studies (18), epidemiological studies (11), professional guidelines (1), 
position statements (6), government reports (8), theory (3), reviews of literature (29), 
bench research (10), articles from peer-reviewed journals (75), professional texts (14), 
and one qualitative study.  Whenever possible, each article was critically evaluated for 
quality and reliability using the Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) checklist as a guideline to evaluate academic peer-reviewed 
articles (Moher, Liberati, Tetzlaff, Altman, & The Prisma Group, 2009). 
Findings 
 Findings are summarized in the following order: definition, incidence, and 
significance for osteoporosis followed by an overview regarding bone physiology and 
pathology associated with bone demineralization, identifying the primary and secondary 
cause of osteoporosis, negative health outcomes, and societal financial burden. Lastly, 
new alternative osteoporosis identifying diagnostics, medications and bioengineering 
treatment such as NIR-LED treatment and whole body vibration (WBV) therapy are 
discussed.   
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Definition and Diagnosis for Osteoporosis 
  
The definition of osteoporosis, evolving over time through a series of professional 
position statements, is often described as compromised bone strength (EFOBD & NOF-
USA, 1997; NIH-CDPO, 2001). It is defined conceptually as a skeletal disease 
characterized by low bone mass and structural deterioration of bone tissue, leading to 
bone fragility and an increased susceptibility to fracture, especially of the hip, spine, and 
wrist (EFOBD & NOFUSA, 1997; NIH-CDPO, 2001).   
The World Health Organization (WHO) defines osteoporosis by diagnostic 
assessment of bone mineral density (BMD) measurements that categorize the degree of 
bone loss (WHOSG, 2003). The diagnosis of osteoporosis is identified by reduced bone 
density of vertebral and/or femur cortical and cancellous bone.  Using dual energy x-ray 
absorptiometry (DEXA) scanning, reported as grams of mineral per area volume, a bone 
mineral density (BMD) that exceeds 2.5 standard deviations (SD) below the mean BMD 
found in 30 year old women, diagnoses osteoporosis (EFOBD & NIHUSA, 1997; Kanis, 
1994; NIH-CDPO, 2001; WHOSG, 2003). (see Table 1)  
Incidence  
In the US, osteoporosis affects approximately 10 million people over the age of 
50 years of those, 8 million are women. In addition, 34 million Americans are at risk for 
developing osteoporosis due to low bone mass (osteopenia) (Harvey, Dennison, & 
Cooper, 2013; A. C.  Looker, Melton, Harris, Borrud, & Shepherd, 2010).  The incidence 
of osteoporosis is more common in women than men due to postmenopausal hormonal 
changes and a longer life expectancy (NIH-CDPO, 2001; WHOSG, 2003).   
 Due to ethnic differences in bone and mineral metabolism (Norris, Micklesfield, 
& Pettifor, 2013), osteoporosis is present more often in Caucasian than Hispanic and 
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African American women.   Few data exist that report ethnic patterns in men; however 
trends are similar to women.  When comparing incidence rates of osteoporosis and 
osteopenia between 2005-2008, 9% of non-institutionalized 50 year old Americans had 
osteoporosis of either the femur neck or lumbar spine and approximately 50% had 
osteopenia (Looker, Borrud, Dawson-Hughes, Shepherd, & Wright, 2012).   
Bone Anatomy 
The generalist clinician should have an appreciation of bone anatomy and 
physiology so that he or she can practice knowledgeably and understand how 
interventions to prevent and treat osteoporosis affect these physiologic pathways.   Bone 
is best described according to its function, architecture, and tissue type.  Bone remodeling 
occurs throughout the lifespan and has a specific systematic process in reabsorbing and 
replacing bone.  
Function.  Anatomically, the function of bone supports the body while standing 
erect, protects vital organs, and assists ambulation and movement through muscular 
system linkages.  Physiologically, bone is responsible for the manufacture of blood cells 
in the bone marrow and serves as a reservoir for phosphorus, magnesium, and 99% of the 
body’s calcium.  Further, the bone’s ability to maintain metabolic function is achieved by 
mineral homeostasis through acid-base balance (Boskey & Robey, 2013; Hadjidakis & 
Androulakis, 2006; Sherwood, 2013).   
There are two parts to the skeletal system:  the axial skeleton (the cranium, thorax 
and vertebral column), and appendicular skeleton (upper and lower extremities) (Porth, 
2009).  Every bone has an extracellular matrix (ECM) which is comprised of two main 
components: mineral composite and collagen, as well as water, proteins, and lipids 
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(Boskey & Robey, 2013).  The mineral composite is made of hydroxylapatite, which are 
mainly calcium phosphate salts, providing strength via crystallization around the collagen 
fibers in the ECM.  Collagen type I is the basic building block of the bone matrix and 
contributes to bone strength (Sherwood, 2013).   
Bone Architecture.  There are two types of bone matrix:  cancellous (spongy) 
bone and cortical (compact) bone.  Both types of bone matrix are found in all bone; 
however, the relative contribution of cancellous and cortical tissues to a given bone varies 
(Porth, 2009).  Cancellous bone, found within the bone’s inner core, comprises 20% of 
the skeleton, and is often referred to as trabecular bone because trabeculae form a lattice 
pattern (Adler, 2000; Hadjidakis & Androulakis, 2006).  The lattice is lined with bone 
marrow and osteogenic cells and is fairly light, but able to withstand tensile strength for 
weight bearing (Porth, 2009; Seeman, 2008), 2008).   Cancellous bone is described as 
being elastic compared to cortical bone (Hadjidakis & Androulakis, 2006).  Vertebrae are 
particularly rich with cancellous or trabecular bone. Cortical bone comprises 
approximately 80% of the skeleton.  It is a rigid, densely calcified, and compact matrix 
that forms the bone’s outer shell, and it is the predominate type of tubular bones found in 
the upper and lower extremities, hip, and wrist.  Structurally, cortical bone is more 
resistant to bending and torque (Hadjidakis & Androulakis, 2006; Porth, 2009).  
Two important considerations in evaluating the bone quality are bone structure 
and strength.  Bone structure determines the energy load that bone can withstand, and the 
energy load in turn affects the bone structure through adaptation by modeling and 
remodeling bone tissue in response to the energy load (Seeman, 2008). Currently, bone 
quality remains indefinable by current dual energy x-ray absorptiometry bone mineral 
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testing (DEXA BMD) testing. Because spine and hip Bone Mineral Density (BMD) can 
estimate approximately 70% of bone strength (Suh & Lyles, 2003), newer technologies 
for measurement of bone quality may be achieved through areal BMD measurement 
using computed tomography (Genant et al., 2008; MacNeil, Boyd, MacNeil, & Boyd, 
2008). BMD, however, does little to help the clinician evaluate bone architecture.  It is 
important to understand that an increase in BMD does not always render improved bone 
quality, a result that may affect true bone strength considerably. Recently, trabecular 
bone scores (TBS) are being researched as an added measurement and may become a 
standard measurement with traditional DEXA testing (TBSiNsight, 2014). 
Bone architecture determines the energy load that a bone can withstand, and the 
energy load in turn affects the bone architecture through adaptation.  Remodeling bone 
tissue responds to the energy load exerted upon that bone structure (Seeman, 2008). The 
greater the energy load, the greater the rate of bone deposition or density and excess load 
beyond bone tensile strength results in fracture (Sherwood, 2013).  Therefore, weight 
bearing exercise is imperative for bone architecture.  Moreover, in order for one to stand 
erect against gravity, the bones collectively must function like levers; they must be stiff 
and able to resist buckling when absorbing energy, such as a spring (Seeman, 
2008).  Bone acting as a “spring” must change shape without cracking, must shorten or 
widen according to the compression that the energy load expends, must lengthen or 
narrow in tension, and remain light enough to allow for rapid motion (Seeman, 2008). If 
bone is too stiff or too flexible, however, bone fragility may occur 
Bone Tissue and Cells.  There are two types of bone tissue: woven and lamellar.  
Both types can be either mineralized or unmineralized (osteoid). Woven bone is not 
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strong and is rapidly deposited as a temporary structure during fracture healing.  Lamellar 
bone is matured bone that forms slowly and is highly organized.  
There are four types of bone cells that contribute to the formation and 
maintenance of bone:  osteoprogenitor cells, osteocytes, osteoclasts, and osteoblasts 
(Porth, 2009). Osteoprogenitor cells are undifferentiated cells that are the source of all 
bone cells except osteoclasts which originate from monocyte/macrophages within the 
hemopoietic lineage.  Osteocytes are mature bone cells that maintain the bony matrix.  In 
addition, they may respond to bone tissue strain and recruit osteoclasts to areas of bone 
requiring bone repair/remodeling (Lanyon, 1993).  There are interconnected 
passageways,  canaliculi, found throughout the calcified matrix that contain extracellular 
fluid (Hadjidakis & Androulakis, 2006) that provide a communication network between 
the neighboring osteocytes and blood system for the exchange of nutrients and 
metabolites because diffusion does not occur is calcified bone (Porth, 2009).      
Osteoclasts and osteoblasts are two types of cells within mineralized bone that 
contribute to mineral homeostasis (Lemaire, Tobin, Greller, Cho, & Suva, 2004). They 
are responsible for building and maintaining bone structure.  Osteoclasts are bone-
resorbing cells that originate from monocyte/macrophages within the hemopoietic 
lineage, and their activity is regulated by osteoblasts, bone-forming cells, and numerous 
hormones and other growth factors, macrophage colony-stimulating factor (M-CSF), 
interleukin-1 (IL-1), and tumor necrosis factor (TNF)  (Hock et al., 2001).  Osteoblasts 
are differentiated mesenchymal stem cells, responsible for lying down the new bone 
matrix that becomes mineralized, thus replacing old bone previously reabsorbed by 
osteoclasts (Hadjidakis & Androulakis, 2006; Hock et al., 2001). 
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There are two pathways that induce osteoclastogenesis.   On the osteoblast 
stromal cell membrane, Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL) 
receptor, binds to the osteoclast precursor cell (macrophage) RANK receptor. When this 
occurs, RANK signaling activates the transcription factor Kappa-B to differentiate into 
osteoclasts (Kumar, 2010).  The other pathway occurs with the osteoblast secretion of M-
CSF and the osteoclast precursor cell (macrophage) M-CSF receptor.  When joined 
tyrosine kinase activity is stimulated, also important to osteoclast formation. This 
signaling occurs in tandem with the RANKL/RANK pathway.  Further bone marrow 
stromal/osteoblast cells secrete osteoprotegerin (OPG), a decoy receptor for RANKL 
preventing RANKL from binding with the osteoclast precursor cell’s RANK receptor.  
Thus, preventing bone absorption and attenuating osteoclast differentiation (Kumar, 
2010). 
Bone Physiology 
Normal Bone Remodeling.  Bone is a connective and living tissue that 
undergoes continuous remodeling.  Approximately every 10 years, a healthy human adult 
skeleton is completely replaced (Lippuner, 2012; Sherwood, 2013) and every year, 5-
10% of bone is replaced in specific bones (WHOSG, 2003). Normal bone remodeling is a 
coupling process between osteoclasts and osteoblasts, between bone gain and loss, where 
bone absorption and bone formation is balanced (homeostasis) (NAMS, Bruzzaniti & 
Baron, 2006; 2010).  As the bone adapts to mechanical load and strain, old bone is 
replaced with new tissue through the coordination between osteoblasts and osteoclasts 
(Hadjidakis & Androulakis, 2006).  Bone remodeling begins with bone resorption in both 
cortical and cancellous bone by the osteoclasts over a period of a few days. 
37 
 
 
 
Osteoprotegerin (OPG) production and is vital to the regulation of osteoclastogenesis, 
menopausal transition and post-menopause, the RANKL secretion by osteoblasts is 
greater than the OPG generation due to loss of estrogen (Tella, Gallagher, Tella, & 
Gallagher, 2013).  
 Bone remodeling begins with bone resorption in both cortical and cancellous 
bone by osteoclasts over a period of 30-40 days (Eriksen, 2010). Osteoclasts attach to the 
mineralized bone surface and resorb bone via secretion of hydrogen icons and cathepsin 
K (Raisz, 1999), creating irregular, scalloped cavities named Howship lacunae in 
trabecular bone or cylindrical Haversian canals in cortical bone. Osteoprogenitor cells 
found in the periosteum and endosteum will differentiate into cuboidal-shaped 
osteoblasts. Osteoblasts lay down a new organic extracellular matrix in two stages; 
ossification, formation of unmineralized bone (osteoid), and calcification that becomes 
mineralized with calcium and phosphate and fills the resorption lacunae over 
approximately 150 days (Eriksen, 2010; Raisz, 1999).   
Bone structure reflects the quality of the bone tissue (EFOBD & NOFUSA, 
1997).  Microarchitectural bone changes may be independently associated with bone 
weakness, but not associated with a change in BMD (Harvey et al., 2013).  An 
extracellular matrix (ECM) of bone is comprised of two main components: mineral 
composite and collagen, as well as water, proteins, and lipids (Gehron-Robey & Boskey, 
2008).  The mineral composite is made of  hydroxylapatite, mainly calcium phosphate 
salts, which provide strength via crystallization around the collagen fibers in the ECM 
(Sherwood, 2004).  Collagen Type I is the basic building block of the bone matrix and 
contributes to bone strength. 
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Pathogenesis of Osteoporosis 
 
There are primary and secondary causes for the pathogenesis of osteoporosis.  
When secondary causes for bone loss cannot be determined, the patient is diagnosed with 
primary osteoporosis (Ardawi, Al-Kadi, Rouzi, & Qari, 2011).  Primary causes of bone 
loss are due primarily to menopause and aging (senile osteoporosis) which overlap 
clinically, as well as the failure to achieve optimal peak bone mass (PBM) and strength 
initially during adolescence (NIH Osteoporosis and Related Bone Diseases (NIH 
Osteoporosis and Related Bone Diseases ~ National Resource Center, 2009; Raisz, 
2008). Achieving peak bone mass (PBM) and bone strength is critical to an individual’s 
overall lifespan skeletal health and is a determinant of the future adult skeleton’s strength 
(Raisz, 2008; WHOSG, 2003).  Optimal PBM may not be obtained due to genetic 
mutations, lack of adequate dietary calcium and vitamin D intake, as well as lifestyle 
choices such as physical activity. Secondary causes occur idiopathically in younger men 
and premenopausal women who present with osteoporotic fragility factures attributed to 
iatrogenic factors and disease pathogenesis (Hudec & Camacho, 2013).  
Osteoporosis arises from the out-of-balance osteoclast/osteoblast activity in 
remodeling bone (Shih, 2012).  Bone loss has been described as a two-stage process in 
women.  The first stage is due to menopausal estrogen loss usually around 51 years and 
the second, that occurs post-menopausally, is a slow continuous loss of bone due to aging 
rather than the loss of estrogen prior to menopausal transition.  The first to two years of 
perimenopause may account for the greatest amount of lost bone; trabecular (37%) and 
cortical (6%) loss found before age 50 (Armas & Recker, 2012; Riggs et al., 2008).  It is 
estimated that menopausal transition spans 5-7 years.  Approximately, 12% of total bone 
mass is lost during this time which is equal to one T-score (-1 SD) of measured bone 
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density by DEXA and corresponds to enough bone loss as diagnosed osteopenia (Armas 
& Recker, 2012; Recker, Lappe, Davies, & Heaney, 2000).  Bone loss occurs because 
osteoclastogenesis becomes proportionally greater than osteoblastogenesis (Shih, 2012).  
The beginning of the second stage varies individually in post-menopausal women and is a 
slow continuous loss of bone due to aging rather than the loss of estrogen.  During this 
later stage cortical and trabecular bone loss occurs at an equal rate until the end of the life 
span.  Unlike women, men begin this slow continuous loss of bone due to aging during 
middle age (Khosla & Riggs, 2005). 
Independent of aging or estrogen deficiency, secondary osteoporosis may be due 
to a group of heterogeneous causes leading to bone loss.  Secondary causes of bone loss 
occur in approximately two thirds of men, over half of premenopausal women and 30% 
of postmenopausal women (Recker, 2011).  One main cause is iatrogenic effects of 
medications that negatively alter the bone remodeling homeostasis.  However, not all 
drugs have negative effect; some medications have been associated with increase bone 
density (see Table 2). Specific attention has centered on proton-pump inhibitor use 
associated with decreased BMD and possible increased hip fracture/fracture risk.  
Calcium absorption is thought to be impaired with gastrointestinal PH changes (Gray et 
al., 2010; Targownik, Lix, Leung, & Leslie, 2010).  It has also been suggested that some 
medications may, in fact, have an off label therapeutic benefit to skeletal health such as 
the combined use of β-blockers and thiazides (Wiens, Etminan, Gill, & Takkouche, 
2006), and lipid lowering agents (statins) (Uzzan, Cohen, Nicolas, Cucherat, & Perret, 
2007), but investigators cannot recommend preventive treatment without further research.   
Further, there are several specific disease states of the endocrine, hematological, gastro- 
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intestinal systems that have their own epidemiologic characteristics and pathogenesis that 
contribute to bone loss (Diem et al., 2007; Haney et al., 2007; Osteogenesis Imperfecta 
Foundation, 2010; Yang, Lewis, Epstein, & Metz, 2006) (see Table 3). 
Outcomes of Osteoporosis 
Two main osteoporosis outcomes are highlighted:  frailty and fall induced 
osteoporotic fractures, specifically hip fracture.  Both of these result in a societal and 
financial burden to treat. Researchers have identified frailty as a precursor to falls and 
falls as a precursor to frailty (Runge & Hunter, 2006).  Falls and fractures accelerate 
frailty in already frail older adults or acutely initiate transitioning into frailty due to a 
“triggering event,” such as a hip fracture.  
In a series of studies, the association between frailty and falls is well documented 
in the literature (Ensrud et al., 2007; Runge & Hunter, 2006) in both men (Ensrud et al., 
2009) and women (Ensrud et al., 2008) and there is considerable research that associates 
osteoporosis with fall-induced fractures (Morrison, Fan, Sen, & Weisenfluh, 2013; 
Schwartz, Nevitt, Brown, & Kelsey, 2005).  Therefore, individuals who may or may not 
be frail, who experience a fall, and who have low bone mass, are more likely to 
experience an osteoporotic induced fracture, which may accelerate or initiate frailty. 
 Frailty, described as a decline in the functioning of the neuromuscular system and 
the loss of physiological reserve to handle minor stresses, increases susceptibility to 
adverse health outcomes and progression of disease and comorbidities (Abate et al., 
2007; Fried et al., 2001; Morley et al., 2013).  Frailty is seen most frequently in older 
adults over 80 years of age.  An individual is identified as being frail when at least three 
of the following factors are present:  unintentional weight loss (10 pounds or more in a 
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year), self-reported exhaustion, weakness as measured by grip strength, observable 
slowed walking speed and self-reported low physical activity (Fried et al., 2001; 
Mahoney, Glysch, Guilfoyle, Hale, & Katcher, 2005; Morley et al., 2013).  The current 
prevalence of frailty in persons aged 65 and older ranges from 4.0% to 17% (Collard, 
Boter, Schoevers, & C, 2012).  
As individuals age they become susceptible to falling.  Falls have been an 
independent indicator for functional decline and are identified as the causal event for 
40% of nursing home admissions (Bischoff-Ferrari, 2009; 2013; Tinetti & Williams, 
1997). Approximately 1.4% of community dwelling older adults experience a low-impact 
fall resulting in fracture annually (Morrison et al., 2013).  Currently, falls remain the 
leading nonfatal injury treated in the emergency room (Centers for Disease Control and 
Prevention National Center for Injury Prevention and Control [CDCP-NCIPC], 2010) and 
the leading cause of death by unintentional injury for individuals 65 and older (Avdic, 
Pecar, & Mujic-Skikic, 2004; CDC-NCIPC, 2003; 2005). Consequently, over the past 
decade, the mortality rate has also increased (Stevens, 2006).  In older adults with low 
bone mass, who are in a pre-frail state, a condition between frail and nonfrail, falling may 
initiate functional decline initiating the progression into a frail state; and they are more 
likely to experience another significant consequence of osteoporosis, fall-induced 
fractures.  
The lifetime fracture risk for white women over 50 years is 50% (Armas & 
Recker, 2012) and for osteoporotic adults 60 ≥ years who experience a fracture, 24% of 
women and 20% of men will re-fracture within five years; and within one year 26% of 
women and 37% men will die, three times greater risk than the general population 
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(Colón-Emeric, 2013; Kannegaard, van der Mark, Eiken, & Abrahamsen, 2010).  Further, 
a little over a half a million low impact falls result in osteoporotic fractures (Morrison et 
al., 2013).  Fall induced hip fracture is the most serious osteoporosis-associated incidental 
fracture resulting in permanent disability (Harvey et al., 2013; WHOSG, 2003).   
   The three most common osteoporotic fall-induced fractures are vertebral 
compression, wrist, and hip. Wrist and vertebral spine fractures are most often 
experienced by women 45-60 years of age, and are thought to be attributed to age-related 
changes of neuromuscular reflexes.  A wrist fracture most commonly occurs when a 
women falls sideways or backwards and uses her arm to break the fall, thus breaking their 
wrist (Melton & Cooper, 2001). Vertebral fractures usually occur asymptomatically while 
performing normal activities of daily living such as lifting, and occur three times more 
often than hip fractures (Harvey et al., 2013). It is important to understand that vertebral 
fractures are painful and affect patient morbidity, while hip fractures affect patient 
mortality.   Therefore, older adults living with back pain tend to self-limit mobility which 
results in a functional decline, thus increasing risk for hip fracture and frailty.   
Hip fractures most commonly occur at the femoral neck resulting from landing 
directly on the hip during a fall (falling sideways) rather than falling forward (NIH-
CDPO, 2001).  As early as 1999, the WHO  declared that hip fracture may become a 
worldwide epidemic by the middle of the 21
st
 century, increasing from an incidence of 
1.7 million in 1990 to a projected 6.3 million by 2050 (Cooper, Campion, & Melton, 
1992).   Further, estimates for the number of hip fracture and costs could possibly double 
or triple by 2040 (US Department of Health and Human Services, 2004).  The majority of 
hip fractures are known to occur in Europe and North America, but over the next 50 
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years, it is projected that 75 % of the world’s total hip fractures will occur in developing 
countries. Reported in a systematic review, there is a global 10-fold variation in the 
global 10 year hip fracture and fracture probability rates and more study is required to 
initiate global strategies to affect rates of hip fracture (Kanis, Oden, et al., 2012).  
Most importantly, of the individuals who experience a fall and consequent hip 
fracture, many do not return to their original functional level nor resume original social 
activities after the fall. Only one-third of older adults regain their pre-fracture functional 
level (NIH-CDPO, 2001) and another third will be admitted to long-term care (NIH-
CDPO, 2001). Half of the people who are ambulatory prior to a hip fracture cannot walk 
independently after the fall (Harvey et al., 2013), and suffer from fear, anxiety and 
depression, which dramatically impacts their quality of life (Ziden, Wenestam, & 
Hansson-Scherman, 2008).   
In summary, osteoporosis is a growing world-wide problem requiring 
international collaboration to investigate and develop strategies to predict and stratify risk 
for falls and fractures, as well as address issues concerning access to appropriate therapy 
and education.  This disease process is silent and usually not diagnosed until a fracture 
has occurred resulting in staggering consequences for the quality of life of many older 
adults.  The population of older adults is expected to increase exponentially, resulting in 
rising health care costs and society burden to treat, as well as a growing population of 
frail older adults.  Therefore, researchers are actively working together to develop new 
technologies for disease diagnostics, osteoporosis medications based on new findings in 
bone biology, as well as new treatment options.   
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New Treatment Insights 
Generalist nurses with osteoporosis pathophysiological knowledge can appreciate 
the new advances for the management of osteoporosis. Alternative diagnostics, 
medications, and bioengineering treatment options are in various stages of discovery.  
Newer technologies for measurement for bone quality may be achieved using areal BMD 
testing, measuring bone for  size, thickness, and volumetric mineral density using volume 
quantitative computed tomography (vQCT) and micro-computed tomography (µCT) 
scanning and are undergoing substantiation for specificity and reliably (Genant et al., 
2008; MacNeil et al., 2008). They potentially may provide valuable BMD measurements 
in monitoring bone response to medical management.    
Trabecular Bone Score (TBS), a measurement of bone microarchitecture not 
captured in BMD testing, is a metric calculated from a two-dimensional lumbar-spine 
DEXA scan image. This measurement is a newly recommended metric to further evaluate 
postmenopausal women for bone loss and strength (Silva et al., 2014).  A lower score 
indicates weaker bone.  In women who experienced fragility fractures, lower TBS scores 
were found, but many of these women were not identified according to DEXA T-score as 
osteoporotic or osteopenic.   Possibly TBS will become a standard measurement for bone 
strength, added to clinical practice guidelines, and be used as a predictor for fracture in 
women not found to be osteopenic.   
Currently, bisphosphonates, which are osteoclast antiresorptives, are the first line 
medication used to manage osteoporosis (see Table 4).  Based upon advances in 
understanding mechanisms in parathyroid (PTH) bone stimulation pathways, a PTH bone 
anabolic, Teriparatide (Forteo ®), is now considered first line treatment for severe 
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osteoporosis (Kanis, Reginster, et al., 2012; Rizzoli et al., 2011).  Another drug in use, 
Denosumab (Prolia ® or XGEVA®), a Receptor Activator of Nuclear Factor Ligand 
(RANKL) -inhibitor has been effective in inhibiting osteoclast formation, thus decreasing 
the incidence of vertebral, non-vertebral and hip fractures (Cummings et al., 2009). 
Current experimental drugs, JTT-305, known as Calcilytics, stimulate PTH secretion in 
vivo [animal study model] (Avdic et al., 2004) and human dose response studies are 
promising (Cabal et al., 2013).  Further, a molecular pathway, Wnt/ß-catenin, responsible 
for osteoblastic differentiation and recruitment has been discovered. The drug, AMG 785, 
consisting of antibodies to antagonize this pathway resulted in significant increases in 
lumbar spine BMD (Kanis, Reginster, et al., 2012; Padhi, Jang, Stouch, Fang, & Posvar, 
2011). 
Some exciting developments in treatment involve using bioengineering equipment 
such as near-infrared light emitting diode (NIR-LED) treatment and vibration therapy.  
Low level light treatment has been found to be effective in many clinical settings, mainly 
improving wound healing and cell regeneration and function, and decreasing 
inflammation/pain (Desmet et al., 2006; Eells et al., 2004; Pinheiro & Gerbi, 2006; 
Pinheiro et al., 2008; Pinheiro et al., 2009; Whelan et al., 2003; Wong-Riley, Bai, 
Buchmann, & Whelan, 2001).  The hypothesis behind light treatment is that light 
absorption spectrum in the far-red to near-infrared range (630-1000nm) and low energy 
densities 4J/cm
2
 positively affects numerous cell functions (Desmet et al., 2006).  
Traditionally, lasers have been used at higher wavelengths and energy densities to cut, 
coagulate, and ablate by intense heat tissue, thus destroying the tissue. At low intensity, 
such as 670 nm, infrared wavelengths are thought to have cellular benefit rather than 
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destructive properties.  When the light is applied to the tissue, a photochemical 
conversion of energy occurs, absorbed by non-specialized cellular photo acceptors that 
enhances the production of energy, adenosine tri-phosphate (ATP), and ultimately 
reduces cellular oxidative stress, known to negatively affect cell function associated with 
aging (Eells et al., 2004; Karu, 1988). Light treatment increases osteoblastogenesis 
(Stein, Benayahu, Maltz, & Oron, 2005; Yamada, 1991) and osteoclastogenesis (Aihara, 
Yamaguchi, & Kasai, 2006) in a cell culture model and in animal models.  It is suggested 
that light treatment promotes osteogenesis increasing amounts of well-organized bone 
trabeculae and vertical bone regeneration (Blaya, Guimaraes, Pozza, Weber, & de 
Oliveira, 2008; Pinheiro et al., 2009; Torres, dos Santos, Monteiro, Amorim, & Pinheiro, 
2008). Based upon this research, low level light treatment may be useful to treat the 
osteoporotic population by applying the light to spine and hip.  However, no current 
studies exist.   
Whole Body Vibration (WBV) has been reported to have potential benefits to 
prevent and treat osteoporosis (Chan, Uzer, & Rubin, 2013).  However this technology, if 
not administered in the correct intensity, has risk to damage the musculoskeletal system.   
Bone is sensitive to mechanical signaling, which is beneficial to build and maintain bone 
mass; however parameters for duration, frequency or intensity remains unclear (Chan et 
al., 2013).  Studies have investigated bone response in postmenopausal women with low 
BMD reporting significant increases in bone mineral density with 6 months of treatment 
(Verschueren et al., 2004), but others report no changes in BMD in 11 weeks of treatment 
(Gomez-Cabello et al., 2014).  As a result, researchers need to develop WBV safety 
protocol studies to determine the parameters for standard treatment, but it appears that 
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low intensity vibration of one gravitational force (1g), earth’s gravitational force, is safe 
and may be effective to treat osteoporosis (Chan et al., 2013).  
Conclusion 
The incidence of osteoporosis remains high within a population expected to reach 
70 million by 2020, with costs to treat projected to double or triple by 2040 in the US 
alone.  Moreover, the worldwide incidence of osteoporosis is expected to reach 200 
million people by 2050, contributing to a significant societal burden worldwide.  Given 
these numbers, the possibility that a nurse will interact with someone with osteoporosis is 
quite real. Having a solid understanding of normal and pathologic bone anatomy and 
physiology will be critical in order to provide evidence-informed care.   
Although, as discussed, there are various promising advances in osteoporosis 
management and professional organizations such as the International Osteoporosis 
Foundation are readily evaluating literature and updating practice guidelines.  This 
organization has an extensive worldwide presence with 12 working groups in bone loss 
health.  The annual report is comprehensive (International Osteoporosis Foundation, 
2013), but how does this information reach the generalist nurses, the healthcare 
professionals who have the potential for the most frequent contact with patients? How 
nurses can best care for persons with osteoporosis is the focus of another manuscript.  
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Table 1 
  WHO Diagnostic Criteria for the Defining Osteoporosis 
  Sources:  Kanis & Adami, 1994; EFOBD & NOFUSA, 1997; WHOSG, 2003  
 
 
Table 2  
   Affecting Medications in Bones 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   Sources:  Gray et al., 2010; Targownik et al., 2010; Uzzna et al., 2006 
  
Definition Bone Mineral Density  T-Score 
Normal  BMD within 1 SD below the mean BMD 
of 30 year old women 
≥ -1 
 
Low Bone 
Mass 
(Osteopenia) 
 
BMD 1-2.5 SD  below the mean BMD of 
30 year old women 
 
Between -1 and -2.5 
 
Osteoporosis 
 
BMD ≤ -2.5below the mean BMD of 30 
year old women 
 
≤ -2.5 
 
Severe 
Osteoporosis 
 
≤ -2.5below the mean BMD of 30 year 
old women that has ≥ 1 fractures 
 
≤ -2.5 with fragility 
fracture 
Initiates Bone Loss Prevents Bone Loss 
Glucocorticoids 
 
Anti-Hormonal 
  
Aromatase Inhibitors 
 
Thiazolidinediones 
 
Acid Suppressants 
 
Anti-Epileptics 
 
Selective Serotonin Receptor 
Uptake Inhibitors 
 
Long-Term Heparin use 
β-blockers 
 
Thiazides, 
 
Statins 
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Table 3  
   Secondary Causes Associated with Bone Loss 
    Sources:  Compston, 2008; Diem et al, 2007; Haney et al., 2007; Osteogenesis 
Imperfecta 
    Foundation, 2010 and Yang et al., 2006 
 
Endocrine Hematological Rhematological GI 
Diseases 
Other 
Hyperthyroidism 
 
Primary  
Hyperparathyroidism 
 
Vitamin D Deficiency 
 
Hypogonadism 
 
Cushing’s Syndrome 
 
Idiopathic 
Hypercalciuria  
 
Paget’s Disease 
 
Diabetes Mellitus 
Bone Marrow 
Mastocytosis 
Rheumatoid 
Arthritis   
Cohn’s 
Disease 
 
Celiac 
Disease  
Osteogenesis 
Imperfecta  
 
Chronic 
Renal Failure 
 
Solid Organ 
Transplant 
 
Chronic 
Obstructive 
Pulmonary 
Disease 
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Manuscript Two 
Nursing Implications for Osteoporosis Management 
Abstract 
Osteoporosis is a worldwide silent epidemic affecting the quality of life of 75 
million people 65 years and older.  Osteoporotic induced fractures, an associated negative 
health outcome, may contribute to initiating or accelerating the downward spiral of 
frailty.  The costs associated with bone loss are expected to increase to $85 billion in 
2020 posing a significant societal financial burden. Given the dearth of geriatric 
clinicians, generalist clinicians will be responsible for rendering the majority of health 
care to populations at risk for this condition.  Currently, osteoporosis and osteopenia are 
significantly underdiagnosed and not usually assessed until after a fracture occurs.  
Among the healthcare team, nurses have frequent patient contact, patient trust, and 
opportunity to improve and implement evidence based practice.    It is critical that the 
care they provide is drawn from the most current evidence. In a prior manuscript, the 
etiology of osteoporosis was reported in preparation for this review. The purpose of this 
review is to provide the generalist nurse with knowledge to appropriately assess and 
identify osteoporosis, implement tailored interventions, provide disease monitoring and 
discuss nursing implications.  Ultimately, nurses, active members of the multidisciplinary 
team, are positioned to assist patients in understanding bone loss. 
Introduction 
Nurses have the most frequent patient contact, are trusted among many patient 
populations (Dinç, Gastmans, Dinç, & Gastmans, 2013), embrace the implementation and 
improvement of evidence based practice (Lee et al., 2013), and are an integral part of the 
67 
 
 
 
multidisciplinary health care tea (Wilkes et al., 2014).  Estimates of cost to treat 
osteoporotic-induced fractures are expected to at least double by 2040 (US Department of 
Health and Human Services [USDHHS], 2004), placing a great societal financial burden 
to care for the anticipated 70 million older adults in 2030 (U.S. Department of Health and 
Human Services Administration on Aging, 2006).  Nurses have an opportunity to guide 
women and men to improved bone health and reduce or reverse bone loss, thus 
preventing fractures and mortality and improving the quality life of older adults through 
thoughtful risk and clinical assessment, attentively monitoring and implementing tailored 
interventions (Teng, Curtis, & Saag, 2009).  In this manuscript, the literature is reviewed 
to provide the generalist nurse with knowledge to implement the nursing process to 
appropriately assess and identify osteoporosis, implement tailored interventions, and 
provide disease monitoring.   
Given the rapidly expanding osteoporosis literature, it is nearly impossible for 
nurses to remain abreast of all new recommendations for patient treatment.  Therefore, 
the purpose of this article is to provide a brief overview of the problem, and identify the 
current practice recommendations for risk assessment, screening, diagnosis, treatment 
options, prevention, and disease monitoring for the management of osteoporosis and 
provide implications for nursing practice and policy. Information is presented in the 
following order: bone loss and fall risk assessment, health history, screening, physical 
exam, diagnostic tests, and tailored interventions, prevention and nursing implications.  It 
will become imperative to identify individuals at risk for falls, screen for bone loss and 
implement appropriate tailored interventions to improve bone loss and prevent falls, in 
order to effectively impact the combined outcomes of morbidity and mortality, and 
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conserve medical resources.  These nursing practice recommendations are aimed toward 
adults 50 years and older.  
Problem 
Nurses must recognize that osteoporosis is a silent killer and not a customary 
disease associated as a general characteristic of aging.  Nonetheless, it is well known that 
bone loss can be currently identified, prevented and managed (National Osteoporosis 
Foundation [NOF], 2010 [revised 2013]).  Osteoporosis, the most common skeletal 
disease seen in older adults, is characterized by low bone mineral density (BMD) with 
microarchitectural bone deterioration that compromises bone strength, thus, increasing 
risk for bone fragility and fracture (National Institutes of Health Consensus Development 
Panel on Osteoporosis [NIH-CDPO], 2001; NOF, 2010 [revised 2013]; Nuti et al., 2009).  
Primary causes of osteoporosis are due primarily to menopause and aging (senile 
osteoporosis) and the failure to achieve optimal peak bone mass (PBM) and strength 
during adolescence. Secondary causes occur idiopathically in younger men and 
premenopausal women who present with osteoporotic fragility factures attributed to 
iatrogenic factors and disease pathogenesis (Bonjour, Theintz, Law, Slosman, & Rizzoli, 
1994; National Institutes of Health Osteoporosis and Related Bone Diseases ~ National 
Resource Center, 2009; Raisz, 2008). 
In the US, 10 million people over the age of 50 years are affected by osteoporosis; 
of these, 8 million are women and an additional 34 million Americans have low bone 
mass (osteopenia) (A. C.  Looker, Melton, Harris, Borrud, & Shepherd, 2010). 
Osteoporosis is more common in women than men due to postmenopausal hormonal 
changes and longer life span and more prevalent in Caucasian women and men than 
69 
 
 
 
Hispanics and African-Americans (Looker, Borrud, Dawson-Hughes, Shepard, & Wright, 
2012).   
Not all individuals at risk for bone loss are identified and treated.  Giangregorio, 
Papaioannou, Cranney, Zytaruk, and Adachi (2006) found that only 30% of patients were 
diagnosed with osteoporosis prior to a fracture. In the National Osteoporosis Risk 
Assessment Study (NORA) of women 50 years and older, almost half of the 200,160 
subjects had low bone mineral density (BMD), osteopenia, and 7% met the criteria for 
osteoporosis and were not receiving treatment.   Further, 11% had a history of an 
osteoporotic related fracture retrospectively beginning at age 45 (Siris et al., 2001).    
For white women over 50 years, the lifetime fracture risk is 50% (Armas & 
Recker, 2012) and every year in the US, there are over a half a million low impact falls 
that result in an osteoporotic fracture (Morrison, Fan, Sen, & Weisenfluh, 2013).  
Currently, falls are the leading cause of death by unintentional injury for individuals 65 
and older (Centers for Disease Control and Prevnetion National Center for Injury 
Prevention and Control [CDCP-NCIPC], 2003; 2005; 2010) .  The estimated lifetime risk 
for experiencing an osteoporotic fracture (vertebral, wrist, and hip) is 40%, similar to the 
lifetime risk for coronary heart disease ((World Health Organization Scientific Group 
[WHOSG], 2003). With an aging population, the incidence of falls will increase, as will 
fracture risk.      
Hip fracture is the most serious incidental fracture associated with morbidity and 
mortality in older adults (Harvey, Dennison, & Cooper, 2013; Johnell & Kanis, 2006; 
Ziden, Wenestam, & Hansson-Scherman, 2008), and the most costly fracture to treat 
(Kilgore et al., 2009).  In 2008, estimated US costs to treat osteoporosis and fractures was 
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reported as $22 billion (Blume & Curtis, 2011).  Hip fractures usually result in 
hospitalization, with mortality rates within the first year reported in men (37.1%) and 
women (26.4%) (Kannegaard, van der Mark, Eiken, & Abrahamsen, 2010).  In fact, 50% 
of those ambulatory prior to fracturing their hip, cannot walk independently (Harvey et 
al., 2013), suffer from fear, anxiety, and depression which dramatically impacts their 
quality of life  (Eastwood et al., 2002; NOF, 2010 [revised 2013]; NIH-CDPO, 2000; 
Ziden et al., 2008).   
Method 
An extensive search of the literature focusing on osteoporosis, its etiology, 
societal and health outcomes published between 2000 – 2013 was conducted.  Databases 
searched included PubMed, CINAHL, Academic Search Complete/EBSCO, Medline, 
National Guideline Clearinghouse, Google Scholar, Primo Central/Ex-Libris, as well as 
references from articles and books.  In order to gather full text copies and guidelines, a 
Google web search was conducted. Articles published prior to 1999 were considered 
seminal and were authenticated from the extrapolated literature.  Further, expert opinion 
literature was reviewed and of note, the Primer on the Metabolic Bone Diseases and 
Disorders of Mineral Metabolism, eighth edition, published by The American Society for 
Bone and Mineral Research,  was utilized to obtain leading expert bone health 
researcher’s opinions (Rosen, 2013).  The term osteoporosis was searched in combination 
with epidemiology, definition, clinical practice guidelines, diagnosis and treatment, risk 
factors and assessment, cost analysis, nursing interventions, exercise, calcium, vitamin D, 
bisphosphonates, and estrogen. The search was limited to English, focused on the age 
71 
 
 
 
group of 50+ years, and utilized US practice guidelines addressing osteoporosis 
management.   
Critical appraisal of the literature followed the recommendations of nursing 
researchers  Polit and Beck (2008) evaluating for existence of research questions, 
hypotheses, study design, methods of sampling and data collection, and analysis.  
Systematic reviews were evaluated using the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA) method (Moher, Liberati, Tetzlaff, Altman, & 
The Prisma Group, 2009).   The search, when feasible, was limited to National Guideline 
Clearing House (2), professional guidelines (5), professional position statements (11), 
meta-analyses (1), systematic reviews (6), clinical trials (5), clinical cohort studies (21), 
epidemiological studies (6), reviews of literature (15), articles from peer-reviewed 
journals (57), professional texts (7), and government reports (19).  
Findings 
Over the past 20 years, clinical practice guidelines have evolved into sophisticated 
tools designed to guide clinical decision making, optimize efficiency and patient care by 
facilitating the translation of research to the bedside and serves as an excellent nursing 
resource.  These guidelines are statements that reflect a systematic review of evidence 
that examines the scientific quality of relevant literature assessing the risks and benefits 
for specific types of clinical care (Institute of Medicine of the National Academies, 
2011).  Their purpose is not to dictate patient care, but to provide healthcare professions 
with quality information to make informed clinical decisions which may be tailored to 
each distinctive patient.   
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Osteoporosis Management 
  The main goals in osteoporosis management are to accurately identify patients at 
increased risk for fracture and educate patients at every opportunity regarding disease 
process, prevention, and treatment options (McCloskey, 2009).  The nurse must be aware 
of the appropriate time in the lifespan to screen individuals for bone loss through health 
history, risk assessment, physical exam, tailored interventions and yearly follow up.  
 Menopausal transition has become the focus in bone health research, suggesting 
screening women prior to the age of 65.  It is thought that the greatest amount of bone 
loss occurs one year prior to the final menstrual period and the first two years after the 
final menstrual period (Lo, Burnett-Bowie, & Finkelstein, 2011).  The exact point in time 
is difficult to determine, however, because definitions of menopausal status lack clarity 
and vary individually.   Updated clinical practice guidelines address the need to consider 
screening perimenopausal women and men age 50-69 years with one osteoporosis risk 
factor  (Lim, Hoeksema, & Sherin, 2009; Michigan Quality Improvement Consortium 
[MQIC], 2014; North American Menopause Society [NAMS], 2010).  Also, some 
researchers believe that risk should be assessed in adolescence (Schettler & Gustafson, 
2004). A synthesis of five clinical practice guidelines can be found in Table 1.   
A disconnect between evidence-based practice and real-world clinical practice in 
diagnosing and preventing osteoporosis despite the great advancement in identifying and 
treating osteoporosis (Teng et al., 2009) presented in the literature,  however, 
improvement is needed in transferring these interventions into clinical settings (NOF, 
2010 [revised 2013]; Rojas-Fernandez, Lapane, MacKnight, & Howard, 2002; Warriner 
et al., 2009).  Actually, identification of osteoporosis was reported to be greater in older 
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adults, yet, treatment occurred more often in younger individuals (Giangregorio et al., 
2006). 
Giangregorio, Papaioannou, Cranney, Zytaruk, and Adachi (2006) in their 
systematic review of 35 studies that investigated osteoporosis treatment after 
experiencing a fragility fracture reported a little less than half were diagnosed with 
osteoporosis prior to fracture; and of those identified with osteoporosis, one third did not 
take calcium/vitamin D supplements or osteoporotic medications, the most common diet 
and medication interventions  Also reported, (Siris et al., 2001) of the National 
Osteoporosis Risk Assessment Study of women 50 years and older,  7% of the subjects, 
not previously diagnosed, met the criteria for osteoporosis and were not receiving 
treatment and 11% had a history of an osteoporotic related fracture retrospectively 
beginning at age 45.   
Once an individual has been screened and is identified at risk or with low BMD 
through risk assessment and/or BMD testing, the individual requires a detailed history 
and physical, diagnostic tests as to evaluate further for fracture risk and rule out other 
secondary causes for low BMD.  Through this work up, interventions can be 
implemented to modify risk factors, and initiate pharmacological treatment if appropriate 
to treat osteoporosis (NAMS, 2010). Therefore, enhancing the nurse’s knowledge about 
appropriate risk assessment, interventions and vigilant monitoring has potential to 
improve patient outcomes.   
Health History.  It is important to not consider a possible diagnosis of 
osteoporosis based solely upon a measurement of low bone mass.  Nurses should begin 
with a detailed health history.  The history should include obtaining information about 
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five major risk factors: calcium intake through diet history, alcohol and cigarette use, 
menarche history, medication review for drugs attributed to bone loss such as 
glucocorticoids, and sun exposure review (NOF, 2010 [revised 2013]; WHOSG, 2003).  
Screening. The National Osteoporosis Foundation (NOF) recommends that all 
post-menopausal women and men 50 years and older receive a comprehensive bone loss 
assessment employing a detailed history and physical, Bone Mineral Density (BMD) 
testing and vertebral imaging, if needed, and a calculation of the World Health 
Organization (WHO) 10-year Fracture Risk Assessment Tool (FRAX
®
) probability score 
(Lim et al., 2009), as well as fall risk assessment (NOF, 2010 [revised 2013]; NAMS, 
2010).  The University of Michigan practice guidelines recommend assessing for risk 
factors to perform the FRAX
©
 in all women at risk, then if needed, measure BMD if the 
10-year hip fracture risk score ≥ 9.3% (equivalent risk of a 65 year old women) (MQIC, 
2012 [revised 2014]).   
Many nurses are aware that the screening measurement of BMD alone is a strong 
predictor for fracture; however, it has low sensitivity because the majority of fractures 
occur in the diagnostic osteopoenic range (McCloskey, 2009).  The combination of BMD 
scores and clinical risk factors increases the discrimination value of predicting fracture 
risk (Kanis et al., 2007).  One tool that includes this combination is the FRAX
©
. This 
tool, typically used in men and women 65 years and older, has also been adopted 
internationally as a valid and sensitive for use in men and women age 40-50.  It is 
available in a desktop application and more information regarding the development and 
international utilization and endorsement of the FRAX can be found in Table 2.   It is 
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administered efficiently, requiring minimal training and is especially useful in 
communities where BMD testing is scarce (NOF, 2010 [revised 2013]).    
The FRAX
©
 tool identifies the most pertinent independent risk factors for fracture 
and bone loss:  prior fragility fracture, parental hip fracture history, tobacco use, history 
or use of long-term oral glucocorticoids, alcohol consumption ≥ to 3 units, and a 
diagnosis of Rheumatoid Arthritis. These factors are then calculated into an algorithm 
with the individual’s body mass index (McCloskey, 2009), as BMI is a significant risk 
factor for bone loss.   Currently, the tool is available in several languages through the 
website or downloaded at http://www.shef.ac.uk/FRAX   (World Health Organization, 
2012). 
In addition to using the FRAX, a multifactorial fall assessment is essential since 
the majority of osteoporotic-induced fractures occur due to falls.  Assessment should 
include an evaluation of orthostatic hypotension, muscle strength, gait and balance with 
use of adaptive aids, functional status, and home environment.  Further, an assessment for 
comorbidities known to increase risk such as a history of falls (strongest predictor), 
depression, syncope, arrhythmia, poor vision, and fear of falling should be included 
(Panel on Prevention of Falls in Older Persons & British Geriatrics, 2011). Lastly, 
performing a comprehensive pharmacology review to identify medications known to 
increase the risk of falling such as benzodiazepines, psychotropics, narcotic analgesics, 
and anticonvulsants is recommended (NOF, 2010 [revised 2013]; Panel on Prevention of 
Falls in Older Persons & British Geriatrics, 2011).    
Physical Exam.  Height loss of 1.5 inches or greater indicates the strong 
possibility for vertebral fracture and requires BMD testing and vertebral imaging (NOF, 
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2010 [revised 2013]; NAMS, 2010). Chronic and acute back pain with percussive 
tenderness over the thoracic spine 11-12 and first lumbar, the most common sites for 
vertebral fracture, should be assessed for the presence of acute vertebral fractures 
((NAMS, 2010; Siminoski, Warshawski, Jen, & Lee, 2006). In addition, weight should be 
monitored for changes in body mass index as this will affect interpretation of future BMD 
values and weight loss over time has been associated with bone loss (NAMS, 2010).  
Although kyphosis, height loss, and back pain can occur without the presence of 
osteoporosis, such conditions call for further evaluation and consideration of the presence 
of osteoporosis, thus being accurate in obtaining height measurements become critical.  
In addition, entering data into the electronic medical record can enhance sharing within a 
healthcare system. Such a strategy would alert nurses to be vigilant when future hospital 
admission occur.  
Diagnostic Tests.  It is important that nurses are familiar with the most common 
tests. A primary care provider would then order BMD testing, as well as routine 
laboratory tests (see Table 3) (Ardawi, Al-Kadi, Rouzi, & Qari, 2011; Dawson-Hughes, 
Harris, Ceglia, & Palermo, 2014; NOF, 2010 [revised 2013]; NAMS, 2010; WHOSG, 
2003)  These laboratory values are useful to rule out secondary causes of bone loss such 
as anemia, multiple myeloma, GI malabsorption, vitamin D deficiency, 
hyperparathyroidism, renal failure, and hypothyroidism.  
Tailored Interventions.  Nurses have the ability to initiate interventions to 
prevent falls, provide patient education to engage health promotion, evaluate medication 
interactions, improve osteoporosis medication compliance and provide yearly bone loss 
monitoring.  Interventions are aimed to impact modifiable bone loss risk factors.  
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However, some risk factors such as not reaching optimal peak bone mass by the end of 
adolescence, aging, sun exposure, genetics, and heredity are non-modifiable.  Others can 
be modified by nutrition, lifestyle choices, body mass index, falls, history of prior 
fracture, low bone density, muscle strength, and frailty (NIH-CDPO, 2001; Suh & Lyles, 
2003; WHOSG, 2003).  
Fall prevention is one of the most important interventions to implement. 
Multicomponent interventions, such as muscle strengthening, balance and weight-bearing  
exercises, referrals to multiple resources such as occupational and physical therapy, home 
care and primary care, and vitamin D supplementation are most effective (Chang et al., 
2004).  Specific examples are provided in Table 4.   Nurses have the opportunity through 
patient education to inform women about bone health early in menopause transition.  
Patient education could be implemented using the resources from the NOF (National 
Osteoporosis Foundation:  Bone Source, 2013). These materials are created to provide 
osteoporosis facts, prevention, fitness programs, as well medication information.  Further, 
electronic medical record programs incorporate patient education topics into the 
outpatient visit summary, taken home by the patient.  This may occur in the outpatient 
setting or during an inpatient admission.   
The most common interventions in the prevention and maintenance of BMD are 
overall lifestyle changes to diet, exercise routines, and lifestyle change. Dietary 
modifications target sufficient calcium/vitamin D and protein intake, in addition to a 
weight and non-weight bearing exercise programs, smoking cessation, and moderate 
alcohol consumption (Carter, Kannus, & Khan, 2001; Kannus, Uusi-Rasi, Palvanen, & 
Parkkari, 2005; NAMS, 2010).   Further, nurses have the ability to assess patient’s needs 
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and refer for physical therapy and nutritional evaluation and gerontological clinical nurse 
specialist consultation. 
Age-related changes of the gastrointestinal tract, such as malabsorption and 
changes in gastric PH can impair calcium and vitamin D absorption (Perez-Lopez et al., 
2012) and some patients require supplementation.  Bone stores 99% of the body’s 
calcium and if intake of calcium is inadequate, calcium is leached from the bones to 
maintain serum calcium homeostasis.  Vitamin D is essential for calcium absorption, as 
well as cardiac and skeletal muscle function.  The best sources for calcium and vitamin D 
absorption are found in a patient’s diet (see Table 5).  Adult calcium intake is 500-700mg 
a day (NOF, 2010 [revised 2013]); therefore, it is important to evaluate the patient’s diet 
history for calcium intake.  General supplementation recommendations are provided in 
Table 5.   
Weight bearing and strengthening exercises are instrumental in preventing falls, 
but also have a known physiological response that improves and preserves bone health 
((National Guideline Clearinghouse [NGC], 2010 [revised 2012]; NOF, 2010 [revised 
2013]).   Implementing these fall prevention weight bearing interventions will achieve 
this positive bone remodeling result (NAMS, 2010; Howe et al., 2011). Postmenopausal 
women who exercised lost 0.85% and 1.03% less bone at the spine and hip, respectively, 
and those who used combinations of weight and strengthening exercise regimes averaged 
3.2% less bone loss than women who did not exercise (Howe et al., 2011). 
The two most important lifestyle changes the nurse can recommend to patients are 
to quit smoking and to consume alcohol moderately.  Smokers lose bone more rapidly, 
reach menopause two years earlier, and have higher rates of fracture than non-smokers 
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(NAMS, 2010).  Low to moderate alcohol consumption [one drink per day or >3 drinks 
per week] has been reported to have protective of bone health effects (Sommer et al., 
2013).  However, women who consume three or more drinks a day are associated with 
low BMD, falls and may indicate alcoholism (NOF, 2010 [revised 2013]). 
Since there are multiple medications to treat osteoporosis, knowledgeable nurses 
are critical to guide the administration and compliance to medication therapy.  There are 
several medications to inhibit bone resorption and stimulate bone formation 
(Kleerekoper, 2008) (see Table 6).  Post-menopausal women who have experienced a hip 
or vertebral facture have a T-score ≤ -2.5, and are osteopenic with a FRAX score of ≥ 
20% or Hip FRAX score of ≥ 3% should be pharmacologically treated for osteoporosis 
(NGCH, 2010 [revised 2012]; NOF, 2010 [revised 2013]; NAMS, 2010).   
Hormone replacement therapy (estrogen-progesterone) and Selective Estrogen 
Receptor Modulators (SERMs) are useful to preserve bone and prevent fracture in the 
beginning of the post-menopausal period; however, patients need to be informed 
regarding the risk factors of developing breast cancer (Chlebowski et al., 2003), deep 
vein thrombosis, and stoke (NAMS, 2010).  Bisphosphonates are the first-line treatment 
to inhibiting bone loss by slowing the osteoclast activity and are reported to decrease 
vertebral fractures 40-70% and hip 15-35% (NAMS, 2010).   Bisphosphonates are 
metabolized through the renal system; therefore, renal function must be evaluated prior to 
initiating therapy and nurses must assist monitoring serum creatinine levels for signs of 
renal failure (see Table 6).  The most common side effect is gastrointestinal upset, 
because the medication must be taken on an empty stomach sitting upright for 30-60 
minutes.  Further, suppressing bone turnover with long term bisphosphonate therapy may 
80 
 
 
 
attribute to bone brittleness, however this  has been reported in small case studies and still 
remains controversial (Neviaser, Lane, Lenart, Edobor-Osula, & Lorich, 2008; NAMS, 
2010). Newer medications such as parathyroid hormone and Denosumab (Prolia or 
Xgeva), a Receptor Activator of Nuclear Factor kappa-B (RANK) Ligand (RANKL) 
Inhibitor, are used in high risk patients for fracture due to breast or prostate cancer (Food 
and Drug Administration, 2002, 2013a, 2013b, 2013c, 2013d). (see Table 6) 
Yearly height and weight measurement, along with repeating BMD testing,  are 
recommended every 2-5 years to monitor an individual’s response to pharmacologic 
treatment and 1-2 years if not treated (Lim et al., 2009; NAMS, 2010; ).  Also, a primary 
care provider may wish to order bone turnover markers (BTMs) measured in 3-6 months 
after initiating medication management.  These are reported to be useful in monitoring 
response to treatment or evaluating treatment adherence (NOF, 2010 [revised 2013]).  
However, clinicians must use caution with interpretation of results because of the lack of 
test assay standardization, diet influences, and variation in day-to-day values (Lim et al., 
2009; Miller et al., 1999; NGC, 2010 [revised 2011]; NAMS, 2010).  Lastly, fall risk 
assessment should be addressed yearly.   
Nursing Implications 
Implications for practice and policy can be drawn from the literature, even as new 
original research questions are proposed to determine cellular bone loss causality and 
potential points in the lifespan to intervene and preserve bone health.  A nurse driven 
comprehensive lifespan bone health program may be beneficial to preserve and treat bone 
loss.  Bone remodeling occurs throughout the lifespan and has a specific systematic 
process in reabsorbing and replacing bone. It is important to understand how crucial to 
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optimize peak bone mass early in the lifespan because individuals whom have low peak 
bone mass are at higher risk for facture and osteoporosis.  Once peak bone mass is 
reached, it must then be preserved throughout the lifespan (Bonjour et al., 1997; Kannus 
et al., 2005; Mahon et al., 2010; Weaver & Heaney, 2008).  Therefore, interventions 
should be implemented in the following areas of practice: beginning with maternal-child 
health, adolescent, and proceeding to perimenopause, menopause and postmenopause.  
Practice  
Nurses have the ability to impact osteoporosis screening, management, and 
medication adherence through patient education in both inpatient and outpatient settings.  
Bone loss is a multifaceted healthcare concern.  Ultimately, research is needed to create 
comprehensive intervention programs that are collectively implemented throughout a 
health care system.   
For example, (Majumdar et al., 2007) designed a Canadian nurse case 
management intervention study.  They divided patients into two groups, usual care, and 
nurse case management.  Usual care received osteoporosis, fall prevention, and dietary 
patient education materials and were encouraged to discuss these materials with their 
caregivers and/or primary care provider.  The intervention group was provided one-on-
one counseling with a nurse case manager.  Here they discussed the risks and benefits of 
bisphosphonate therapy, arranged BMD testing, and if needed obtained prescriptions 
from their primary care provider. This program was implemented throughout three 
hospital health care systems and was found to be cost-effective, with a cost of $50 per 
patient and requiring approximately 70 minutes of case management.  Osteoporosis 
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treatment was significantly improved in the nurse case manager group over the standard 
care group (67% vs. 26%) (Majumdar et al., 2007).  
Further, Australian researchers created a patient education nurse driven program 
that provided post-fracture information.  One group received a patient education letter 
and the other group received in addition to the letter free BMD testing (Bliuc, Eisman, & 
Center, 2006).  A significant increase in osteoporosis workup was found in those who 
received a letter and free BMD, but no effect in treatment rates (6%) was seen.  Further, 
23% of patients contacted their physician, and of these only 25% were recommended 
treatment.  Comparing these two studies results, one-to-one patient education and case 
management is a key to improving osteoporosis management outcomes.   
These above mentioned intervention programs can be replicated in the outpatient 
setting.  Anticipating future shortages of primary care providers, nurses will be 
responsible to care for those at risk for bone loss.  The best clinical setting for generalist 
nurses to impact the negative outcomes for osteoporosis are in outpatient care settings 
because approximately 994 million patients are seen annually (Hsiao, Cherry, Beatty, & 
Rechtsteiner, 2010).  Most concerning is the lack of registered nurses working in this 
setting.   
Over the past five years, 2008-2013, only (9%) and (7%) of registered nurses 
(RNs) were employed in the outpatient clinics compared to (62%) and (60%) of medical 
assistants, respectively (Bureau of Labor Statistics, 2008a, 2008b, 2013a, 2013b).  Of 
concern is the report from the American Academy of Ambulatory Care (2012) that RNs 
are performing below their scope of practice while unlicensed assistive personnel are 
performing above their scope of practice. Since 2008, the US has undergone a major 
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change in health care delivery, mainly the enactment of the Healthcare Affordability Act, 
resulting in shifting services from the inpatient to outpatient settings.  In 2013, 58% of 
RNs worked in inpatient settings; therefore, it is evident that there is a significant 
difference in the access to registered nurses for the majority of the patient population 
(Bureau of Labor Statistics, 2013a). 
Due to perceived cost savings, hospital systems choose to employ more 
unlicensed personal than registered nurses, thus providing “nursing care” through 
numerous types of licensed and unlicensed nursing staff.  Role confusion exists because 
of lacking standardization or quality control which may impact negatively patient safety. 
Use of RNs in outpatient settings has demonstrated improvement in quality patient 
outcomes and safety, patient satisfaction, reducing adverse events and 
hospital/emergency room visits (American Academy of Ambulatory Care, 2012; Haas, 
2008). Critical to improving osteoporosis outcomes is recognition that educated RNs are 
needed not only to provide bone health risk assessment and patient education in the post-
menopausal population, but across the lifespan.  
With this said, nurses in outpatient clinic settings, can develop a comprehensive 
bone health educational programs that provides intervention at the four points of the 
lifespan:  maternal/infant health, pediatrics, peri-menopause/menopause (women’s 
health) and post-menopause (gerontology).  Each point in the life span has implications 
for nursing practice.  Much is known about post-menopausal bone loss; however, 
researchers are beginning to study other points in the lifespan. This is evident by the 
addition of approximately 30 more chapters added to the Primer on the Metabolic Bone 
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Diseases and Disorders of Mineral Metabolism, eighth edition, providing new advances 
in basic bone biology and clinical osteoporosis management (Rosen, 2013).  
Maternal/Infant. No discussion is complete without recognizing the importance 
of early bone health assessment.  The tenets of fetal bone development are beneficial to 
later in life bone health.  The body of literature concerning maternal/infant calcium and 
vitamin D status is developing.  It is known that calcium demands are greater during 
pregnancy and lactation, instrumental to fetal growth, and commonly prescribed if a 
women’s intake is < 500 mg/day, but the use of vitamin D supplementation remains 
vague.  However, there is concern that the physiological demands of pregnancy for 
calcium and vitamin D are not being met by the use of prenatal vitamins and require 
assessment during prenatal visits (Hacker, Fung, & King, 2012).   
Vitamin D deficiency and insufficiency is prevalent in western and non-western 
pregnant women. It is associated with impairing fetal bone development, low birth 
weight, and poor childhood growth (Cooper, Javaid, Westlake, Harvey, & Dennison, 
2005; De-Regil, Palacios, Ansary, Kulier, & Pena-Rosas, 2012; Mahon et al., 2010). 
However, due to limited quality studies,  recommendations to use vitamin D 
supplementation remains questionable as there is inconsistent results regarding  efficacy 
and safety for use during pregnancy (De-Regil et al., 2012), this topic continues to be 
actively researched today as a worthwhile intervention. 
Vitamin D deficiency, common in the newborn population, is found more often in 
African American newborns.  There is concern regarding the vitamin D contents of breast 
milk, which is dependent on the mother’s vitamin D status, and infant formulas.  Both 
provide an adequate intake of essential vitamins and minerals but not necessarily enough 
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vitamin D (Weaver & Heaney, 2008).  Of infants supplemented with 400IU of vitamin D 
daily, an increase in mean vitamin D measurement was found but not to optimal newborn 
levels (Hanson, Armas, Lyden, & Anderson-Berry, 2011).  Further research is required to 
provide clear recommendations for supplementing vitamin D in pregnancy and newborns.   
Pediatrics.  Pediatric researchers regard bone loss as a “pediatric disease with 
geriatric consequences” (Randi-Schoenfeld, Ng, Henderson, & WU; 2010 p. 104 ) and 
believe evaluation should begin in adolescence (Schettler & Gustafson, 2004).  High 
calcium intake in prepubertal girls has been associated with increased Peak Bone Mass 
(PBM) accrual, and adolescence milk consumption positively affects postmenopausal 
BMD.   Because 90% of PBM is attained by age 18 (NIH Osteoporosis and Related Bone 
Diseases ~ National Resource Center, 2009) preventive medicine (Randi Schoenfeld, Ng, 
Henderson, & Wu, 2010) and physical therapist researchers (Magee, Stuberg, & 
Schmutte, 2008) have engaged to develop adolescent educational interventions.  An 
internet based educational program significantly improved knowledge, self-efficacy, and 
calcium consumption, but was not as effective to impact life-style change (Randi 
Schoenfeld et al., 2010).   
Nurses can assess calcium and vitamin D intake, provide nutritional guidelines, 
present adolescent health patient education, and monitor status throughout adolescence.  
Further, evaluation for specific adolescent risk factors associated with impairing PBM; 
anorexia nervosa, exercise-induced amenorrhea, use of oral contraceptives, poor 
adolescent physical activity, and cigarette smoking should be added to the electronic 
medical record (Anderson, Chad, & Spink, 2005; Krall & Dawson-Hughes, 1993; Martin 
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et al., 2004; Randi-Schoenfeld et al., 2010; Schettler & Gustafson, 2004; WHOSG, 
2003).  
Perimenopause.  This is one of the most significant gaps in the literature: 
identifying menopausal transition, specifically perimenopause.  It is alarming that only 
one preventive guideline recommends screening all patients with potential risk, therefore 
peri-menopausal (NGC, 2010 [revised 2012]).  However, others screen peri-menopausal 
women only if they present with risk factors, most likely a fracture (NGC, 2010 [revised 
2012]; NOF, 2010 [revised 2013]; NAMS, 2010).  
Bone loss is reported to be stable during pre-menopause, but accelerates 
significantly in late perimenopause (Finkelstein et al., 2008).  In the 5-7 year span of 
perimenopause and menopause, approximately, 12% of total bone mass is lost; which is 
equal to one T-score (-1 SD) of measured bone density by DEXA, and corresponds to a 
diagnosis of osteopenia (Armas & Recker, 2012; Recker, Lappe, Davies, & Heaney, 
2000).  Most bone loss studies and interventions have focused on post-menopausal 
women; however, menopausal status definitions lack clarity (Lo et al., 2011).  Therefore, 
menopausal transition has come into the forefront of the bone health research and may be 
useful to identify when to screen women for bone loss.   
 The stage of menopausal transition is not evaluated regularly but is defined as 
premenopausal; regular menstrual cycles between 26-32 days, peri-menopausal; cycles 
longer than 35 days, irregularity > 5 days between cycles or hot flashes > 5 days per 
cycle, and postmenopausal; > one year between cycles.  In a nine year prospective study, 
trabecular bone loss in midlife women averaged 3.2% per year, a 28.8 % total loss of 
bone with the greatest percentage of loss occurred between years 2-6, accelerating in late 
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peri-menopause (Seifert-Klauss et al., 2012). Researchers in search of bio-markers for 
perimenopause found accelerated bone loss was associated with increased gonadotropin 
levels, follicle stimulating hormone, luteinizing hormone and 17 β –estradiol, and may be 
helpful to determine a women’s menopausal stage (Seifert-Klauss et al., 2012) (see Table 
7).  The above definitions and values were successfully supported by study data to 
determine pre and post menopause (Seifert-Klauss et al., 2012), but the use of clinical 
bone markers, osteocalcin, bone-specific alkaline phosphatase, and c-terminal telopeptide 
cross-linked collagen type I,  were not able to operationally define the perimenopausal 
state.  However, during menopausal transition, bone markers were the greatest.  These 
menopausal transition indicators could be incorporated into a women’s yearly 
gynecological exam assessed by nursing.   The question remains whether bone health 
screening occurs too late in the life-span.  
Post-Menopause.  The majority of post-menopausal women more than likely will 
have experienced some degree of bone loss (Reid, 2013).  However, it still remains a 
significantly under diagnosed condition as osteopenia presents asymptomatically (Teng et 
al., 2009; USDHHS, 2004).  Because the greatest amount of bone lost early in 
menopausal transition is trabecular bone, bone loss is not discovered until a patient 
presents with back pain as a result of a vertebral facture (Rachner, Khosla, & Hofbauer, 
2012).   
Nursing is an active member of the multidisciplinary team positioned to assist 
patients in understanding bone loss.  Through risk and clinical assessment, attentive 
monitoring, will assist to improve osteoporosis health outcomes by early identification 
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and implementing timely interventions, thus in turn precludes fractures and mortality, 
improving the quality life of older adults and averting the transition into frailty. 
Policy 
Policy implications are twofold.  First, in order to be effective, hospital systems 
must employ more registered nursed in their clinic systems to provide assessment and 
second, to provide research data to support screening perimenopausal women beginning 
at age 45.  Exploring the literature, specifically, employment of outpatient registered 
nurses was positively associated with cost-savings and patient outcomes.  Specific 
articles written to reflect policy implications are lacking; found were the political agenda 
and position statements formulated by the American Academy of Ambulatory Care 
Nursing website (American Academy of Ambulatory Care, 2014).   
Perimenopause has been a focus in the literature since the mid-1990s.  However, 
the prevention and screening for osteopenia or evaluating perimenopausal women for 
bone loss is lacking.  The phases of menopausal transition are becoming more 
understood, but lack of research supporting early screening of women without risk factors 
is void in the literature.  Therefore, it is uncertain with limited statistical evidence that 
practice guidelines will change in the near future, but active programs of research exist.   
The University of Michigan successfully has investigated follicle-stimulating 
hormone (FSH) levels in 629 women, aged 24-44 for 14 years, and identified four 
menopausal transitions with eight chronological aging periods occurring between ages 
26-60 years (Sowers et al., 2008).  Further they found, spine and femoral neck bone loss 
accelerated at FSH stage 3, defined as FSH levels of 34 mIU/ml corresponding 2-3 years 
before their final menstrual period (FMP).  Bone loss continued into FSH stage 4 and 
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they concluded that accelerated bone loss was associated with 2 years prior and 2 years 
after their FMP (Sowers et al., 2010).  
In 2012, the University of Michigan Management and Prevention of Osteoporosis 
practice guidelines recommended the inclusion that all men and women patients having 
clinical risk factors for  bone loss to calculate a FRAX
© 
score.  Based on this research, 
perimenopausal women  would be included (MQIC, 2012 [revised 2014]) and then if 
needed, measure BMD if the 10-year hip fracture risk score ≥ 9.3% (equivalent risk of a 
65 year old women) (Lash, Van Harrison, McCort, Nicholson, & Velez, 2013). 
Implementing this tool is non-invasive and quickly administered and has the potential to 
be included routinely during yearly visits and potentially identify those not outwardly at 
risk with beginning stages of bone loss.   
Conclusion 
Nurses are active members of the multidisciplinary team positioned to assist 
patients in understanding bone loss.  Osteoporosis and osteopenia are significantly 
underdiagnosed and usually are not assessed until after a fracture occurs.  Osteoporosis 
research over the past two decades has been extensive.  However, only a modest impact 
has been show in decreasing fracture rates; thus, the societal economic impact to treat 
remains high and will only increase as the population ages.  Nurses have an opportunity 
through thoughtful risk and clinical assessment and attentive monitoring, to improve 
osteoporosis health outcomes.  Through early identification of bone loss, implementing 
timely interventions that improve or prevent bone loss will in turn preclude fractures and 
mortality, and ultimately improve the quality life of older adults and averting the 
transition into frailty.  
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Tables 
Table 1  
Osteoporosis Management Practice Guideline Synthesis 
  WHO (2003) ACPM (2009) NAMS (2010) MQIC (2012[revised 2014]) NOF (2013) 
Risk  
Assessment 
Screen  No recommendation ♂/♀ ≥ 50 ♀ ≥ 65  All at Risk PM ♂ & ♀ ≥ 50  
Use FRAX - + + Consider Peri-M +  PM PM ♂ & ♀ ≥ 50  
Fall Risk + - + + + 
Clinical  
Evaluation 
DEXA Preferred +  + + + + 
   Age None Stated All ♀ ≥ 65 
♂ ≥ 70 
All ♀ ≥ 65  
♂ ≥ 70 
White ♀≥ 65  
♀/♂ FRAX score > 9.3%  
♀ ≥ 65  
♂ ≥ 70  
    Order DEXA  
With Risk Factor 
 
Any of below 
 
 ♀/♂ 50-69 
 
♀ ≥ 50 
 
+  
 
♂ & ♀ 50-69 
       Fx/ Fragility Fx + + ♀ ≥ 50 + ♂ & ♀ after 50 
       2
nd Causes  + + + PM  + + 
       Peri-menopause Premature Premature Consider Consider No-consider with risk 
       Steroid use 6 months > 3 months + + 3 months 
       X-ray Osteopenia Consider w/risk + - - - 
       Low BMI + + + + + 
       Maternal hx of  hip fx + - Parental 1
st o Relative ≥ 50 Parental 
       Kyphosis-Height Loss + - + + + 
       Rheumatoid Arthritis  - + + + + 
       Alcohol use >  2 day - + + ≥ 3 day + 
       Smoker + + + + + 
 Adolescent Screen - - - - No 
 Vertebral Imaging - - + Only Assess Height yearly + 
 R/O Secondary Causes + - + + + 
 Labs  -    
   CBC, CMP, TSH + cortisol - +  - PTH, Urine: cortisol, 
histamine, protein 
electrophoresis 
   Serum 25(OH) D  - - +  + 
   Biomarker + Limited utility + ? Predict Fx Risk 
Diagnosis WHO Definition + + + FRAX >20% + 
Interventions Age to Implement - - - All PM  & ♂ 50 ≥ 
 Advise Diet +  + -  
  Calcium: mg/day, Age        
      
      Children-Adolescence 
Elderly 
 
No 
1200 
♀/♂ ≥50 
- 
1500 
♀ ≥ 50 
- 
1,200 
 ♂ & ♀ 
- 
1,000,  ♂ 50- 70   
1,200 , ♀ 51 ≥ ♂ 71 ≥ 
- 
  Vitamin D:  IU/ daily, Age 400-800  
Elderly 
800-1,000 
♀/♂ ≥50 
800-1,000 
♂ & ♀ 
800-1,000  800-1,000, PRN in 
♂ & ♀ ≥50 
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  WHO (2003) ACPM (2009) NAMS (2010) MQIC (2012) NOF (2013) 
 Exercise       
   Weight Bearing + + + + + 
   Muscle Strengthening + - + + + 
   Balance Training- PT/OT     + 
   Adolescence + - - - + 
 Fall Prevention + - + + + 
 Lifestyle      
    Patient Education + + ? ? + 
    Smoking/Alcohol Cessation + + + + + 
Medication Treat      
   w/ Hip or Vertebral Fx - - + PM + + 
   T-Score ≤ -2.5    + + + PM + + Includes Lumbar 
 
 
  Osteopenia PM 
  Osteopenia and  
    FRAX score ≥ 20% 
        OR  Hip-≥ 3% 
Consider 
- 
 
- + 
+ 
 
 
Consider 
+ 
♀ & ♂ ≥50 
+ 
   Steroid Use & T-Score ≤ -1.0 - - - + - 
                            Duration - unknown - - 3 – 5 years 
 Medication Preference Counsel HRT 
Consider 
SERM 
Bisphosphonat
es 
*Bisphosphonates 
*Estrogen 
*Raloxifene & 
    Teriparatide  
 
 
Bisphosphonates  
SERM Raloxifene  
   in younger PM  
ET/EPT early PM 
Teriparatide PM   
    high risk for fx 
Calcitonin NOT 
   first- line treatment 
Use Generic 
Steroids:  Use 
Bisphosphonates 
Men:  Alendronate 
Clinician Choice 
Monitoring Repeat DEXA - 2 years 2-5 years/untreated 
1-2 years/treated 
Clinical Changes 
If normal 
Insufficient evidence when 
to repeat 
2-5 years 
 Height/BMI + - Yearly Yearly + 
 Fall Risk - - Yearly - + 
 Biomarkers  - Use to monitor 
Response/Adherence 
No - 3-6 months, Monitor 
Response /Adherence 
WHO = World Health Organization, ACPM = American College of Preventive Medicine, NAMS = North American Menopause Society, MQIC = Michigan Quality Improvement 
Consortium, NOF = National Osteoporosis Society 
FRAX = Fracture Risk Assessment Tool, ♂ = Female, ♀ = Male, Peri-M = Perimenopausal, PM = Post-Menopausal, FX= fracture, HX = History 
CBC = Complete Blood Count, CMP = Complete Metabolic Panel, TSH = Thyroid Stimulating Hormone, PTH = Parathyroid Hormone 
PRN = as needed, PT/OT = Physical – Occupational Therapy, BMI = Body Mass Index, DEXA = dual energy x-ray absorptiometry, SERM = Selective estrogen receptor 
modulators, ET/EPT = Estrogen/Estrogen-Progesterone Therapy, HRT = Hormone Replacement Therapy 
+ = guideline recommends, - = absent in guideline 
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Table 2 
Osteoporosis Management Resources 
Organization Link Resources 
Who Fracture Risk Assessment 
Tool 
www.shef.ac.uk/FRAX/ 
 
Desktop application 
iPhone© application 
Web Version 3.8 
 
International Osteoporosis 
National Osteoporosis Foundation 
Japan Osteoporosis Foundation 
www.iofbonehealth.org 
www.nof.org 
www.jpof.or.jp 
 
Management 
Practice Guidelines 
Data & Publications 
Patient Education Materials 
 
The European Society for Clinical  
and Economic Aspects of  
Osteoporosis and Osteoarthritis  
www.exceo.org 
 
Publications 
Reports 
National Guideline Clearing House www.guideline.gov 
search/search.aspx?term= 
osteoporosis 
162 Reported Osteoporosis 
Practice Guidelines 
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Table 3 
   Baseline Laboratory Tests for Osteoporosis 
 
        Sources:  Clinical Laboratory Reference, 2013; Jacobs-Kosmin, 2013; NOF, 2010[revise 
           2013] 
        CBC = Complete Blood Count, HCT=Hematocrit, HG=Hemoglobin, PLT= Platelets,  
           WBC= White Blood Count, BMP= Basic Metabolic Panel, CA=Calcium, MG=Magnesium,  
          CRT=Creatinine, TSH- Thyroid-Simulation Hormone  ALT-Alanine Aminotransferase,  
         AST=Aspartate Aminotransferase, 25(OH)D=Serum 25-Hydroxyvitamin D   
  
Baseline Labs Disorder Reference Range 
CBC 
 
 
 
 
 
Serum Chemistries 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TSH 
 
 
Liver Function 
Tests 
 
Serum 25-
Hydroxyvitamin D  
Low HCT/HG: Anemia, Sickle Cell, Multiple 
Myeloma, Alcohol Abuse 
 
 
 
 
Hypercalcemia:  Malignancy or 
Hyperparathyroidism 
 
Hypocalcemia:  absorption of calcium from 
bone, GI Malabsorption  
 
Low Magnesium:  alters calcium absorption 
and metabolism 
 
Low Creatinine:  associated with increased 
hyperparathyroidism   
 
Elevated Creatinine:  Multiple Myeloma, Renal 
failure 
 
Elevated TSH:  Hypothyroidism  
 
 
Elevated ALT/AST:  Alcohol Abuse, Liver 
Disease 
 
 
Low values indicates Vitamin D Deficiency 
HCT   35-52 % 
HG    12-18 g/dL 
PLT   150-450 
10
3
/mm
3
 
WBC  4-11 10
3
/mm
3 
 
CA     8.6-10.2 
mg/dL 
 
 
 
 
MG     1.6-2.6 
mEq/dL 
 
CRT   0.6-1.3 
mg/dL 
 
 
 
 
TSH  0.3-3.0  
mIU/L 
 
ALT  10-40 IU/L 
AST  10-34 IU/L 
 
25(OH)D  30ng/mL   
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Table 4 
   Fall Prevention 
            AGS = American Geriatrics Society 
  
Intervention Component  
Muscle Strengthening  
 
 
 
 
 
 
Balance 
 
 
 
 
Weight Bearing Exercise 
 
 
 
 
 
 
Referrals 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Diet 
Core & Lower Extremities: In home program 
 Ankle cuff weights 3 times a week:  2-5 lbs., 2 sets of 10 repetitions 
2 times a day for 10-20 min.(Gardner et al., 2001)  
 LiFE in-home exercise program; set of integrated balance and 
strength train exercises integrated into activities of daily living 
(Clemson et al., 2012)   
 
 Walking; tandem; on toes-heels, backwards, sideways 
 Turning Around, Stair Climbing, Stepping & Picking Up Objects, 
Sit to Stand 
          (Campbell et al.,1997; Clemson et al., 2012; Gardner et al., 2001) 
 
 TaiChi (Bischoff-Ferrari, 2013) 
 Dancing (Howe, Rochester, Neil, Skelton, & Ballinger, 2011) 
 Yoga (Tiedemann et al., 2013) 
 Walking-Jogging; 30 min- three times a week  Increase 5 min. 
per week until total of 30 min  (Gardner et al., 2001; Bischoff-
Ferrari, 2013)  (Heike A. Bischoff-Ferrari, 2013)  (Heike A. 
Bischoff-Ferrari, 2013)  (Heike A. Bischoff-Ferrari, 2013) (Heike 
A. Bischoff-Ferrari, 2013)      
 
Optometry; cataract evaluation (Bischoff-Ferrari, 2013) 
Primary Care 
    Neuropathy-Arthritis Evaluation 
    Medication review; Beers List (AGS 2012 Beers Criteria Update 
     Expert Panel, 2012) 
Community Fall Prevention Programs  
Home Health: NOF, 2010[revised 2013] 
      Home Assessment; remove obstacles, throw rugs, install bathroom 
      assistive devices 
      Footwear Evaluation; use athletic shoes  (Menz et al., 2006) 
      Functional Assessment; include fear of falling evaluation 
      Homemaker Services 
      PT- OT; assistive device evaluation,  
      Lifeline Monitoring 
 
Vitamin D Supplementation-800-1000 IU daily (Bischoff-Ferrari, 2013) 
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Table 5 
Bone Loss Prevention 
 Sources: Lim et al., 2009; NOF, 2010 [revised 2013]; NAMS, 2010; Office of Dietary Supplements:  
National   Institutes of Health, 2013, 2012; National Research Council, 2011 
 
(National Research Council, 2011; Office of Dietary Supplements:  National Institutes of Health, 2013; Office of Dietary 
Supplements:  National Institutes of Health, 2012)(National Research Council, 2011; Office of Dietary Supplements:  
National Institutes of Health, 2013; Office of Dietary Supplements:  National Institutes of Health, 2012)(National Research 
Council, 2011; Office of Dietary Supplements:  National Institutes of Health, 2013; Office of Dietary Supplements:  
National Institutes of Health, 2012)(National Research Council, 2011; Office of Dietary Supplements:  National Institutes of 
Health, 2013; Office of Dietary Supplements:  National Institutes of Health, 2012) 
  
Intervention Component  
Diet  Modification 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Weight Bearing 
Exercise 
 
Medication 
Management 
 
Lifestyle Modification 
 
 
 
Monitoring 
Diet History:   
 Calcium rich foods: milk, cheese,  yogurt, fortified juices 
 Vitamin D rich foods: fish (salmon-tuna), fish liver oils, fortified 
milk and cereals 
 Moderate sun exposure 
 
Supplementation:   
 Institutes of Medicine 
                Men aged 50-70- 1000 mg of calcium daily 
                Women >  51 & Men > 7- 1,200 mg calcium daily 
 
 Collective Guideline Recommendations 
                Women & men age 50 and older: 1200-1500mg of calcium  
                daily, 800-1,00 IU  Vitamin   D daily 
 
 
Walking-Jogging; 30 min- three times a week 
 
 
Administration and Side Effect Profile See Table 5 
 
 
Smoking cessation 
Moderate alcohol consumption 
Healthy basal metabolic index  
 
Yearly follow up:  height-weight, BMD 2-5 years, Fall Risk 
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Table 6 
Osteoporosis Medications 
Sources:  Chlebowski et al., 2003; FDA, 2002, 2013a, 2013b, 2013c, 2013d, 2013e; Kleerekoper, 
2008  
Medication Administration/Monitoring Common Side Effects 
Hormone Replacement 
   Selective estrogen receptor modulators 
EVISTA 
 
 
Bisphosphonates: 
        Alendronate (Fosamax) 
        Risedronate (Actonel) 
 
        Boniva 
 
 
 
 
 
          Zoledronic Acid (Reclast) 
 
 
 
Parathyroid:   
          Teriparatide (Forteo) 
 
 
 
 
 
 
 
 
 
 
Receptor Activator of Nuclear Factor 
kappa-B (RANK) Ligand (RANKL) 
Inhibitor: 
            Denosumab (Prolia/Xgeva)  
 
 
 
 
Prescribed Post-Menopausal 
 
 
 
 
Take on empty stomach with 8oz. of 
water sitting upright for 30 min.    
 
 
Oral: Take on empty stomach with 8oz. 
         of water sitting upright for 60 min 
 
IV:  administer over 15-30 sec every 3  
       months 
 
 
IV:  administer over 15 min every 1-2 
        years 
Pre-treat with acetaminophen 
 
 
Use in high risk for fracture and  
       secondary bone loss  
Administer subcutaneously daily  
Do not stop abruptly- 
        rapid bone loss ensues   
Do not use in patients with: 
   Skeletal radiation treatment 
   Bone metastases 
   Hyperkalemia 
   History of skeletal cancers 
 
Use high risk for fracture with bone loss 
due to breast or prostate cancer: 
    Bone metastases from solid tumors or 
    giant cell tumor of bone 
Administered subcutaneously every six 
    months 
Monitor for hypocalcaemia, cellulitis, 
    rash, Osteonecrosis of the Jaw (ONJ) 
    and atypical femur fractures 
Do not stop abruptly-rapid bone loss 
   ensues  
Blood Clot 
Breast Cancer 
Stroke 
 
 
GI Upset 
 
 
 
GI Upset 
Renal Failure: 
    monitor creatinine 
     levels 
 
 
Arthralgia 
Headache 
Myalgia or fever 
 
 
Leg cramps 
Nausea 
Dizziness 
Risk of osteosarcoma 
 
 
 
 
 
 
 
Fatigue 
Hypophosphatemia 
Nausea 
Arthralgia 
Headache 
Back pain 
Extremity pain 
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Table 7 
    Standard Menopausal Status Laboratory Values 
 
Laboratory Test Pre-Menopause Post-Menopause 
FSH 1.5 – 8.5 mIU/ml 30-100 mIU/ml 
 
LH 
 
1 – 15 mIU/ml 
 
20-60 mIU/ml 
 
Estradiol 
 
30-120 pg/ml    FP 
100-210 pg/ml  LF 
 
10-35 pg/ml 
FSH=Follicular Stimulating Hormone, LH=Luteinizing Hormone, FP=Follicular Phase, LF=Luteal 
Phase 
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CHAPTER THREE:  METHODOLOGY  
This chapter is divided into two sections: the experimental protocol and 
procedures are presented in the first section, and the series of four experiments performed 
during protocol development are presented in the second section.  The actual written 
protocols and procedures may be found in Appendices A-G. 
 Introduction  
Bone loss in astronauts, a subject of scientific and practical interest to NASA, 
(Willey, Lloyd, Nelson, & Bateman, 2011) occurs as a consequence of microgravity 
environments; bone loss in older adults, a major focus of this investigator, occurs as a 
consequence of aging and/or pathological disease processes. This shared interest in bone 
loss led to a collaborative relationship between this investigator and the NASA Ames 
Research Center Bone and Signaling Laboratory, located in Mountain View, California. 
Bone loss is thought to occur due to an imbalance in osteoblast and osteoclast 
activity. A search of the literature for an appropriate experimental protocol revealed that, 
although there were a few protocols for investigating the effects of Near Infrared Light 
Emitting Diode (NIR-LED) in osteoblast cell culture models (Renno et al., 2007; 
Yamada, 1991), there were no existing protocols to examine the effects of NIR-LED on 
Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL)-induced 
osteoclastogenesis (osteoclast proliferation and differentiation) in cell culture.  Therefore, 
the first step in this study was to develop a protocol that would allow the investigation of 
the effects NIR-LED photobiomodulation affecting osteoclast proliferation and 
differentiation in a cell culture model.  The purpose of this chapter is to describe the 
development of a new experimental protocol conducted at the NASA Ames Bone and 
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Signaling Laboratory.  A custom designed protocol resulted in an experimental design 
that would allow the investigation of NIR-LED treatment in a cell culture model as an 
intervention possibly to prevent and/or treat bone loss. 
Before undertaking the creation of an experimental protocol, a review of the 
literature was conducted to identify any experimental protocols similar to this study’s 
hypothesis. The literature search yielded five similar experimental protocols and 
procedures investigating the use of NIR-LED treatments affecting osteoclastogenesis 
(Aihara, Yamaguchi, & Kasai, 2006), osteoblastogenesis (Renno et al., 2007; Yamada, 
1991) and other different cell-type culture models (Wong-Riley et al., 2001; Wong-Riley 
et al., 2005). This protocol was developed by first creating a template that combined 
aspects of an existing experimental protocol investigating osteoclastogenesis at NASA 
Ames Bone and Signaling Laboratory. The existing experimental protocol was entitled 
“collection medium protocol” (see Appendix A) and was created by a post-doctoral 
fellow for another experimental project that investigated the effects of heavy ion 
irradiation on osteoclastogenesis in cancellous tissues under the conditions of 
musculoskeletal disuse (Yumoto et al., 2009). This osteoclast cell culture protocol was 
found to be successful in yielding consistent proliferation and differentiation of osteoclast 
cells therefore; it was used as a template protocol model.  
Section One 
Protocol Description 
Each experiment took 7 days to complete and was comprised of the following 
steps:  Step 1) preparation of the RAW 264.7 cell line derived from mouse leukemia 
monocyte macrophages and culture medium for cell propagation (see Appendix B); Step 
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2) propagation of the RAW 264.7 cell line (see Appendix C); Step 3) cell plating (see 
Appendix D) and RANKL induction: cell culture days 0 and 1 (see Appendix E); Step 4) 
NIR-LED treatment—single light treatment groups: cell culture day 2; NIR-LED 
treatment—multiple light treatment groups: cell culture day 2, 3, 4, 5; Step 5) TRAP 
staining: cell culture day 7 (see Appendix F); and Step 6) manual cell counting rules (see 
Appendix G).  The final schematic experiment timeline which will be discussed in detail 
in the second portion of the manuscript is presented in Figure 1. 
Figure 1 
   
Experiment Protocol Timeline 
 
 
 
 
 Protocol Development There are six steps in this experiment protocol and 
procedure. The first step is to obtain fresh cultured cells from a manufacturer, and 
second, propagate the cell line to prepare for experiment cell plating.  The third step is to 
cell plate the experiment according to experimental groups.  After this, the fourth step is 
to conduct the intervention, providing NIR-LED treatment to experimental groups, and 
fifth, at experimental end, stain the cells in preparation for the sixth step, manual cell 
counting.  Problems encountered during the development of the experimental protocol 
and decisions made to change the protocol or procedure as to avoid confound variables to 
the experiment are presented in section two.    
 
 
 Day 0              Day 1               Day 2           Day 3                     Day 4                 Day 5           Day 6                Day 7 
------TRAP Staining ---- 
   Add 
RANKL 
 
NIR TRT  
       #1  
NIR TRT 
      #4  
Change Medium:   
Add fresh RANKL 
        NIR TRT 
              #3 
 
Plate 
RAW 
Cells 
NIR TRT  
       #2  
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Step 1:  Preparation of the Cell Line and Culture Medium 
Cell line: The RAW 264.7 cell line is derived from mouse leukemia monocyte 
macrophages obtained from American Type Culture Collection (ATCC).  This cell line 
was developed by Raschke and colleagues in 1978 and is kept in a cell repository for 
purchase through the ATCC for research (American Type Culture Collection [ATTC], 
2009; Raschke, 2010; Raschke, Baird, Ralph, & Nakoinz, 1978) (See Figure 2).  A 
microscopic cell appearance example is presented in Figure 2.  The letter of permission 
can be found in Appendix J. 
 
Figure. 2 
  RAW 264.7 Cell Appearance  
 
(American Type Culture Collection, 2009)   
http://www.atcc.org/~/media/6FC6DC948CC64496A158674CEFEE7826.ashx 
Frozen RAW 264.7 cells were shipped directly from ATCC to the laboratory and 
were handled under bio-safety level 2, moderate risk-suitable for personnel with specific 
training in handling pathogenic agents  (U.S. Department of Health and Human Services 
Public Health Service, 2007), and were  stored at -80°C in a polypropylene 3ml conical 
tube.  
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Culture Medium:  In the late 1950’s, Eagle (Sigma-Aldrich, 2010) developed 
one of the first cell culture growth mediums called Basal Medium Eagle (BME).  Eagle 
then modified this medium with a higher concentration of essential nutrients which was 
named Modified Eagle's Medium (MEM). Dulbecco (JR Scientific Inc., 2007) made one 
of the many modifications to Eagles BME, thus naming the culture medium Dulbecco’s 
Modified Eagle's Medium that contains a four-fold concentration of amino acids and 
vitamins compared to BME to support growth of primary mouse and chicken cell cultures 
it is one of the most widely used cell culture growth mediums.  Alpha Modification of 
Modified Eagle's Medium (ά-MEM) was developed to grow hybrid mouse and hamster 
cells (Atlanta Biologicals, 2010) and is further supplemented with additional amino acids 
and vitamins. 
The ATCC recommends a base culture medium consisting of Dulbecco’s 
Modified Eagle's Medium (DMEM) (Raschke, 2010) stored at 2-8°C with the added 
components of 10% fetal bovine serum (FBS) (ATTC, 2009; Invitrogen, 2010a).  
However, the Ames Bone and Signaling Laboratory found that RAW 264.7 cell growth 
was greater when ά-MEM Invitrogen Catalog number: 12571071 (Invitrogen, 2010b) 
with the added components of 10% FBS (Yumoto et al., 2009)   was used for experiments 
stored at 2-8°C.   
Cell culture growth medium was prepared prior to cell line thawing (RAW 264.7 
cells) and the manufactures procedure for heat inactivation was followed (HyClone, 
2003).  The culture medium used for RAW 264.7 cell propagation was ά-MEM, with 
10% FBS.    The FBS was derived from the blood of animals (bovine, equine, porcine).  
Fetal bovine serum must be heat inactivated and filtered prior to being added to the base 
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medium.  The FBS was heat inactivated by heating in a 56°C water bath to destroy heat-
labile complement proteins. The medium was ready for cell culture propagation and cell 
line thawing was initiated.  Both procedures are found in Appendix B. 
Step 2:  Propagation of the RAW 264.7 Cell Line  
The goal was to propagate a healthy cell line for experimentation and there are 
two stages in this step.  To begin, cells must be propagated over a week to observe for 
proper cell function and judge their viability for experimentation.   
According to Cooper (2000), cell division is variable depending on cell type, but 
most eukaryotic cells in culture divide approximately every 24 hours.  There are two 
basic parts of the cell cycle:  mitosis (nuclear division) and interphase (DNA replication).  
During cell mitosis there is the separation of the daughter chromosomes, ending with 
cytokinesis (cell division). Since mitosis and cytokinesis only last for about one hour, the 
majority of the cell cycle is spent in interphase where cell growth and DNA replication 
occur to prepare for cell division in RAW 264.7 cells.  By allowing newly plated cells to 
proliferate over several days, the researcher is able to observe the morphology (cell 
appearance) and behavior of the cell line (RAW 264.7) prior to experimentation. In order 
for successful propagation to occur, the cell line was maintained in an incubator (Thermo 
Scientific:  CO
2
 Series II water jacketed) at 37°C in 5% CO
2
 for no longer than 30 days, 
and passaged (as described below) (Rice University, 2010) every three days with 10% 
FBS with ά-MEM according to the ATCC cell propagation guidelines to maintain 
optimal cellular metabolism and health (Raschke, 2010).  The incubator provides an 
environment maintained at a consistent temperature.  Once the cell line is determined to 
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be healthy by observed cell growth by increasing cell confluence (coming together), cells 
may be used for experimentation.  
RAW 264.7 cell passaging:  Passaging culture cells means to split or divide cells 
from mature cell culture plates.  This procedure is done to maintain the viability and 
growth of cells within the cell culture line.  When RAW 264.7 cells are left in culture for 
an extended period of time, usually greater than three days, they become confluent (run 
together) and grow in clumps.  If the cells are not “split up” they will grow on top of one 
another and will eventually die due to the lack of surface area upon which to grow.  Cell 
passage is the method by which cell clumps are dislodged via cell scraping and then sub-
cultures are created.  A certain percentage of cells are re-suspended with fresh medium in 
new cell culture dishes according to cell concentration ratios. (see Appendix. C) 
Step 3. Cell Plating Procedure 
 This step required two experimental days, Day 0 (Plate labeling & cell plating) 
and 1 (RANKL induction).  
Day 0:  Plate labeling: Each plate was labeled according to experimental 
condition:  number of light treatments (1 or 4), energy density (varied by experiment: 4.5 
or 45 J/cm
2
), RANKL dose (varied by experiment: 0, 25, or 50 ng/ml or 0, 2.5, 10, 25 or 
50ng/ml).  The following is a labeling example used for the experiments:  control (no 
light treatment), single light treatment, and multiple light treatment groups, respectively.  
1. Control [0-0-0], translates to [0] light treatment, energy density [0 J/cm
2
], and RANKL 
Dose [0 ng/ml].    2.  Single [1-4.5-50], translates to [1] light treatment, energy density 
[4.5 J/cm
2
], and RANKL Dose [50 ng/ml].   3. Multiple [4-45-25], translates to [4] light 
treatments, energy density [45 J/cm
2
], and RANKL Dose [25 ng/ml].  
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Experimental conditions, RANKL dose, and energy density are described in 
subsequent sections in which the NIR-LED equipment and procedure are explicated.   
However, in the first four experiments due to the limitations of the WARP™ 10, the 
surface area of light illumination could optimally irradiate 2 wells at one time (well row 
B by columns 3-4).  Therefore, multiple 24-well plates had to be used (see Figure 3 in 
List of Figures).  In the final two experiments, the WARP™ 75 surface area of light 
illumination was great enough to irradiate a maximum of 15 wells at one time (well row 
A-B by columns 2-6). 
   The experimental condition labeling procedures for the final two experiments 
used a higher sample number than our first four experiments summarized in Appendix H, 
Table 1. Summarizing the steps involved to cell plate the experiment included:   the 
number of wells for each cell culture plate was calculated.  Second, medium was placed 
into the wells, and then from the propagated cell line culture, a cell suspension was 
calculated to determine the amount of cells to be deposited into each well.  On Day 0 
(first day of experiment) RAW 264.7 cells were plated at 2 x 10
4
 cells per well (4x10
4
 
cell/ml) in two center wells of a 24-well plate (well diameter: 1.77mm) for the first four 
experiments and 5 wells for the last two experiments for each experimental condition. 
The full procedure is found in Appendix D.  
Day 1- RANKL Induction Procedure:  The plates were cultured for 24 hours 
prior to RANKL induction.  At the end of the 24 hour period, RANKL was added to each 
plate well at a dose of 0, 2.5, 10, 25 or 50ng/ml.   This particular cell line requires the 
induction of Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL) in order to 
promote osteoclast formation.  The induction method is a follows:  Osteoblast stromal 
120 
 
 
 
cell membrane RANKL receptor, binds to the osteoclast precursor cell (macrophage) 
RANK receptor. When this occurs, RANK signaling activates the transcription nuclear 
factor Kappa-B to differentiate into osteoclasts (Kumar, 2010).   
In order to calculate the correct RANKL dose added to the cell culture, a serial 
dilution was used.   A serial dilution is a stepwise dilution of a substance, in this case 
RANKL.  At each step of dilution, the dilution factor changes as seen in Table 2, 
Appendix H. 
The original stock concentration of RANKL from the manufacturer was 100µg/ml 
(PeproTech).  Converted to ng this would be 100 x 10
3 
ng/ml.  For experimental use, 
RANKL was aliquoted into smaller volumes (10µl) at a 1250ng/ml concentration (see 
Appendix E) 
Step 4:  NIR-LED Treatment 
 
NIR-LED treatment was initiated on Day 2 for all experiments regardless of 
whether the experiment was testing single or multiple light-treatments.  Experiments in 
which multiple light-treatments were the focus had repeated exposure on Days 3-5 for a 
total of 4 light treatments.  A continuous wave NIR-LED WARP™10 (Quantum Devices, 
Barnevelle, WI) with a wavelength of 670nm, power intensity of 60mw/cm
2
 and energy 
density of 5 J/cm
2   
was used in the experiments because it was shown in previous studies 
to produce positive cellular effects  (Desmet et al., 2006; Eells et al., 2007; Eells, 2004; 
Karu, 1988; Liang, Whelan, Eells, & Wong-Riley, 2008; Pinheiro et al., 2002; Whelan et 
al., 2003; Whelan et al., 2008; Wong-Riley et al., 2001; Wong-Riley et al., 2005).  The 
dosage of light treatment was determined by applying the following formula:  Power 
(mW/cm
2
) x Time (seconds) ÷ 1,000 = Energy Density (J/cm
2
) in order to deliver 4.5 
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J/cm
2
 and 45 J/cm
2
.  To ensure delivery of an accurate energy density of 4.5 J/cm
2
 and 45 
J/cm
2
, each light treatment was timed to 80 seconds to deliver 4.5 J/cm
2
 and to 800 
seconds to deliver 45 J/cm
2
. 
Light treatment began on cell culture Day 2 (Stein et al., 2005; Yamada, 1991) 
under a sterile laminar hood with the dish lid in place. When multiple light treatments 
occurred, three more consecutive days of treatments for a total of four treatments were 
performed.  The plates receiving multiple light treatments were treated according to the 
following protocol.  On culture day two of the light treatment, plate 1 was treated first and 
then plate 2, 3, and 4 were treated. On culture day three of the light treatment, plate 2 was 
treated first, and then plates 3 and 4 were treated while plate 1 was placed at the end of the 
treatment order. On culture day four of the light treatment, plate 3 was treated first and 
then plates 4, 1, and 2.  On culture day five of the light treatment, plate 4 was treated first 
and then plates 1, 2 and 3 were treated. This was to control for objectivity and amount of 
time the plates were out of the incubator.   
Step 5:  TRAP Staining Day 7 
For purposes of these experiments, TRAP staining (SIGMA #387) was the method 
employed for manual osteoclast cell counting. Using a visual cell counting classification 
tool, those multinucleated cells that were stained with a light pink/purple were identified 
by light microscopy (inverted microscope, 10x magnification; Nikon Eclipse TS100) and 
counted. The procedure used for TRAP cell staining was obtained from SIGMA Acid 
Phosphatase Leukocyte Kit (prod #387) (see Appendix F). Cells were fixed with a 
formaldehyde solution to stop the cellular activity and prepares them for staining. The 
cells were stained with fast garnet solution which identifies the release of the enzyme, 
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TRAP. The cells that were both stained a light pink/purple and were multinucleated were 
assumed to be releasing TRAP and, therefore, were considered osteoclast cells.   
Step 6:   Manual Cell Counting Classification Tool 
When macrophages differentiate into osteoclast cells, the enzyme, bound in the 
cell membrane, Tartrate-Resistant Acid Phosphatase (TRAP) is stained for cell counting.   
This enzymatic activity has been historically regarded as one of the reliable markers of 
osteoclast identification (Nakano, Toyosawa, & Takano, 2004).  There are several 
methods to identify osteoclast cells, such as TRAP staining (Susa, Luong-Nguyen, 
Cappellen, Zamurovic, & Gamse, 2004), TRAP5b ELISA assay (Halleen et al., 2000), or 
computer imaging of histological slides (Reed, Conzemius, Robinson, & Brown, 2004). 
However, for this study a visual cell counting classification tool was developed to 
guide in the cell counting process (see Appendix G).  Plates were blinded.  To be  
counted as an osteoclast, all cells were  TRAP+ stained with a pink/purple or dark purple 
bordering on black (if nuclei were visible).  To determine the faintest acceptable pink, the 
stain color should match the RANKL control pink stain.  The counted cells should be 
stained darker than the control faint pink.  The cell was counted if there were three or 
more nuclei present. While clumps of TRAP+ mono-nucleated cells were not counted, 
and cells connected by cell processes were counted as separate cells.  Mean osteoclast 
well counts per well and standard deviations were calculated by taking the sum of 
multinucleated TRAP+ osteoclast cells for each well and dividing by the well surface 
area, expressed as cells per cm
2
. To determine light treatment effects, differences 
between osteoclast cell counts in treatment plates and controls were calculated.  
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Six experiments were conducted.  Presented below are the first four experiments 
conducted.  These four experiments were used as an exercise by which to develop the 
experimental protocol and procedure to ensure the reliability of equipment and cell 
culture and procedure techniques.  Results are reported with the subsequent change to the 
experimental protocol and procedure.  The final two experiments are presented in 
Chapter IV, in the manuscript entitled, Effects of Photobiomodulation in Osteoclast 
Formation in Vitro: a Pilot Study and represent the culmination of the dissertation work.   
The following are the equipment testing experiments for the WARP™ 10 and 
WARP™ 75 NIR-LED lights [e1386, e1389] which are followed by the four WARP™ 
10 NIR-LED experiments (e1386, e1380, e1383, e1384, and e1385).  Each experiment is 
identified by an experiment number (assigned and recorded by the NASA Bone and 
Signaling Laboratory).  Problems that occurred and the resolution to correct the problem 
within the protocol are discussed for each experiment.  
Equipment Testing Experiments 
 In order to determine the functionality and possible experimental confounding 
effect of the WARP™ 10 and WARP™ 75, NIR-LED lights, two equipment tests were 
conducted.  
e1386: WARP™ 10 and e1389:  WARP™ 75 Equipment Tests:  In laser 
medicine the most common use of lasers has been in surgery to cut, coagulate, or ablate 
tissue.  The laser’s mechanism of action in this instance is to destroy tissue and provide 
precise surgical incisions. This is achieved by heating the tissue at a high irradiation 
intensity and energy density.  However, there are other uses for lasers.   
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The rationale for testing the equipment was to determine possible confounding 
variables that could affect the experiments.  In the 1980’s photobiomodulation—referred 
to in the literature as low-level laser therapy, cold-laser therapy, or laser biostimulation—
was introduced.  This laser “light treatment” uses light in the infrared to near-infrared 
region of the absorption spectrum (630-1000nm) which is known to affect numerous cell 
functions that are dependent on the energy production in the mitochondria (Desmet et al., 
2006; Karu et al., 1987). At low light intensity, such as 670 nm, a photochemical 
conversion of energy absorbed by non-specialized photoacceptors on the mitochondria 
and generates heat (Karu, 1988; 1999; Letokhov, 1991).  Raising the temperature of these 
molecules triggers biochemical reactions that may activate or inhibit cellular enzymes 
that turn cellular functions “on” and “off” (Karu, 1999).  This may result in positive or 
negative events.  If the heat generated exceeds the optimal cell line temperature for cell 
growth, in this case body temperature (37°C), it is referred to as “heat shock”.   Heat 
shock at 41°C can stress the cells and result in the release of heat shock proteins, which 
may cause harm to the cell (Levin, Wickliffe, Leppla, & Moayeri, 2008). Several 
investigators reported that continuous wave light treatment generates minimal local 
heating of photoacceptors because the wavelength used is of low irradiation intensity 
(670nm) (Karu, 1992; Letokhov, 1991), thus, heat shock is avoided.   
Because there were only a few studies testing local heating of photoacceptor 
molecules, this principle was investigated. In addition, there was concern regarding 
possible heat shock due to the use of the WARP™ 10 and WARP™ 75, because they 
were commercial continuous wave light sources that  automatically shut off every 80 
seconds requiring a manual restart.  Therefore, the 80-second light treatment (4.5 J/cm
2
) 
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did not require manual restarts, but the 800 second light treatment (45J/cm
2) 
required 10 
manual restarts.  This manual restarting of the light treatment causes a brief surge of local 
heating. This surge could be considered pulsing light treatment which has been shown in 
the literature to give a greater biological effect than continuous wave light treatment 
(Karu, 1992).      
Light treatment temperature testing was performed with a thermistor in both the 
WARP™ 10 (e1386) and WARP™ 75 (e1389) as described in the “Light Treatment 
Procedure”.  Cell culture plates were removed from the 37°C incubator and placed on a 
metal table.  The temperature of the cell culture medium at the beginning of the 
experiment was 30.7°C – 32.3°C.  The temperature testing procedure at room 
temperature was repeated two or three times at 80 seconds and 800 seconds (the length of 
both light treatment groups in this experiment). During the light treatment exposure the 
temperature of the cell culture medium never rose above 37°C.   
Treated with the WARP™ 10 for 80 seconds, the cell culture medium had an overall 
drop in temperature of 0.9°C – 1.4°C, while that treated for 800 seconds had an overall 
drop in cell culture medium temperature of 5.6°C–7.6°C.  The cell culture medium 
treated with the WARP™ 75 had an overall drop in temperature of 1.8°C for both the 80- 
and 800-second light treatment.  During the WARP™ 75 multiple light treatments (which 
required 10 manual restarts), temperature of the cell culture medium initially dropped by 
0.9°C–2.3°C, but then at approximately 265 seconds (4 minutes, 25 seconds) into the 
treatment, the temperature increased overall by increments of 1.6°C–1.8°C.   It was 
concluded that heat shock had most likely not occurred because temperature change did 
not reach 41°C.   
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Section Two 
Four Protocol Development Experiments 
NIR-LED Experiments 
Experiments e1380 and e1383 tested multiple light treatments and single light 
treatments.  Experiments e1384 and e1385 tested only single light treatment. All 
experiments tested energy densities of 4.5 & 45 J/cm
2
.  Lastly, RANKL dose response 
was tested at 0, 25, & 50 ng/ml in experiments e1380, e1383, e1384, e1385. (see 
Appendix H Table 3)   
Experiment # 1:  e1380 
In this experiment, six complications were encountered. Each complication is 
discussed with its subsequent decision made in changing the protocol or procedure.  This 
experiment multiple light treatments and single light treatments at 4.5 J/cm
2
 and 45 J/cm
2
 
at RANKL doses of 0, 25, and 50ng/ml were tested.  A lack of osteoclast cell 
differentiation was noted in this first experiment. The following are the encountered six 
complications. 
1.  A lack of osteoclast cell differentiation may have occurred due to premature 
RANKL induction. In accordance with the “collection medium protocol” (see Appendix 
A) RANKL induction occurred 6 hours after cell plating.  Possibly, the RAW 264.7 cells 
did not have enough time to adhere to the well plate and proliferate sufficiently for 
osteoclast cell differentiation. Correction: Therefore, other NIR-LED cell culture model 
experiments found in the literature (Renno et al., 2007; Wong-Riley et al., 2001; Yamada, 
1991) were consulted and the decision was made to induct RANKL 24 hours after cell 
plating to allow for better cell/plate adhesion.  This decision was reached because it was 
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thought that when the medium was changed, many free floating cells were extracted 
leaving too few cells to propagate and adhere. 
2. A lack of osteoclast cell differentiation may have occurred due to 
miscalculating the cell density when preparing a cell suspension used to plate cells at cell 
density of 4 x 10
4
  cells per/ml.  An error was made in loading the hemocytometer: there 
were too few cells counted in the cell suspension.  Correction. In subsequent 
experiments, the investigator consulted with the lab technician to avoid errors such as 
checking mathematical calculations and observing the investigator’s pipetting technique 
because many cell wells were void of cells mid-well due to investigator aggressive 
pipetting, resulting in loss of reliable data collection.  The investigator practiced pipetting 
to prevent mid-well washing, hemocytometer calculation, and propagating cells RAW 
cells.   The importance of consistent cell plating with correct cell suspension is 
imperative because if too many or few cells are plated, cell wells may encounter cell 
confluence (making cell counting difficult) or non-cell adhesion. 
3. A lack of osteoclast cell differentiation may have occurred due to leaving all of 
the cell culture plates out of the incubator during all of the light treatments.  Correction. 
In future experiments each cell culture plate was kept outside the incubator only for the 
length of its light treatment, approximately 80 to 800 seconds.   A decrease in cell well 
medium temperature may affect cell differentiation adding a confounding variable 
because the control did not encounter the same experimental conditions. 
4. A lack of osteoclast cell differentiation may have occurred due to pre-mature 
NIR-LED shut-off and limitations of the WARP™ 10 unit.  Because the WARP™ 10 is a 
commercial product for the general public, it is battery powered and automatically turns 
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off every 80sec to avoid overheating because of repeated consecutive use.  In addition, 
over the span of the treatment time the light intensity may have diminished due to it being 
battery operated affecting the dosing of NIR-LED photobiomodulation and altering 
reliable data collection.  Correction.  These limitations had to be accepted during these 
preliminary experiments and were controlled by manually restarting the WARP™ 10 by 
switching to rechargeable batteries which were cooler and may have delayed overheating, 
by changing to fresh batteries more frequently, and by allowing the light to cool five 
minutes between the 45 J/cm
2
 treatments. This was done to avoid heating the cell culture 
medium. 
5. A lack of osteoclast cell differentiation may have occurred due to the 
investigator error of cell plating only two control wells. It was determined that two 
control wells were too few because one well was lost due to contamination, leaving only 
one control well. Correction. An extra set of control wells per experimental condition (n 
= 5). In the final experiments reported in chapter four, two sets of controls were plated (n 
= 10) to prevent the loss of controls.  If an experiment’s controls do not produce reliable 
cell counts or are flawed, the experiment data cannot be interpreted.  If the first control 
was flawed, then the second control was used for data analysis.   
6.  Lastly, a lack of osteoclast cell differentiation may have occurred due to 
possible RANKL derogation.  In order to determine if  the potential cause for poor 
osteoclastogenesis occurring in experiment e1390, it was thought that possibly the 
PeproTech RANKL may have derogated due to freezing/thaw cycles or perhaps the 
carrier protein, Bovine Serum Albumin (BSA), added to the RANKL delusion was 
responsible for the lack of osteoclastogenesis. This also may have occurred due to using a 
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manufacturer of RANKL (PeproTech) that differed from the manufacturer of the “culture 
medium protocol” (Sigma) (see Appendix A).   Therefore, experiment e1382 was 
conducted by the lab technician who compared osteoclastogenesis using PeproTech 
RANKL and Sigma RANKL and BSA vehicle control. Correction.  Based on 
experimental results, PeproTech RANKL was chosen for subsequent experiments 
because it yielded three times more osteoclasts with doubled RANKL, larger cell size, 
and dark-pink and/or purple TRAP+ stained cells with bright distinctive nuclei compared 
to Sigma RANKL.  Further, BSA did not affect cell growth or morphology.  Therefore, 
RANKL could be reconstituted for future experiment use in sterile pyron-free water with 
0.1% BSA carrier protein which will remain stable for three months stored at -20
o
C.  
Consequently, RANKL used in e1390 was derogated and any unused RANKL that was 
prepared for osteoclast induction was discarded after use and not refrozen.   If the 
cytokine added to cell cultures is derogated, a poor biological signal results and data 
analysis may be flawed due to derogated cytokine versus a freshly suspended cytokine. 
Conclusion. Because of the above complications the data collected in this 
experiment were not reliable and were not analyzed. However, alterations were made to 
the experimental protocol in experiment #2 (e1383).  Overall, the investigator acquired 
cell culture knowledge in technique, control of samples, cytokine preparation, cell 
plating, and suspension.  The most important protocol change was the increase in number 
of control cell wells because losing control data nullifies an entire experiment. New 
information and learning was evident by understanding how manufactures of RANKL 
may differ, inexperienced cell culture skills can alter data collection reliability, as well as 
simple miscalculation errors.   
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Experiment # 2:  e1383 
With these protocol changes mentioned above, the biphasic dose response curve 
for both RANKL dose and energy density were repeated in our next experiment to 
illustrate the expected dose response to photomodulation and RANKL dose.  If 
insufficient energy or RANKL dose was delivered, there would be no response because 
the dose minimum threshold was not met.  However, if too much energy or RANKL 
dose, minimum threshold was crossed then biostimulation disappears and only 
bioinhibition occurs (Huang, 2009).   A new treatment variable was added, multiple light 
treatment,  the literature reflected a gap in this type of NIR-LED light treatment (Huang, 
2009). This experiment tested multiple light treatments and single light treatments at 4.5 
J/cm
2
 and 45 J/cm
2
 at RANKL doses of 0, 25, and 50ng/ml.   
1. It was noted that the expected normal RANKL dose response during 
osteoclastogenesis was reversed between RANKL doses 25 ng/ml and 50 ng/ml in one of 
the control plates. A normal dose response during osteoclastogenesis would be a one-fold 
increase from the 25ng/ml to the 50 ng/ml doses.  Correction. Because there was a 
correct dose response in the treatment plates, it was unclear where an error had been 
made. Possibly the RANKL dose was inversely inducted.  The backup control was used 
for data analysis.  No changes were made to the protocol. 
2. Investigator error was noted in miscalculating the cell density when preparing a 
cell suspension for plating cells, even though this was checked by the lab technician.  An 
error may have been made when loading the hemocytometer, again resulting in too few 
cells for the cell suspension.  However, there was success in osteoclastogenesis 
throughout all experimental and control plates, so it was thought that enough cells 
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adhered to the cell plate. The lab technician questioned the cell plating density because 
there was confusion in the lab notes from the “conditioned medium protocol”.  The 
“conditioned medium protocol” stated that the cell plating density was 4x104 cells/ml (see 
Appendix A).  Usually, cell plating density is reported as the number of cells per well not 
the number of cells per milliliter.  The lab notebook stated the cell plating density to be 
2x10
4
 cells/well.  This may result in too few cultured RAW cells and therefore few 
osteoclasts may differentiate with RANKL.  Correction. To check if the cell plating 
density was correct, the lab technician calculated that 4x10
4 
cells/ml equals 2x10
4
 
cells/well.  The protocol continued to use 4x10
4 
cells/ml.  Due to this continued problem 
of calculating the cell density and cell plating, the lab technician calculated and 
performed the cell density and cell plated experiment e1384 as to correct problems with 
intra-rater reliability. 
Conclusion. The effects of single light treatments at energy densities of 4.5 J/cm
2
 
and 45 J/cm
2
 at RANKL doses of 0, 25 and 50ng/ml are presented in Figures 4 and 5. 
Comparing single NIR treatment at 4.5 and 45 J/cm
2 
and RANKL dose 25ng/ml the there 
was less of a biostimulatory effect by 54% (see Figure 4) and 32% respectively (see Figure 5). 
To a lesser extent, osteoclastogenesis was inhibited in RANKL dose 50ng/ml at 4.5 J/cm
2 
and 45 J/cm
2
, 37% and 10% respectively compared to controls. The dose response of 
RANKL may have reached minimal threshold at 25ng/ml and require testing a lower 
RANKL dose.  However, light treatment was not biostimulatory at both energy densities.  
If a normal biphasic energy density dose response was evident, there should be evidence 
of stimulatory effect.  Therefore, a lower energy density variable (2.25 J/cm
2
) was added 
to the experiment #4 e1385 protocol.  It is premature to determine if these energy 
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densities are biostimulating or bioinhibiting, as it is possible the energy density is too 
intense for the RAW RANKL induced osteoclast in vitro cell type compared to other 
light treatment cell culture studies using similar variables. Further knowledge was gained 
in regards to protocol development based upon dose response curves. 
Figure 4    
  e1383 WARP™ 10:  Single NIR treatment  4.5 J/cm2 RANKL dose 25 &50ng/ml   
 
 
Figure 5.  
  e1383 WARP™ 10: Single NIR treatment 45 J/cm2 RANKL dose 25 &50ng/ml 
 
 A summary of the effects of multiple light treatments at energy densities of 4.5 J/cm2 
and 45 J/cm
2
 at RANKL doses of 0, 25 and 50ng/ml are presented in Figures 6 and 7.  
Multiple light treatments at 4.5 & 45 J/cm
2
 and RANKL dose 25ng/ml inhibited 
osteoclastogenesis by 70% (see Figure 6) and 44%, respectively compared to controls 
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(see Figure 7). No effect was seen in RANKL dose 50ng/ml at 4.5 J/cm
2 
and 45 J/cm
2
 or 
in single vs. multiple light treatment groups.  The same rational was applied to these 
results as above to investigate variables that may produce a stimulatory response. 
Therefore, the protocol was simplified to test single light treatment at 4.5 J/cm
2 
and 45 
J/cm
2
 with RANKL doses 0, 25, and 50ng/ml in order to gain a better understanding of 
the inhibition or biostimulatory effect. 
 
Figure 6 
  e1383 WARP™ 10  Multiple light treatment  4.5 J/cm2  RANKL dose 25 &50ng/ml 
 
Figure 7 
  e1383 WARP™ 10 Multiple light treatment  45 J/cm2  RANKL dose 25 &50ng/ml 
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Experiment #3 e1384 
 Two complications problems were encountered in this experiment which tested only 
single light treatments at 4.5 J/cm
2
 and 45 J/cm
2
 at RANKL doses of 0, 25, and 50ng/ml. 
 1. Increased cell well confluence, cell floaters, and large cell clumps were noted in all 
control plates starting on cell culture day 1. It was noted that the expected normal 
RANKL dose response during osteoclastogenesis was reversed between RANKL doses 
25ng/ml and 50 ng/ml in the control plates (see Figure 8).  The experiment was continued 
because all other cell wells in treatment plates were progressing normally.  However, 
when TRAP staining was performed fewer TRAP+ cells were noted in the control wells 
and it was determined that the control plates were flawed.  Correction.  The data from the 
controls were was not to be used in the data analysis; however the results from this 
experiment could be used to determine NIR-LED effects between single-treatment 4.5 
J/cm
2
 and 45 J/cm
2 
light treatment groups. In reflection, it would have been more cost 
effective to have stopped the experiment and restart the protocol. The loss of controls 
nullified the majority of the experimental data. 
Figure 8 
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Problem 2: A protocol error was made on Cell Culture Day 0 which is the day 
that RANKL is added to the medium.  Usually the cell culture medium is changed only 
on Day 3; however the investigator mistakenly changed the medium and then added 
RANKL on Day 0. There was a concern that some cells were discarded with the medium, 
leaving too few cells to adhere to the cell plate. Resolution:  In order to control for this 
change in the protocol to determine the reliability of the data collected from e1384 NIR 
#3 another experiment e1385 NIR #4 was conducted to determine if changing medium on 
cell culture Day 0 vs. Day 3 would effect osteoclastogenesis. 
  Conclusion: Presented in Figure 9 is the comparison of the effects of single light 
treatments at energy densities of 4.5 J/cm
2
 and 45 J/cm
2
 at RANKL doses of 0, 25 and 
50ng/ml. Comparing Single Light treatments at an energy density of 4.5 J/cm
2
 vs. 45 
J/cm
2
 at RANKL dose 25ng/ml and 50ng/ml, 4.5 J/cm
2
 inhibited osteoclastogenesis by 
29% and 5%, respectively. It appears that the 4.5 J/cm
2
 treatment dose stimulated 
osteoclastogenesis less than the 45 J/cm
2
 light treatment dose. The RANKL dose appears 
to produce a stepwise progression, therefore the RANKL dose should be replicated with 
possibly additional low dose RANKL added.  It is unclear if the energy density response 
is significant, and the experiment would benefit from testing at a lower energy density.   
 
Figure 9 
  e1384 WARP™ 10 Single Light Treatment 4.5 J/cm2vs. 45 J/cm2   RANKL dose 25 &50ng/ml 
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Experiment #4 e1385 
This experiment was performed using the final protocol developed from the 
previous experiments. The purpose of this experiment was to determine if changing the 
medium on cell culture day 0 instead of cell culture day 3 affected osteoclastogenesis in 
e1384.  This experiment tested only single light treatments at 4.5 J/cm
2
 and 45 J/cm
2
 at 
RANKL doses of 0, 25, and 50ng/ml.  There were no problems associated with this 
experiment and it was determined that changing the medium did not affect 
osteoclastogenesis.   
Conclusion 
RANKL induced osteoclast formation by RAW cells occurred as expected in all 
experiments, however in e1383 and e1384 a typical dose-dependent response (0, 25, 50 
ng/ml) was not observed in controls but in treatment groups. In all experiments using 
light treatment without the induction of RANKL at these doses and regimes, no effect 
was measured on osteoclast formation.  A single NIR light treatment at energy density 
4.5 J/cm
2
 may inhibit RANKL (25ng/ml)-induced osteoclast formation seen in e1383. 
However, controls were in inverse dose response.  Multiple light treatments may be more 
effective in inhibiting osteoclastogenesis than single light treatment alone as seen in 
e1390.  Based upon these summarized data, protocol modifications were made 
accordingly and effects were noted for future comparison to pilot data.  The final protocol 
timeline reflects the experimental design divided by cell culture Days 0-7.  (see Figure 1) 
In some of the experimental control groups, there was a progressive biological 
dose response in osteoclast cell count that correlated to increasing doses of RANKL.  
Low dose RANKL-induced cell cultures had lower osteoclast cell counts compared to 
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RANKL-induced cell cultures with progressively increasing RANKL doses.    After a 
successful experimental protocol was developed, the next step was to use this protocol in 
a pilot study to obtain reproducible data validating the experimental methodology.  A 
pilot study was planned with the use of a more reliably functioning light source (WARP 
™ 75) (as determined by e1389) to allow for greater control to deliver light treatments 
with low variability of energy density and light intensity.  Added lower doses of RANKL 
dose 2.5 and 10ng/ml and lower energy density dose 2.25 J/cm2 was added and multiple 
vs. single light treatments will be retested.  
Presented in the next chapter are the results of the final two experiments that were 
used for data analysis in the Chapter IV manuscript, Effects of Photobiomodulation in 
Osteoclast Formation in Vitro: a Pilot Study.  
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CHAPTER FOUR:  DATA ANAYLSIS 
The following chapter is a manuscript reporting the findings from the final two 
experiments e1837 and e1390 and represents the culmination of this dissertation work.  
This manuscript was presented at the 62
nd
 International Astronautical Congress:  African 
Astronaissance, Cape Town, South Africa, on October 3-7, 2011. 
Effects of Photobiomodulation in Osteoclast Formation in Vitro: A Pilot Study 
   
Abstract 
 
Introduction: Near-Infrared Light Emitting Diode (NIR-LED) 
photobiomodulation has been found to be effective in improving wound healing, bone 
regeneration, mitochondrial function, and attenuating cellular oxidative stress. Little is 
known regarding the use of NIR-LED and the formation of osteoclasts, which break 
down bone. Purpose: Determine if the use of NIR-LED 670nm photobiomodulation may 
attenuate or amplify osteoclast differentiation in the RAW264.7 cell line. Methods:  
RAW264.7 cells were cultured for 24 hours and induced to differentiate into osteoclasts, 
using the cytokine Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL). 
Cultures were divided into groups according to RANKL dose (0, 2.5, 10, 25, 50 ng/ml) 
and different energy densities (2.25, 4.5, 45 J/cm²), treated with light either once or on 
four consecutive days using the WARP™ 75 (Quantum Devices, Barneveld, WI). 
Osteoclast-like cells were stained for Tartrate-Resistant Acid Phosphatase (TRAP). 
Analysis: Multinucleated, TRAP+ cells were scored as osteoclasts, counted manually by 
microcopy. Results were expressed as means and standard deviations, and groups were 
compared by one-way ANOVA with posthoc Tukey. Results: RANKL-induced 
osteoclast formation by RAW264.7 cells occurred as expected in all experiments. Light-
treatment alone had no observable effect. A single light-treatment at 4.5 J/cm
2
 with 
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RANKL added (10 - 50ng/ml) suggested a biostimulatory effect upon osteoclastogenesis 
compared to controls, as multiple light-treatments compared to single light-treatment 
were less stimulatory in the energy density 4.5 J/cm
2 and RANKL dose 25ng/ml group. 
The effects of the NIR-LED treatment on osteoclastogenesis are RANKL dose and light-
intensity specific. Conclusion: Effects of NIR-LED treatment on osteoclastogenesis are 
RANKL dose and light-intensity specific. NIR-LED light-treatment affects RANKL-
induced osteoclast formation suggestive of a biostimulatory effect, and multiple light 
treatments compared to single light treatment may biostimulate osteoclastogenesis less.  
Introduction 
Older adults often experience complications of muscle (Degens & Alway, 2003, 
2006; Trappe, 2009) and bone loss during the process of aging (Khosla & Riggs, 2005), 
after prolonged bed rest during hospitalization (Crepaldi & Maggi, 2005), and/or from 
self-limiting behaviors due to the fear of falling after returning home after 
hospitalization (Fletcher & Hirdes, 2004). Microgravity during space flight simulates 
these complications in astronauts. Research concerning these skeletal health problems 
that develop and validation of countermeasures to the pathological consequences of 
microgravity during long-duration space flights involves interventions and procedures 
designed to mitigate health issues and performance hazards present in a space 
environment (Clement, Bukley, & Paloski, 2007).  It is highly likely that lessons learned 
from this research could be applied to the development of innovative technologies for 
interventions that may improve bone cell function and skeletal health in at-risk older 
adults.  Some researchers investigating bone loss in microgravity environments believe 
that there is the potential for translational research that could affect the pathology of bone 
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loss in the aging population (Rittweger, 2007).  Collaboration between clinical and bench 
science researchers may develop, enhancing the use of new technologies that may 
mitigate bone loss for the older adult population to prevent fracture (Rittweger, 2007).   
Translation of NASA Technologies.  Quantum Devices Incorporated 
(Barneveld, WI) developed a NASA technology, entitled High Emissivity Aluminiferous 
Lighting Substrate 
TM
 (HEALS), to grow plants for long-term space flight.   In 2000, 
they received a Space Technology Hall Of Fame Award for their Innovation of Light 
Emitting Diodes for Medical Applications (National Astronautical Space Agency, 2008; 
Quantum Devices Incorporated, 2004).  They successfully developed a commercial 
device, the Warfighter’s Accelerated Recovery by Photobiomodulation (WARP 10), a 
portable Near Infrared Light Emitting Diode (NIR-LED), used in combat to provide first 
aid for minor injuries and pain.  Further, this application is proposed to be helpful in 
improving medical care for long-term space flight (Whelan et al., 2001; Whelan, 2000). 
It may be beneficial to explore other medical implications for the use of the WARP 10 
as an innovative intervention that may improve bone cell function and skeletal health.  
Thus, proposed use of this technology was to study the effects of NIR-LED treatment 
on osteoclast cell differentiation.   
Statement of the Problem 
Defining of Osteoporosis.  One major area of musculoskeletal health research is 
the study of the pathogenesis of osteoporosis. The conceptual definition for osteoporosis 
was determined to be a skeletal disease of compromised bone strength. A disease 
characterized by low bone mass (bone mineral density) and/or structural deterioration of 
bone tissue (microarchitecture), leading to bone fragility and an increased susceptibility 
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to fractures, especially of the hip, spine, and wrist (European Foundation for 
Osteoporosis and Bone Disease & National Osteoporosis Foundation of USA, 1997; 
National Institutes of Health Consensus Development Panel on Osteoporosis, 2001).  The 
operational definition for osteoporosis was determined by a set of diagnostic 
measurements.  Currently, there is no reliable measurement for bone strength; however, 
bone mineral density (BMD), a surrogate measurement, estimates approximately 70% of 
bone strength (Suh & Lyles, 2003).  
Bone structure reflects the quality of the bone tissue, such as the architecture, 
turnover, accumulated damage to the bone tissue and the amount of mineralization 
(European Foundation for Osteoporosis and Bone Disease & National Osteoporosis 
Foundation of USA, 1997).  It has been reported that microarchitectural bone changes 
may be independently associated in bone weakness, but not associated with a change in 
BMD (Harvey, Dennison, & Cooper, 2013).  Osteoporosis is the most common bone 
disorder (National Institutes of Health Consensus Development Panel on Osteoporosis, 
2001), a growing worldwide public health problem due to the increasing numbers of 
individuals over the age of 65 (Suh & Lyles, 2003) and is reported to affect an 
estimated 44 million Americans (National Osteoporosis Foundation, 2010).  It has 
been reported that bone degradation increases risk for fall-induced fractures (Grahn 
Kronhed, Blomberg, Lofman, Timpka, & Moller, 2006) and specifically hip fracture, a 
well-documented problem within this population (Lim, Hoeksema, & Sherin, 2009) 
which has markedly increase health care cost (World Health Organization Scientific 
Group, 2003). 
It is projected that by the year 2030, the United States (U.S.) population of 
142 
 
 
 
older adults will double to 71.5 million (U.S. Department of Health and Human 
Services Administration on Aging, 2006) . In 2007, data from the U.S. Census 
Bureau estimated that there are more than 84,000 centenarians in the U.S., and their 
population is projected to increase sevenfold by 2040 (U.S. Census Bureau & U.S. 
Department of Commerce Economics and Statistics Administration, 2007). This aging  
population  is  at  risk  for disability, morbidity, and mortality related to bone loss which 
is  an  identified  risk  factor  for  fracture resulting from a fall (Hall, Williams, Senior, 
Goldswain, & Criddle, 2000; Ostir, Ottenbacher, & Markides, 2004). 
Fifty-five percent of people aged 50 years and older are affected by osteoporosis 
(National Osteoporosis Foundation, 2010 [revised 2013]). There has been only a 
modest decline in the rate of osteoporosis over the past 15 years despite the 
development of interventions using medications and weight-bearing exercise. According 
to the World Health Organization, osteoporosis has the potential to become an epidemic 
by the middle of the 21st century, from an incidence of 1.7 million in 1990 to a 
projected 6.3 million by 2050 (World Health Organization, 1999). 
Bone Physiology. In brief, the physiology of bone homeostasis includes the 
activity of four cell types responsible contribute to the formation and maintenance of 
bone:  osteoprogenitor cells, osteocytes, osteoclasts, and osteoblasts (Porth, 2009). 
Osteoprogenitor cells are undifferentiated cells that are the source of all bone cells except 
osteoclasts which originate from monocyte/macrophages within the hemopoietic lineage.  
Osteocytes are mature bone cells that maintain the bony matrix.  In addition, they may 
respond to bone tissue strain and recruit osteoclasts to areas of bone requiring bone 
repair/remodeling (Lanyon, 1993).  There are interconnected passageways,  canaliculi, 
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found throughout the calcified matrix that contain extracellular fluid (Hadjidakis & 
Androulakis, 2006) that provide a communication network between the neighboring 
osteocytes and blood system for the exchange of nutrients and metabolites because 
diffusion does not occur is calcified bone (Porth, 2009).      
Osteoclasts and osteoblasts are two types of cells within mineralized bone that 
contribute to mineral homeostasis (Lemaire, Tobin, Greller, Cho, & Suva, 2004). They 
are responsible for building and maintaining bone structure.  Osteoclasts are bone-
resorbing cells that originate from monocyte/macrophages within the hemopoietic 
lineage, and their activity is regulated by osteoblasts, bone-forming cells, and numerous 
hormones and other growth factors, macrophage colony-stimulating factor (M-CSF), 
interleukin-1 (IL-1), and tumor necrosis factor (TNF) (Hock et al., 2001).  Osteoblasts are 
differentiated mesenchymal stem cells, responsible for lying down the new bone matrix 
that becomes mineralized, thus replacing old bone previously reabsorbed by osteoclasts 
(Hadjidakis & Androulakis, 2006; Hock et al., 2001). 
There are two pathways that induce osteoclastogenesis.   On the osteoblast 
stromal cell membrane, Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL) 
receptor, binds to the osteoclast precursor cell (macrophage) RANK receptor. When this 
occurs, RANK signaling activates the transcription factor Kappa-B to differentiate into 
osteoclasts (Kumar, 2010).  The other pathway occurs with the osteoblast secretion of M-
CSF and the osteoclast precursor cell (macrophage) M-CSF receptor.  When joined, 
tyrosine kinase activity is stimulated, also important to osteoclast formation. This 
signaling occurs in tandem with the RANKL/RANK pathway.  Further bone marrow 
stromal/osteoblast cells secrete osteoprotegerin (OPG), a decoy receptor for RANKL, 
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preventing RANKL from binding with the osteoclast precursor cell’s RANK receptor.  
This prevents bone absorption and attenuating osteoclast differentiation (Kumar, 2010). 
In healthy remodeling tissue of the adult skeleton, 5-10% of existing bone at 
specific bone sites is replaced every year, but it is not replaced uniformly throughout the 
skeleton (World Health Organization Scientific Group, 2003). As to not alter the 
bone’s shape, bone resorption and formation occur within the same space (resorption 
lacunae) of the bone. Bone remodeling occurs in both spongy or trabecular (cancellous) 
tissue and dense/compact bone (cortical) tissue, which together comprise intact bone. 
The percentage of cancellous and cortical tissues in a given bone varies according to the 
type of bone. Vertebrae are particularly rich with cancellous tissue, while the hip and 
wrist are rich with cortical composites of bone (Wyngaarden, Smith, & Bennett, 1992).  
Normal bone remodeling is a coupling process, a balance between bone gain and 
loss, where bone absorption and bone formation are balanced  (North American 
Menopause Society, 2010). Bone remodeling begins with bone resorption in both 
cortical and cancellous bone by osteoclasts over a period of 30-40. Osteoclasts attach to 
the mineralized bone surface and resorb bone via secretion of hydrogen icons and 
cathepsin K (Raisz, 1999, 2008), creating irregular, scalloped cavities named Howship 
lacunae in trabecular bone or cylindrical Haversian canals in cortical bone. Osteoblasts 
lay down a new organic extracellular matrix in two stages:  ossification, formation of 
unmineralized bone (osteoid), and calcification that becomes mineralized with calcium 
and phosphate and fills the resorption lacunae over approximately 150 days (E. Eriksen, 
2010; Raisz, 1999). 
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Bone Pathology.  Osteoporosis arises from an imbalance in osteoclast/osteoblast 
homeostasis (uncoupling) in remodeling bone (Lemaire et al., 2004; Manolagas & Jilka, 
1995). Bone loss in osteoporosis has been described in a two-stage model.  The first stage 
is the loss of sex steroids (estrogen) resulting in rapid trabecular bone loss by 20-30% and 
in cortical bone loss by 5-10% (Khosla & Riggs, 2005) due to an increase in 
osteoblast/osteoclast activity (Parfitt, 1990).  Osteoclastogenesis is proportionally greater 
than osteoblastogenesis during this period of time (Jilka, Weinstein, Takahashi, Parfitt, & 
Manolagas, 1996).  The duration of this first stage differs according to individual 
variables, but does not last indefinitely (Jilka et al., 1996). This stage usually lasts 5-10 
years in women (Drake & Khosla, 2013). Stage two follows approximately 8-10 years 
postmenopausal which is a period of time of slow continuous bone loss due to aging 
where cortical and trabecular bone loss occurs at an equal rate until the end of the life 
span (Drake (Drake & Khosla, 2013; Parfitt et al., 1983).  Men also experience a slow 
process of bone loss from middle age to the end of the lifespan that is similar to the 
second stage of bone loss seen in postmenopausal women (Drake & Khosla, 2013).  
Aging, in addition to loss of sex steroids or parathyroid hormone (Parisien et al., 1992; 
Steiniche et al., 1989), has been associated with bone loss and a decrease in the thickness 
of the bone wall and a decrease growth factors.   These growth factors are the precursors 
for osteoblastogenesis (Ho et al., 1987) and directly influence osteoclastogenesis (Lips, 
Courpron, & Meunier, 1978; Parfitt et al., 1983).  
There are four major pathways for the pathogenesis of osteoporosis:  failure to 
achieve optimal peak bone mass and strength, accelerated bone loss due to increased 
bone absorption, inadequate bone remodeling, and increased falls (Raisz, 2008).  Bone 
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loss (Crepaldi & Maggi, 2005) is one of the general characteristics of aging, along with 
increased mortality, vulnerability to disease (Cristofalo, 1988), progressive deterioration 
of tissues (Looker, Melton, Harris, Borrud, & Shepherd, 2010; Shock, 1985), and other 
conditions.  Bone loss is a problem that worsens as people age. Osteoporosis arises from 
the out-of-balance osteoclast/osteoblast activity in remodeling bone.  Because vertebrae 
are particularly rich in cancellous tissue (Wyngaarden et al., 1992), vertebral compression 
fractures are the most commonly associated osteoporosis bone injury (Neyhart & Gibbs, 
2002).  Hip and wrist fractures commonly result from cortical composite weakening; 
occurring later in life than is usually the case with vertebral fractures (Wyngaarden et al., 
1992).  Therefore, bone strength is impaired, predisposing older adults to fractures when 
they fall.  Thus, there are numerous risk factors associated with bone loss. 
Falls and Fractures. Serious injury occurs in 10-15 % of falls (Centers for 
Disease Control and Prevention, 2006). In the U.S., osteoporosis causes 1.5 million 
fractures every year. There is considerable research that associates osteoporosis with fall-
induced fractures (Kendler et al., 2010; Schwartz, Nevitt, Brown, & Kelsey, 2005; World 
Health Organization Scientific Group, 2003).  The lifetime risk for osteoporotic fractures 
(vertebral, wrist, and hip) is estimated to be 40% which is similar to the lifetime risk for 
coronary heart disease (World Health Organization Scientific Group, 2003).Vertebral 
compression fractures are the most commonly associated osteoporosis bone injury. 
Unlike vertebral fractures, hip and wrist fractures commonly result from cortical 
composite weakening that can occur later in life (Wyngaarden et al., 1992). Ninety 
percent of osteoporotic-induced fractures, specifically hip fractures among older adults in 
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the U.S., are caused by falls (Cummings, Kelsey, Nevitt, & O'Dowd, 1985; Grisso et al., 
1991).  
Falls Morbidity and Mortality.  Hip fracture mortality rates have been reported 
to be three times higher for individuals with hip fracture as opposed to the mortality rate 
of the general population (Kannegaard, van der Mark, Eiken, & Abrahamsen, 
2010). The rate of mortality associated with hip fractures within the first year is 
estimated to be 20% - 35% (Goldacre, Roberts, & Yeates, 2002; North American 
Menopause Society, 2010) and is greatest immediately after the fracture (Center, 
Nguyen, Schneider, Sambrook, & Eisman, 1999). Long-term care is required for 
approximately 25% of women, and 50% have some form of immobility (North 
American Menopause Society, 2010). Currently, the majority of hip fractures occur in 
Europe and North America. Over the next 50 years, due to demographic changes in the 
number of older adults living in developing counties, 75 % of the world’s total hip 
fractures will occur in developing countries (World Health Organization, 1999). 
Healthcare Expenditures.  The World Health Organization reported in 2003 
that osteoporosis-induced fractures burden society by depleting available resources. In 
1992, in the state of California, it was estimated that 62.4% of expenditures were used 
for inpatient care, 28.2% for long-term care, and 9.4% for outpatient care to treat 
osteoporotic-induced fractures (Ray, Chan, Thamer, & Melton, 1997). However, these 
figures do not take into account indirect costs such as lost wages or the decreased 
productivity of caregivers and the patient (National Institutes of Health Consensus 
Development Panel on Osteoporosis, 2001). Researchers using the 1999-2005 Chronic 
Conditions Warehouse dataset (Iowa Foundation for Medical Care, 2008) reported that 
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the U.S. Medicare beneficiaries receiving payments for osteoporotic-induced fracture 
incurred a cost of $7,788 (95% CI, $7,550-$8,025) for an average wrist fracture. The cost 
to treat an average open hip fracture was $31,310 (95% CI, $31.0073-$31,547) per 
beneficiary (Kilgore et al., 2009).   Further, in 2005, it was estimated that the annual 
cost to treat osteoporosis associated fractures will increase 50% by year 2025— $17 to 
$25 billion—due to the growth of the aging population (Burge et al., 2007). 
Due to the cost treating osteoporotic fall-induced fractures, the development of 
effective interventions meant to slow the progression of or reverse bone loss could be 
instrumental in decreasing the financial burden of healthcare for the aged, as well as 
enhancing the quality  of  life  for  aging  persons  by  helping  them avoid long-term 
care placement. Implementing a new intervention, such as the use of 
photobiomodulation (light-treatment), may have the potential to preserve bone density 
and prevent bone loss. 
Background 
 Biological Aging & Oxidative Stress.  The theory of biological aging has been 
associated with cellular oxidative stress and mitochondrial dysfunction (Melov, 2000), 
and this may induce bone loss (Srinivasan & Avadhani, 2007). Oxidative stress can 
result from the generation of excess free radicals (Beckman & Ames, 1998) which causes 
an imbalance with cellular antioxidants which in turn damages cellular components and 
function (Sheweita & Khoshhal, 2007). Specifically, free radicals are unpaired electrons 
on the electron orbitals or electron shells of a molecule. In this unstable state, the free 
radicals are highly reactive with other molecules, and can instigate oxidative cell 
destruction. The oxygen molecule has an atypical placement of electrons within electron 
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orbitals, and during chemical reactions, oxygen prefers to accept one electron at a time 
rather than two electrons. Accepting two electrons at a time would keep the oxygen 
molecule in a stable state. When electrons are accepted one at a time, the oxygen 
molecule becomes unstable and superoxide (O-) and hydrogen peroxide (H2O2) are 
generated. These reactive oxygen species undergo further biochemical cellular 
reactions, and the result is that an extremely reactive molecule, such as hydroxyl 
radicals (OH-), is produced (Beckman & Ames, 1998) and affects mitochondrial 
function, responsible for cellular energy production.   
 Mitochondrial Dysfunction.  It is suggested that mitochondrial dysfunction via 
oxidative stress may instigate premature apoptosis (programmed cell death) and alter 
mechanical signaling in bone (Booth & Criswell, 1997; Hock et al., 2001; Yalin et al., 
2005). In a recent study using the RAW264.7 cell culture model (osteoclast precursor 
cells), without the addition of osteoclast differentiation factors, hypoxia-mediated 
mitochondrial stress increased reactive oxygen species (increased oxidative stress), which 
resulted in osteoclastogenesis (the formation of bone-resorbing cells) (Srinivasan & 
Avadhani, 2007).  
Proposed Intervention.  Photobiomodulation—referred to in the literature as 
low-level laser therapy, cold-laser therapy, or laser biostimulation—was introduced in 
the 1980s. Laser “light-treatment” uses light in the infrared to near-infrared region of the 
absorption spectrum (630-1000nm), such as a NIR-LED, and known to affect numerous 
cell functions that are dependent on the energy production in the mitochondria 
(Desmet et al., 2006; Karu, Piatibrat, & Kalendo, 1987). It has been postulated that the 
mechanism of the effect of a low-power laser works at the cellular level due to changes 
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in components of the electron transport chain system within the mitochondria (Karu, 
1988).  The electron transport system of the cell is directly related to the production of 
Adenosine triphosphate (ATP), the primary energy compound for the cell. These 
discoveries have been investigated using a NASA invented NIR-LED technology as 
previously mentioned (J. T. Eells et al., 2004; Sommer, Pinheiro, Mester, Franke, & 
Whelan, 2001; Whelan et al., 2008). 
NIR-LED Treatment.   Light-treatment in numerous studies has been 
documented to have beneficial cellular level mechanisms that reduce oxidative stress, 
improve mitochondrial function, and prevent premature apoptosis (Desmet et al., 2006; 
Eells et al., 2004; Karu et al., 1987). NIR-LED (630-1000nm) photobiomodulation—an 
FDA-approved treatment—has been found to be effective in improving wound (Whelan 
et al., 2003; Whelan, 2001), improving bone regeneration (Pinheiro et al., 2009), 
improving mitochondrial function (Wong-Riley, Bai, Buchmann, & Whelan, 2001), 
attenuating cellular oxidative stress (Desmet et al., 2006; Eells et al., 2004; Karu et al., 
1987), decreasing inflammation and  pain (Whelan et al., 2003), aiding in recovery of 
ischemic cardiac injury (Oron, 2006; Oron et al., 2001), and attenuating retinal/optic 
nerve degeneration (Eells, 2007; Eells, 2004; Liang et al., 2006). 
NIR-LED Cellular Effects.  Specifically, NIR-LED treatment, using an 
absorption spectrum of 670nm, activates the mitochondrial photo acceptor molecule 
cytochrome c oxidase (CO), specifically, Complex IV (COX IV) of the electron chain 
transport system (Karu, 1999). If cytochrome c (COX) does not properly function, the 
cell electron transport system performs poorly, which alters the production of ATP, and 
premature cell death can occur. Therefore, the use of light as a treatment to improve 
151 
 
 
 
oxidative metabolism and mitochondrial function in bone tissue may prevent bone 
demineralization and preserve cell life. 
Research has been completed that has increased our understanding of NIR-
LED effects with osteoblast cell function (in vitro) (Renno, McDonnell, Parizotto, & 
Laakso, 2007; Yamada, 1991), bone graft biomaterials (in vivo) (Pinheiro et al., 2008; 
Pinheiro et al., 2009; Torres, dos Santos, Monteiro, Amorim, & Pinheiro, 2008), and 
bone formation (in vivo) (Blaya, Guimaraes, Pozza, Weber, & de Oliveira, 2008). In 
one study that investigated osteoblastogenesis, it was found that low-level laser 
irradiation in cell culture significantly increased osteoblast proliferation and 
differentiation (Stein, Benayahu, Maltz, & Oron, 2005),  another study found that 
photobiomodulation increased bone formation (Torres et al., 2008), increased the 
amount of well-organized bone trabeculi (Pinheiro et al., 2008), and enhanced vertical 
regeneration of bone (Blaya et al., 2008). 
The evidence that NIR-LED increases osteoblastogenesis and bone formation is 
documented in the literature, but little is known regarding the effects of NIR-LED on 
osteoclastogenesis.  Osteoblastogenesis and osteoclastogenesis need to be coordinated—
i.e., achieve “coupling” (Rodan & Martin, 1981)—to attain a healthy balance 
(homeostasis) between bone gain and bone loss. It is with aging that the “uncoupling” of 
the bone remodeling cycle occurs, resulting in increased bone resorption (Kiel, Rosen, 
& Dempster, 2008; Lemaire et al., 2004).  It is documented in the literature that 
osteoblastogenesis is increased with NIR-LED (Stein et al., 2005).  Therefore, in order 
to develop effective and safe interventions for a vulnerable population, such as older 
adults, it is imperative to investigate the cellular-level effects of NIR-LED to determine 
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if osteoclastogenesis is amplified or suppressed due to uncoupling. 
Research Questions and Hypothesises 
Our primary goal in this study was to determine the effects of NIR-LED 
treatment on osteoclast cell differentiation (osteoclastogenesis) in cell-cultured 
RAW264.7 cells using the WARP 75 ™ NIR-LED light. Our specific research questions 
and hypotheses were as follows: 
 Question 1. Is there a difference in osteoclast cell count between single light-
treated Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL)-induced cell 
cultures as compared to non-light-treated controls?  Hypothesis. Single light-treatment of 
RANKL-induced cell cultures will attenuate osteoclastogenesis. 
Question 2.  Is there a difference in osteoclast cell count between light-treated 
RANKL-induced cell cultures treated at different energy densities of light-treatment 
(2.25, 4.5 and 45 J/cm
2
) compared to non-light-treated controls?  Hypothesis. Light-
treatment of RANKL-induced cell cultures at a higher energy density (45 J/cm
2
) will 
have a greater attenuation of osteoclastogenesis compared to lower energy densities (2.25 
and 4.5 J/cm
2
). 
Question 3. Is there a difference in osteoclast cell count between single light-
treated RANKL-induced cell cultures compared to multiple light-treated RANKL-
induced cell cultures?  Hypothesis. Multiple light-treatments of RANKL-induced cell 
cultures will have a greater attenuation of osteoclastogenesis compared to single light-
treated RANKL-induced cell cultures. 
Materials and Methods 
  Experiment Timeline.  This pilot study is a description of two experiments using 
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the WARP™ 75 light source. RAW 264.7 cells (obtained from the American Type 
Culture Collection [ATCC]) were plated on cell culture Day 0 and then incubated at 37˚ 
Celsius for 24 hours. RANKL was added to cell culture medium on Day 1 at specific 
experimental doses 0, 25, and 50ng/ml. Light-treatment began on Day 2 for all 
experiments regardless of whether the experiment was testing single or multiple light-
treatments. Experiments that tested multiple light-treatments had repeated exposure on 
Days 3-5 for a total of 4 light-treatments. The culture medium was changed and fresh 
RANKL was added to the medium on Day 4 in all experiments. On Day 7, cells were 
stained for Tartrate-Resistant Acid Phosphatase (TRAP), and were prepared for cell 
counting. 
The first experiment tested only a single light-treatment; the second experiment 
tested multiple and single light-treatments. All experiments tested energy densities of 
4.5 and 45 J/cm
2
, but the second experiment tested an additional energy density of 
2.25 J /cm
2 to explore an energy density light-treatment dose response.  Lastly, 
experimental controls were tested for RANKL dose response at 0, 25, and 50ng/ml in 
all experiments, and experimental controls were tested in the first experiment for 
RANKL dose response at RANKL dose 0, 2.5, 10, 25 and 50ng/ml. 
Cell Plating Procedure.  On Day 0, RAW 264.7 cells were plated at 2 x 10
4 
cells per well (4x10
4 cell/ml) in 15 wells of a 24-well plate (well diameter: 1.77mm) 
for each experimental condition. The WARP™ 75 (Quantum Devices, Barneveld, WI) 
illumination surface covered 15 wells (well rows A-C by columns 2-6). Some 
experimental conditions did not require the full 15 wells; in those cases, only 10 wells 
were used. Plates were divided into experimental treatment groups according to 
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experimental condition: number of light-treatments (1 or 4), energy density (varied by 
experiment:  2.25, 4.5 or 45 J/cm
2
), and RANKL dose (varied by experiment:  0, 2.5, 
10, 25, or 50 ng/ml) with respective negative controls.  The cells were cultured for 24 
hours prior to RANKL induction. At the end of the 24-hour period, RANKL was added 
to each well at 0, 2.5, 10, 25 or 50ng/ml, according to the experimental design. 
  Light-treatment Procedure. A continuous wave NIR-LED (WARP™75) with a 
wavelength of 670nm, power intensity of 60mw/cm
2 , and energy density of 5 J/cm
2 
was used in the experiments because it was shown in previous studies to produce 
positive cellular effects (Desmet et al., 2006; Eells, 2007; Eells, 2004; Karu, 1988; 
Liang, Whelan, Eells, & Wong-Riley, 2008; Pinheiro et al., 2002; Whelan et al., 2003; 
Whelan et al., 2008; Wong-Riley et al., 2001; Wong-Riley et al., 2005). The dosage of 
light-treatment was determined by applying the following formula: Power (mW/cm
2
) x 
Time (seconds) ÷ 1,000 = Energy Density (J/cm
2
) in order to deliver 4.5 J/cm
2 and 
45J/cm
2
. In order to ensure delivery of an accurate energy density of 4.5 J/cm
2 and 45 
J/cm
2
, light-treatment was timed to 80 seconds to deliver 4.5J/cm
2 and to 800 seconds to 
deliver 45 J/cm
2
. 
  Light-treatment began on cell culture Day 2 (Yamada, 1991; Stein, 2005) under a 
sterile laminar hood with the dish lid in place. Because one of the objectives of a 
particular experiment was to test multiple light-treatments versus single light-treatment, 
additional light-treatments were performed, once per day on three consecutive days. 
Analysis 
 TRAP staining (SIGMA #387) was the method used for manual osteoclast cell 
counting (Nakano, Toyosawa, & Takano, 2004).   Using a visual cell counting 
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classification tool, those multinucleated cells that were stained light pink/purple were 
identified by light microscopy (inverted microscope, 10x magnifications; Nikon Eclipse 
TS100) and counted. Mean osteoclast cell counts per well and standard deviations were 
calculated by taking the sum of multinucleated TRAP+ osteoclast cells for each well and 
dividing by the well surface area, expressed as cells per cm
2
. To determine light-
treatment effects, the difference between osteoclast cell counts in treatment plates and 
controls was calculated. Results are expressed as means and standard deviations, and 
groups were compared by one-way ANOVA with posthoc Tukey (p<0.05). 
Results 
Our experimental groups were organized according to the number of light-
treatments, energy density, and RANKL dose. Our first experiment tested single light-
treatments at energy densities of 4.5 J/cm
2 and 45 J/cm
2 at RANKL doses of 0, 2.5, 10, 
25, and 50ng/ml; it demonstrated the experimental RANKL dose response curve, which 
resulted in the expected stepwise two-fold increase in biological signal  (see Table 1).  
In treatment groups, stepwise dose response occurred approximately two fold between 
energy densities 4.5 and 45 J/cm
2 at RANKL dose 2.5ng/ml.  However, in the RANKL 
group 25 and 50 ng/ml at energy densities of 0, 4.5, and 45 J/cm
2 
were practically 
inversed.  The 10ng/ml RANKL group, only modestly increased at energy densities of 0, 
4.5, and 45 J/cm
2
  (see Table 2). 
One-way ANOVA comparing different energy densities for the single light-
treatment were computed. In the first experiment, significant difference found between 
groups indicated an increased biostimulatory effect in energy density 45 J/cm
2 and 
RANKL dose 2.5ng/ml compared to controls and energy density 45 J/cm
2 was more 
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effective in amplifying osteoclast formation compared to 4.5 J/cm
2  (F (2,12)= 61.17, 
p<.0001).  Further, energy densities of 0, 4.5 and 45 J/cm
2 at RANKL dose 10ng/ml (F 
(2, 12) = 8.04, p < .006) an increase in osteoclastogenesis was found compared to no-
light treatment.  (see Table 2). Energy densities of 0 J/cm
2 (M = 484.4, SD = 87) and 4.5 
J/cm
2 (M = 485.2, SD = 53) yielded the same biostimulatory effect in the RANKL dose 
50ng/ml experiment compared to the energy density groups of 45 J/cm
2
 (M = 419.4, SD 
= 130). (see Table 2) 
 Our second experiment tested the effect of single light- treatment at energy 
densities of 2.25, 4.5, and 45 J/cm
2 at RANKL doses of 0, 25, and 50ng/ml; it also 
compared multiple light-treatments versus a single light-treatment at an energy density 
of 4.5 J/cm
2
. In this experiment, the expected dose response curve yielded a stepwise 
increase in the 25ng/ml RANKL dose compared to control, however the stepwise 
response in the 50ng/ml was only increased modestly. (see Table 3)  This may be 
attributed to possibly the minimum dose threshold was met by RANKL dose 25ng/ml, 
but at the 50ng/ml dose, biological signal may drop.   
In treatment groups, dose response in RANKL dose of 25 ng/ml and 50ng/ml 
occurred in the 2.25 and 4.5 J/cm
2 treatment groups; however, the single light-treatment 
(45 J/cm
2
) group and the multiple light-treatment (4.5 J/cm
2
) group did not yield the 
expected two-fold response. This finding may be attributed to the minimal energy 
density threshold being met as biological signal is lost at the 45 J/cm
2
. This decrease 
may also be attributed to light treatment effect. (see Table 4) 
The energy density of 4.5 J/cm
2 was the most effective in amplifying 
osteoclastogenesis (M = 491.4, SD = 65) in the RANKL dose 25ng/ml experiment 
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compared to 45 (M = 289.2, SD = 77) and 2.25 J/cm2 (M = 274.4 SD =92), as the 45 
J/cm
2 was less effective in stimulating osteoclastogenesis compared to the 4.5 J/cm
2
 (see 
Table 4). However, the first experiment in the RANKL dose 10ng/ml experiment, equal 
amplification was seen in both energy densities 4.5 (M = 68.8, SD = 13) and 45 J/cm
2
 
(M = 69.6, SD =11) as compared to the control (M = 45.6, SD = 7). (see Table 2) 
In order to determine which pairs of means were significantly different, a post hoc 
Tukey honestly significant difference (HSD) test was used.  Significant differences were 
found between the groups, no-light treatment group and energy density 4.5 J/cm
2 
at 
RANKL dose 25ng/ml.  Energy density 4.5 J/cm
2 
significantly amplified 
osteoclastogenesis compared to no light treatment and was more effective in osteoclast 
formation than the 2.25 J/cm
2
 (F (3,16) = 4.52, p <.0176). Further significance 
differences between groups were found in energy density 4.5 J/cm
2
 and no light 
treatment, 2.25 and 45 J/cm
2
 in RANKL dose 25ng/ml (F (3,16) = 12.51, p < .0001). (see 
table 4)  Osteoclastogenesis increased in the energy density of 4.5 J/cm
2
 compared to no-
light treatment and was more effective than the 2.25 J/cm
2
.  A decrease in 
osteoclastogenesis also was seen with 45 J/cm
2
 compared to 4.5 J/cm
2
 (see Table 4). 
Further, a one-way ANOVA comparing single versus multiple light treatments for 
energy density 4.5 J/cm
2 and RANKL dose 0, 25and 50ng/ml were computed. A 
significant difference was found between single and multiple light treatment as well as 
no light treatment compared to single light treatment in the RANKL dose 25ng/ml 
groups (F (2, 11) = 24.8, p < .0001) (see Table 5). In RANKL dose 25ng/ml, 
biostimulation in the multiple light-treatment group was less (M = 258.6, SD = 30.9) 
compared to single light-treatment (M = 511.5, SD = 52.3). The post hoc Tukey HSD 
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test indicated a significant difference between single versus multiple light treatment (p = 
.01) and single versus no light treatment (p = .01). 
Discussion 
Developing interventions to preserve bone density and to  prevent or reverse the 
pathogenesis of osteoporosis (bone loss) is important because osteoporosis is a major 
public health problem estimated to affect 44 million Americans (National Osteoporosis 
Foundation, 2010). The U.S. population of older adults will be approaching 70 million by 
2020; the financial burden to treat osteoporosis in older adults and osteoporotic-induced 
fractures will be cost prohibitive and burdensome to the health care system (World Health 
Organization Scientific Group, 2003).  
Since the mid-1990s, overall there has been a decline in the incidence of low 
femur BMD (Looker et al., 2010).  Because health care expenditures for osteoporosis 
associated fractures by 2025 will double (Burge et al., 2007), it may be helpful to 
determine the most efficacious point in time to implement an intervention to 
prevent/delay the onset of elemental bone loss (osteopenia). Commonly, studies 
investigate interventions for post-menopausal women when loss of BMD has mostly 
occurred.  The most common preventive osteoporosis non-pharmacological 
intervention is weight bearing exercise (Howe et al., 2011; Schmitt, Schmitt, & Doren, 
2009).  Pharmacological interventions include prescribing calcium and vitamin D 
supplements (Elders et al., 1991; Rahmani & Morin, 2009; Shea et al., 2002; Weaver 
& Heaney, 2008), estrogen/progestin (Cauley et al., 2003) and bisphosphonates 
(Bonnick et al., 2007; Pols et al., 1999).  The motivation to investigate the effects of 
NIR-LED light-treatment on osteoclastogenesis is to begin a program of research 
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developing a possible non-invasive intervention that may be appropriate for 
perimenopausal and postmenopausal women. 
We investigated the effects of NIR-LED light-treatment using the WARP 75™ 
on osteoclastogenesis in the RAW 264.7 cell line. The purpose of this study was to 
pilot test a new protocol designed to answer the broad research question: Does NIR-
LED photobiomodulation affect RANKL-induced osteoclastogenesis in a cell culture 
model?  The integrity of our experiments and controls were evaluated by successful 
results of RANKL-induced osteoclast formation by RAW cells.  Our controls (negative 
RANKL cell cultures) and the use of light treatment alone did not result is a measured 
effect on osteoclast formation.  
Our first hypothesis predicted that a single light-treatment of RANKL-induced 
cell cultures would inhibit osteoclastogenesis; however, only two out of 19 single 
light-treatment experimental groups actually inhibited osteoclastogenesis compared to 
the control and were non-significant. In fact, two out of the 19 single light- 
treatment experimental groups significantly increased osteoclastogenesis. (see Table 2 
and 4). 
Our second hypothesis predicted that light-treatment at a higher energy density 
would less stimulatory toward osteoclast formation than lower energy densities; this 
was found true, since in our first experiment energy density 45 J/cm
2 stimulated 
osteoclastogenesis less than the 4.5 J/cm
2 in the RANKL dose 25 and 50ng/ml group. 
On the other hand, in the 10ng/ml group, there was not a difference in effect between 
4.5 and 45 J/cm
2
, but in the 2.5ng/ml group there was a significant difference between 
0, 4.5 and 45 J/cm
2
 groups indication an increased biostimulatory effect with increased 
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energy density.  The second experiment demonstrated 45 J/cm
2
 was less 
biostimulation compared to 4.5 J/cm
2 in the RANKL dose 25 and 50ng/ml group. 
Our third hypothesis predicted that multiple light treatments would stimulate 
osteoclastogenesis less than single light-treatments. It was found that multiple light-
treatments compared to single light-treatment was less stimulatory in amplifying 
osteoclastogenesis at energy density 4.5 J/cm
2 and RANKL dose 25ng/ml group, as 
shown in Table 5. 
In order to evaluate our results, examples of low level laser light treatment 
models in the literature that investigated osteoclastogenesis using a gallium aluminum 
arsenide (Ga-Al-As) semiconductor laser (Aihara, Yamaguchi, & Kasai, 2006) and 
others investigating osteoblastogenesis with a helium neon (He-LE)  laser (Stein et al., 
2005; Yamada, 1991) were consulted. Further, two NIR-LED animal models studies 
were found (Blaya et al., 2008; Torres et al., 2008).   
The two cell culture models investigating osteoblastogenesis used helium neon 
(He-LE) laser light in the near-infrared light spectrum and reported amplification of 
osteoblastogenesis. The two animal studies that investigated bone as a living tissue and 
histologically identified osteoblast and osteoclast activity, collectively, found that near-
infrared light treatment enhanced bone formation (Torres et al., 2008) and bone 
architecture (Blaya et al., 2008).  This is similar to our results of biostimulation with 
NIR-LED light treatment. 
Aihara and colleagues (2006) studied rat osteoclast precursor cells using a 
continuous wave 810nm Ga-Al-As semi-conductor laser, with a power intensity of 
50nW. Cell cultures were inducted with a RANKL dose of 10ng/ml and exposed to 
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light treatment for 1, 3, 6, or 10 min/day for 8 consecutive days, delivering energy 
densities of 9.99, 27.99, 55.98, and 93.30 J/cm2, respectively. They report a 1.3-fold 
increase in osteoclastogenesis in the 27.99 and 55.98 J/cm2 groups (Aihara et al., 
2006). In contrast, our NIR-LED continuous wave 670nm, power intensity 60mw, 
tested single light-treatment at energy densities at 2.25, 4.5, and 45 J/cm
2 at RANKL 
doses 0, 2.5, 10, 25, and 50ng/ml, as well as multiple light-treatments (4 consecutive 
days) at an energy density of 4.5 J/cm
2
. We report an increase in osteoclastogenesis 
with a similar energy density; however, this was demonstrated with one single light-
treatment. Aihara and colleagues (2006) suggest photobiomodulation and higher 
energy densities amplify osteoclastogenesis. Overall, we found that a single light- 
treatment increased osteoclastogenesis, but when comparing the 4.5 J/cm
2 group to the 
highest energy density group, 45 J/cm
2
, the 4.5 J/cm
2 group was more effective in 
increasing osteoclastogenesis and multiple light-treatments stimulated 
osteoclastogenesis less compared to a single light-treatment. These contrasting 
results may be attributed to the use of different types of light sources and our 
experimental model testing single-light treatment. 
Yamada (1991) studied the clonal osteoblastic MC3T3-E1 cell line using  
single light treatment with a continuous wave 632.8nm, power intensity of 3.03mW/cm
2
  
He-Le laser at energy densities 0.01, 0.1, and 1.0J/cm
2
.  Light treatment was 
administered on cell culture day 2, as compared to our continuous wave 670nm, power 
intensity of 60mW/cm2, NIR-LED light at an energy density of 2.25, 4.5, and 45cm2 
administered on cell culture day 2. They found a significant increase in 
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osteoblastogenesis (p < 0.05) at energy densities of 0.01 to 1.0 J/cm
2 (Yamada, 1991). 
Stein and colleagues used human osteoblast cells for cell culture. A single light-
treatment was administered on cell culture days 2 and 3 with a 632nm, power intensity 
180mW/ cm
2 He-Le laser, at energy densities 0.14, 0.43, and 1.43 J/cm
2
. They also 
found a significant increase in osteoblastogenesis (p < 0.05) (Stein et al., 2005). Both 
of these studies used low-energy densities, suggesting that lower energy densities had a 
biological effect on osteoblastogenesis; thus, we tested an energy density of 2.25, which 
was not found to significantly increase or decrease osteoclastogenesis. 
We chose to test higher energy densities than in the osteoblastogenesis studies 
because they were comparable to the successful 670 nm NIR-LED light treatment 
studies used in a human model (Whelan et al., 2003) and in a neuronal cell culture 
model (Wong-Riley et al., 2001; Wong-Riley et al., 2005). Further, these studies by 
Whelan (2003) and Wong- Riley (2001, 2003) used the same NIR-LED light source 
manufacture (Quantum Devices, Barneveld, WI) as ours. However, our NIR-LED light 
source was a commercial product rather than the scientific grade NIR-LED. 
Bone loss occurs rapidly during early menopause; osteoclastogenesis is, thus, 
proportionally greater than osteoblastogenesis (Eriksen, 1990; Jilka et al., 1996) 
followed by an age-related steady continuous loss of bone until the end of the life 
span (Parfitt, 1990). Loss of estrogen in women results in rapid trabecular bone loss by 
20-30% and in cortical bone loss by 5-10% (Khosla & Riggs, 2005; Parfitt, 1990). 
However, it has been hypothesized that it may not be the mismatch of 
osteoclastogenesis/osteoblastogenesis, but a decrease in the number of 
stromal/osteoblastic cells (Manolagas & Jilka, 1995). A study (Jilka et al., 1996) 
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investigating the validity of a senescence-accelerated osteopenic mouse model for the 
study of metabolic bone disease reported a correlation between low bone mineral 
density and impaired osteoblastogenesis due to a low number of stromal/osteoblastic 
cells. The impairment of osteoblast formation resulted in a secondary impairment of 
osteoclastogenesis. When adding exogenous stromal/osteoblast cells from neonate 
mouse clavaria cells to the aging and osteopenic ex vivo marrow cell cultures, 
osteoclastogenesis was restored (Jilka et al., 1996). This may suggest that the imbalance 
between osteoblast/osteoclast activities may be due to the number of bone cells. 
If osteoclastogenesis activity is thought to be proportionally greater than 
osteoblastogenesis during the aging process, then as indicated by our results, as well as 
those of Aihara and colleagues, NIR light treatment increases osteoclastogenesis. 
Therefore, if osteoblastogenesis and osteoclastogenesis both increase by light treatment 
and the bone remodeling cycle is already “uncoupled”, that is, imbalanced due to aging, 
NIR-LED treatment could result in the same disrupted bone remodeling process seen 
before light-treatment. The literature suggests that osteoblastogenesis and 
osteoclastogenesis increase with low-energy light treatment, as we found. However, it 
remains, based on our limited data, that the multiple light-treatments of NIR-LED 
increases or decreases osteoclastogenesis, as opposed to multiple light-treatments, 
increased osteoclastogenesis with a Ga-AL-Gs diode laser. Regardless, both light 
sources deliver low-energy irradiation in the near-infrared range. 
In this study, we investigated the effects of NIR-LED treatment solely on 
osteoclastogenesis, but it would be useful to investigate both osteoblastogenesis and 
osteoclastogenesis under the same experimental conditions to compare their rates of 
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amplification or inhibition with NIR-LED treatment. After the effects of NIR-LED 
light-treatment are determined by testing each cell type in culture, the next step would 
be to investigate the effects of NIR-LED light-treatment on the bone remodeling 
process, because the biological effects of NIR-LED light-treatment on a system of 
homeostasis may be different from the biological response found in separate osteoclast 
and osteoblast cell cultures. 
The long-range goal of this program of research is to discover and test 
interventions that may increase bone strength and integrity in the older adult population 
to prevent bone fracture (specifically hip fractures) and improve skeletal health. There 
is not sufficient evidence to draw a firm conclusion regarding the effects of NIR-LED 
light-treatments on osteoclastogenesis in these pilot experiments. However, the majority 
of the experimental groups yielded an increase in osteoclastogenesis. Furthermore, these 
data must be interpreted with caution, since they are pilot data and meant to assist us in 
designing other experiments. Several limitations to this study are discussed below; 
they include the use of a commercial light source rather than a scientific grade light 
source, the possibility of cell culture heat shock, and investigator subjectivity in manual 
osteoclast cell counting. 
Commercial NIR-LED Light Source. The light sources used in these 
experiments are commercial grade and approximately calibrated at the factory for 
energy density, wavelength, and light intensity. The scientific grade light source has the 
advantage of controls for fine-tuning these variables. The commercial grade light source 
used in the experiments turned off automatically every 80 seconds, requiring manual 
restarting of the light during the 45 J/cm² experiments. This may have resulted in 
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measurable effects on osteoclast formation similar to pulsing light-treatment (Karu, 
1992, 1993). The manual restarting of the light-treatment (WARPTM 75) caused a 
brief temperature surge in testing during development of the protocol, but the cell 
culture medium never rose above 37
o
C. Temperature surges could be considered pulsing 
light-treatment, which have been shown in the literature to give a greater biological 
effect than continuous wave light-treatment (Karu, 1992). Given the existence of 
temperature surges, heat shock cannot be ruled out; if heat shock did occur, the cultured 
cells may have been stressed by the abrupt change in temperature resulting, in an effect 
that was not brought about by the light-treatment.  What is needed to control for these 
possible confounding variables is a light source utilizing a built-in timing mechanism 
and the capability to manually tune specific energy densities and light intensities.  This 
would give the investigator greater control to test specific irradiation wavelengths, 
energy densities, and light intensities and to prevent heat shock by using consistent low 
radiation intensity (670nm) (Karu, 1992; Letokhov, 1991), 1991). In future experiments, 
obtaining a scientific grade continuous wave NIR-LED would be necessary for ensuring 
reliable results. 
Manual Cell Counting.  Lastly, the manual cell counting technique is a 
subjective process relying on visual interpretation of color and identification of cell 
nuclei. A visual cell counting classification tool was developed to guide in the cell 
counting process (see Appendix G).  To be counted as an osteoclast cell, all cells were  
TRAP+ with a pink/purple or dark purple bordering on black (if nuclei were still visible).  
To determine the faintest acceptable pink, the stain color should match the RANKL 
control pink stain.  The counted cells should be stained darker than the control faint pink.  
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The cell was counted if there were three or more nuclei present. Clumps of TRAP+ 
mono-nucleated cells were not counted, and cells connected by cell processes were 
counted as separate cells.  The plates were blinded and the investigator took frequent 
breaks.  Alternative methods for osteoclast quantification are described in the literature:  
computer-imaging software that quantifies osteoclast by color, shape, and nuclei; and 
by a TRAP5b assay (Alatalo, Halleen, Hentunen, Monkkonen, & Vaananen, 2000; 
Halleen et al., 2000).  The computer software captures multiple images within specific 
boundaries demarcated by a gridded disk in the cell culture well, and counts osteoclasts 
based on these specifications. This method of quantifying osteoclastogenesis is less time 
consuming than manual cell counting. 
Another way to confirm manual cell count reliability is the use of spectroscopy as 
rapid screening method to determine osteoclast differentiation from a  collected cell 
culture medium has been demonstrated with the serum marker TRAP5b (Halleen et al., 
2000).  The advantage to utilizing a TRAP5b assay is it changes data collection from a 
binary value to total biological activity value.  For example, osteoclasts with greater 
numbers of nuclei are more effective in removing old bone and recruited macrophages 
could be measured.  This is another method to compare cell count to biological signal.  
One method may be more valuable than the other or affirming of experiment results. 
Conclusion 
It is clear that the effects of the light on osteoclastogenesis are RANKL-dose and 
light-intensity specific. We conclude at this time that a NIR-LED single light-treatment 
may amplify osteoclastogenesis, and multiple light treatments may impair RANKL-
induced osteoclastogenesis. The use of NIR-LED light therapy may be a beneficial 
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intervention to return the bone remodeling process to homeostasis and preserve bone 
integrity. 
It remains unknown how NIR-LED light therapy affects the intricate 
physiological signaling between osteoblasts and osteoclasts, as well as what effects it 
may have on bone remodeling and absorption. NIR-LED may decrease oxidative stress, 
preventing premature apoptosis, which is thought to occur with aging. 
Continued experiments are planned with the use of a scientific-grade NIR-LED 
light source that will allow for greater control of energy density and light intensity. 
Repeated experiments will produce a larger sample size and enable a more substantial 
statistical analysis. Understanding that aging impairs osteogenesis (bone remodeling) 
due to an imbalance or “uncoupling” of osteoclastic/osteoblast activity, interventions 
aimed at correcting this pathogenesis will further the science to provide knowledge in 
reaching the goal of developing an intervention that may restore physiological function, 
preserve or improve bone quality, improve bone mineralization with the hope of 
preventing bone fragility and fracture, and ultimately improve the bone architecture to 
withstand mechanical insult such as a fall. 
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Table 1 
  Experiment 1 
 Dose Response Curve RANKL Dose 0, 2.5, 10, 25 and 50ng/ml with NO LIGHT TREATMENT
 
 
 
 
 
Table 2 
  Experiment 1 
  Single Light Treatment for RANKL Dose 2.5, 10, 25 and 50ng/ml with Energy Density of 0, 4.5, 45 J/cm
2 
 
* = significant  
 
 
Table 3 
  Experiment 2 
 Dose Response Curve RANKL Dose 0, 2.5, 10, 25 and 50ng/ml with NO LIGHT TREATMENT 
 
 
 
 
 
 
 
Table 4 
  
 Experiment 2 
 Single Light Treatment for RANKL Dose 0, 25 and 50ng/ml with Energy Density of 0, 2.25, 4.5, 45 J/cm2 
 
   * = significant  
 
 
RANKL Dose  0 ng/ml 2.5  ng/ml  10  ng/ml 25  ng/ml 50ng/ml    
 M (SD) M (SD) M (SD) M ( SD)           M ( SD)           F P < .05 
 0  J/cm
2
 0.9 (1) 25.4 (2) 45.6 (7) 250.6 (53) 484.4 (87) 102.22 0.0001 
Single Light Treatment  
Energy Density J/cm
2
 
 
0 J/cm
2
 
 
4.5 J/cm
2
 
 
45 J/cm
2
 
  
 M (SD) M (SD) M ( SD)           F P < .05 
 0 ng/ml 0.9 (1) 0.8 (1) 0 1.33 0.3000 
2.5ng/ml 25.4 (2) 24.8 (5) 51.2 (6) 61.17 0.0001* 
10ng/ml 45.6 (7) 68.8 (13) 69.6 (11)  8.04 0.0060* 
25ng.ml 250.6 (53) 226.2 (32) 194.2 (34) 2.41 0.1318 
50ng/ml 484.4 (87) 485.2 (53) 419.4 (130) 0.78 0.4803 
RANKL Dose  0 ng/ml 25 ng/ml  50 ng/ml   
 M (SD) M (SD) M (SD) F           P < .05           
 0  J/cm
2
 0 (0) 254.4 (39) 276.8 (58) 69.86 0.0001 
Single Light Treatment  
Energy Density J/cm
2
 
 
0 J/cm
2
 
 
 
2.25 J/cm
2
 
 
 
4.5 J/cm
2
 
 
45 J/cm
2
 
  
 M (SD) M (SD) M (SD) M ( SD)           F P < .05 
 0 ng/ml 0 0 3 (3)  1 (1) 4.52 0.0176* 
25ng/ml 245.4 (40) 274.4 (92) 491 (65) 289.2 (77) 12.51 0.0001* 
50ng/ml 276.8 (58) 316 (64) 336.8 (82) 297.6 (33) 0.86 0.4831 
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Table 5 
  Single versus Multiple Light Treatments  
  Energy Density 4.5 J/cm
2
 and RANKL Dose 0, 25 and 50ng/ml  
 
Number of Treatments Single Multiple None   
 M (SD) M (SD) M (SD) F P< .05 
0 ng/ml 3.4 (3) 0.8 (1) 0 4.12 0.0434* 
25ng/ml
 
491(65) 344 (70.6) 245.4 (39) 21.41 0.0001* 
50ng/ml 336.8 (81) 358 (61.7) 276.8 (58) 1.92 0.1890 
   * = significant  
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CHAPTER FIVE - DISCUSSION, CONCLUSIONS AND IMPLICATIONS 
The purpose of this dissertation was to pilot test a new protocol designed to 
answer the broad research question:  Does Near-Infrared Light Emitting Diode (NIR-
LED) treatment affect Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL) 
induced osteoclastogenesis in a cell culture model? This study was conducted at the 
NASA Ames Bone and Signaling Laboratory and consisted of four protocol development 
experiments (Chapter Three) and two experiments for collection of data (Chapter Four).  
In order to gain a robust understanding for the pathogenesis of bone loss, specifically 
osteoporosis, three extensive reviews of the literature were completed.  The first required 
an understanding of the cellular mechanisms of NIR-LED and a search for existing NIR-
LED light treatment protocols using a cell culture model, specifically with RAW 264.7 
cells.  Based upon this knowledge, the second and third searches were conducted to 
translate bench research into applicable knowledge for generalist nurses resulting in two 
manuscripts that informed nursing practice regarding bone physiology and pathology and 
nursing implications.  The manuscripts describe gaps in the literature, provide literature 
updates and implications for future research.     
Synthesis of the Manuscripts 
There are various updated clinical practice guidelines and many concerned 
researchers, however, the point remains that by 2030, the US older adult population is set 
to double with a significant portion over the age of 85 (U.S. Department of Health and 
Human Services Administration on Aging, 2006), increasing the incidence of falls.  The 
costs to treat osteoporosis induced fractures estimated at $22 billion (Blume & Curtis, 
2011).  Most hip fractures result in hospitalization, and within the first year, 
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approximately 37% of men and 26% of women will die from complications associated 
with these fractures (Kannegaard, van der Mark, Eiken, & Abrahamsen, 2010). Of the 
individuals who survive the first year many do not return to their pre-fall functional status 
and suffer from fear, anxiety, and depression, all of which dramatically impacts their 
quality of life (Eastwood et al., 2002; Harvey et al., 2013; National Institutes of Health 
Consensus Development Panel on Osteoporosis [NIH-CDPO], 2001; National 
Osteoporosis Foundation [NOF], 2010 [revised 2013]; Ziden et al., 2008). Ultimately, the 
overall gap found in the osteoporosis literature was the inability to effectively identify 
and treat patients prior to a fracture.  Although osteoporosis research has been extensive 
over the past two decades, only a modest impact has been shown is decreasing fracture 
rates; thus, the societal economic impact to treat remains high and will only increase as 
the population ages (Bilezikian & Cusano, 2013; Bonjour, Schurch, Chevalley, Ammann, 
& Rizzoli, 1997; Burge et al., 2007; Challen, 1997; Chan, Uzer, & Rubin, 2013; Cohen & 
Shane, 2013; Cummings et al., 2009; Looker, 2010; Looker, Melton, Borrud, & 
Shepherd, 2012; Looker et al., 1997; Looker et al., 2008). 
Two manuscripts were generated in order to understand nursing implications and 
to identify gaps in the literature.  The first manuscript provides the generalist nurse with a 
review of the literature defining osteoporosis from a physiological perspective; reviewing 
bone anatomy and physiology, overviewing the pathogenesis of osteoporosis, 
osteoporosis outcomes, and presenting new treatment insights applicable to bone 
physiology.  The second manuscript’s focus is a review of nursing implications pertinent 
to osteoporosis such bone loss and fall risk assessment, interventions, prevention, and 
monitoring.  These manuscripts identified the need for the experimental study.  
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Therefore, results of the pilot data from the NASA Ames Bone and Signaling Laboratory 
extrapolated from the developed bench research protocol (Chapter Three) testing the 
effects of NIR-LED on osteoclastogenesis are reported in the third manuscript. 
The first manuscript provided insight into understanding the etiology and 
consequences of osteoporosis.  The generalist nurse was presented with the most current 
definition of osteoporosis, an overview of bone physiology and pathology, including its 
causes, and negative health outcomes, including the societal financial burden to treat 
osteoporotic induced fractures. Further, new methods to evaluate bone architecture   
volume quantitative computed tomography (vQCT), micro-computed tomography (µCT) 
and Trabecular Bone Score (TBS) (Silva et al., 2014) were discussed. Newer medications 
were discussed such as parathyroid bone anabolic (Teriparatide [Forteo®]), Receptor 
Activator of Nuclear Factor Ligand (RANKL)-inhibitor (Denosumab [Prolia ® or 
XGEVA ®]), and experimental drugs; Calcilytics, stimulate PTH secretion in vivo 
[animal study model] (JTT-305), and a newly discovered molecular pathway antagonist, 
Wnt/ß-catenin, responsible for osteoblastic differentiation and recruitment (AMG 785). 
The second manuscript provided the generalist nurse with the knowledge base to 
appropriately assess and identify osteoporosis, implement tailored interventions, provide 
disease monitoring and understand pertinent nursing implications for practice and policy.  
Ultimately, nurses are active members of the multidisciplinary team and are positioned to 
assist patients in understanding bone loss. Several gaps in the literature were highlighted:  
few prospective studies exist to understand the specifics of the pathogenesis of bone loss 
in the young and peri-menopausal women (Seifert-Klauss et al., 2012).  This raises the 
question; are clinicians screening for bone loss too late in the lifespan?  Also, the 
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majority of investigators have overlooked osteoporosis in men, as well as significantly 
under diagnosing osteoporosis in general.  In fact, some believe early diagnosis is 
overlooked due to other comorbidities concomitantly occurring because they receive 
more medical consideration, such as cardiac disease, simply because early osteopenia 
occurs asymptomatically (Rachner, Khosla, & Hofbauer, 2012).  Too often the diagnosis 
of osteoporosis is made after a fracture. Thus, interventions are aimed towards preventing 
further bone loss and consequential fractures, not efforts towards early diagnosis, 
consequently not preventing the first fracture (Rachner et al., 2012).  Osteoporosis must 
be recognized as a disease that affects individuals across their entire life-span.   
The main study of this dissertation tested the effects of NIR-LED 
photomodulation on osteoclast formation investigating for a possible intervention that 
may have benefits for bone health.  This research could be applicable to improving bone 
health for long-term space flight and general population.  A protocol was developed over 
a series of four experiments in preparation for a two experiment studies that constituted 
the pilot study.  The NASA award winning light treatment device used in this study was 
created by Quantum Devices Incorporated, originally named, High Emissivity 
Aluminiferous Lighting Substrate 
TM
 (HEALS), used to grow plants for space flight.  
Using this technology, Quantum Devices Incorporated developed a commercial device, 
Warfighter’s Accelerated Recovery by Photobiomodulation (WARP™ 10 & 75), a 
portable NIR-LED, used in combat to provide first aid for minor injuries and pain 
(National Astronautical Space Agency, 2008; Quantum Devices Incorporated, 2004; 
Whelan, 2004). The size and portability of the NIR-LED was ideal for testing effects in a 
cell culture model.   
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RANKL-induced osteoclast formation by RAW264.7 cells occurred as expected 
in all experiments. Light-treatment alone had no observable effect. A single light-
treatment at 4.5 J/cm
2
 with RANKL added (10 - 50ng/ml) suggested a biostimulatory 
effect upon osteoclastogenesis compared to controls, as multiple light-treatments 
compared to single light-treatment were less stimulatory in the energy density 4.5 J/cm
2 
and RANKL dose 25ng/ml group. The effects of the NIR-LED treatment on 
osteoclastogenesis are RANKL dose and light-intensity specific. Concluding, NIR-LED 
light-treatment affects RANKL-induced osteoclast formation, but multiple light 
treatments compared to single light treatment may stimulate osteoclastogenesis less.  
Although pilot data results must be cautiously interpreted, it was determined that 
osteoclastogenesis was affected by NIR-LED light treatment. This was the first study that 
investigated the effects of NIR-LED light treatment on osteoclastogenesis. 
Limitations 
Several study limitations existed.  Challenges existed with producing consistent 
negative control dose response curves.  Experiment one was successful, but experiment 
two, the RANKL stepwise dose response curve did not occur as expected. In fact, the 
RANKL dose 25 and 50ng/ml had approximately the same biological effect.  Thus, the 
results of the first experiment yields more reliable results suggesting that single light 
treatment is biostimulatory to osteoclastogenesis.  Because the controls in experiment two 
were inversely related, caution must be used in interpreting results.  Single light treatment 
appeared to be biostimulatory and multiple light treatments were less stimulatory 
compared to controls.   
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Evaluating the RANKL dose response curves, it appears that the RANKL dose 
50ng/ml may meet the minimum dose threshold and adding a higher dose of RANKL 
dose 75ng/ml would be advantages to more fully evaluate the dose response.   The energy 
density dose response curve is variable.  However, based on experiment one, the energy 
densities of 2.25 J/cm2 appears to be possibly meeting the minimal threshold, and then 
increased biostimulation at the 4.5 J/cm2 is stepwise, but 45 J/cm2 biostimulation 
decreases.  Continuing testing energy densities in this stepwise dosing would be 
beneficial to replicate.   
These pilot data are to be interpreted with caution as the protocol has not 
consistently produced trending results.  However, with pilot data, dose response curves 
can be adjusted and statistical control can be evaluated.  Each experiment is unique and 
the end result is to produce physiologically meaningful data.  Ultimately, a successful 
program of research should progress from cell culture into an animal model and then into 
clinical studies, thus bringing bench research to the bedside. Further, in cell culture 
animal and human cells will biologically respond differently to a same RANKL dose and 
energy density.  Once the protocol produces trending reliable results, and the most 
important independent variables are identified, then at least three repeated experiments 
must be conducted producing robust data appropriate to support or refute the hypothesis.  
Because the experiments compare multiple variables between groups, better statistical 
control of these comparisons could benefit from using the Holm-Bonferroni method 
(Abdi, 2010).  This type of analysis controls the family-wise error rate (probability of 
type I errors) and is more powerful that the Bonferroni correction. Lastly, a power 
192 
 
 
 
analysis should be calculated to ensure enough data is collected to reach significance 
(Faul, Erdfelder, Lang, & Buchner, 2007). 
Several limitations were encountered using a commercial light source rather than 
a scientific grade light source, the possibility of cell culture heat shock, and investigator 
subjectivity in manual osteoclast cell counting. The light sources used in these 
experiments were commercial grade calibrated at the factory for energy density, 
wavelength, and light intensity. A scientific grade light source has controls to fine-tune 
variables and fans to cool the light. 
 The commercial grade light source used in the experiments turned off 
automatically every 80 seconds, requiring manual restarting of the light during the 45 
J/cm² experiments. This may have resulted in measurable effects on osteoclast formation 
or inhibition similar to pulsing light-treatment which has a certain parameter of time set 
between the light’s on/off times (Karu, 1992).  Manually restarting the WARPTM 10 
may have caused a brief temperature surge during protocol development, but the cell 
culture medium never rose above 37
0
 C , the temperature maintained by the incubator.  
These temperature surges may be considered pulsing light-treatment, shown superior to 
continuous wave light treatment dependent on cell type to inhibit or stimulate cells 
(Hashmi et al., 2010).  With this said,  these possible temperature surges, could result in 
heat shock; if heat shock did occur, the cultured cells may have been stressed by the 
abrupt change in temperature resulting in an effect that was not brought about by the 
light-treatment.   
Modifications to the experimental protocol are required for future research studies 
addressing these confounding variables created by the commercial light source.  By using 
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a light source with a built-in timing mechanism and capability to manually tune specific 
energy densities and light intensities, giving greater control to test specific irradiation 
wavelengths, energy densities, and light intensities, and to prevent heat shock by using 
consistent low radiation intensity (670nm) (Karu, 1992; Letokhov, 1991). In future 
experiments, obtaining a scientific grade continuous wave NIR-LED would be necessary 
for ensuring reliable results.   
Lastly, the manual cell counting technique is a subjective process relying on 
visual interpretation of color and identification of cell nuclei.  A visual cell counting 
classification tool was developed to guide in the cell counting process (see Appendix G).  
To be counted as an osteoclast cell, all cells were  TRAP+ with a pink/purple or dark 
purple bordering on black (if nuclei were still visible).  To determine the faintest 
acceptable pink, the stain color should match the RANKL control pink stain.  The 
counted cells should be stained darker than the control faint pink.  The cell was counted if 
there were three or more nuclei present. Clumps of TRAP+ mono-nucleated cells were 
not counted, and cells connected by cell processes were counted as separate cells.  The 
investigator took frequent breaks.  Alternative methods for osteoclast quantification are 
described in the literature:  computer-imaging software that quantifies osteoclast by 
color, shape, and nuclei; and by a TRAP5b assay (Alatalo, Halleen, Hentunen, 
Monkkonen, & Vaananen, 2000; Halleen et al., 2000).  The computer software captures 
multiple images within specific boundaries demarcated by a gridded disk in the cell 
culture well, and counts osteoclasts based on these specifications. This method of 
quantifying osteoclastogenesis is less time consuming than manual cell counting. 
Using spectroscopy as a rapid screening method to determine osteoclast total 
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biological signal from the collected cell culture medium has been demonstrated with the 
serum marker TRAP5b (Halleen et al., 2000).  The advantage to utilizing a TRAP5b 
assay is it changes data collection from a binary value to total biological activity value.  
For example, osteoclast cell with multiple nuclei yield a higher biological signal and may 
be more effective in removing old bone. These data compared to cell count are a 
beneficial intra reliability measure.  
Overall, three different perspectives of the bone loss literature were reviewed.  
The first two manuscripts provide implications for nursing practice, public policy, and 
future research; specifically health system wide comprehensive patient education 
programs implemented across the life-span. The third manuscript presented pilot data that 
must be interpreted with caution, but it can be determined that the study provided a solid 
robust experimental protocol suitable for continued research. Continued experiments are 
planned with the use of a scientific-grade NIR-LED light source that will allow for 
greater control of energy density and light intensity. Repeated experiments will produce a 
larger sample size and enable a more substantial statistical analysis. It remains unknown 
how NIR-LED light therapy affects the intricate physiological signaling between 
osteoblasts and osteoclasts, as well as what effects it may have on bone remodeling and 
absorption, but new literature does provide some insight.  
Implications 
Implications for practice, policy, research and nursing research are offered based 
on the results of this study. Nurses are able to evaluate a patient’s health care needs 
holistically and integrate all physiological systems related to the human condition.  For 
example, a bone health scientist could make a suggestion for older adults to follow a 
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vegan diet in order to preserve bone health.  This dietary lifestyle is readily available 
along the Pacific coast, and may be an ineffective intervention, because a vegan diet is 
not as prevalent in the Midwest.  Based upon the nurse’s prior rural home health 
experience within the farming community, these older adults would not be willing to 
remove dairy, eggs and meat from their diet based simply upon the social norms within 
their personal culture.  Therefore, implementing an educational program to follow a 
vegan diet would most likely not be effective in a rural farming community.  
Practice.  Nurses have the opportunity to impact osteoporosis screening, 
management and medication adherence through patient education.  Because bone loss is a 
multifaceted healthcare concern, the nurse can view the problem of attaining and 
maintaining bone health across the human life-span.  Nurses have the most frequent 
patient contact, are trusted among many patient populations (Dinç & Gastmans, 2013), 
embrace the implementation and improvement of evidence based practice (Lee et al., 
2013), and are an integral part of the multidisciplinary health care team (Wilkes et al., 
2014). Nurses have the opportunity to guide women and men to improve bone health and 
reduce or reverse bone loss, thus preventing fractures and mortality and improving the 
quality of life of older adults through thoughtful risk and clinical assessment, attentively 
monitoring and implementing tailored interventions (Teng, Curtis, & Saag, 2009). 
 Effective nurse driven interventions have shown to be economical ($50 per 
patient), successful using 70 minutes of one-on-one  nurse case management by simply 
providing patient education regarding the risks and benefits of bisphosphonate therapy, 
arranging BMD testing, and assisting if needed to obtain prescriptions from their primary 
care provider (Majumdar et al., 2007).  With this said, nurses in outpatient clinic settings, 
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can develop a comprehensive bone health educational programs that provides 
intervention at the four points of the lifespan:  maternal/infant health, pediatric, peri-
menopause/menopause (women’s health) and post-menopause (gerontology).   
Policy.  In order for a comprehensive bone health program to be effective, 
hospital system must employ more registered nurses(RNs) in their clinic systems to 
provide assessment and work in collaboration with advanced practice nurses to provide 
data to support screening perimenopausal women beginning at age 45 for bone loss.  
Between 2008-2013 only (9%) and (7%) RNS were employed in outpatient 
clinics compared to (62%) and (60%) of medical assistants, respectively (Bureau of 
Labor Statistics, 2008a, 2008b, 2013a, 2013b).  Many of these nurses are performing 
below their scope of practice while unlicensed assistive personnel are preforming above 
their scope of practice (American Academy of Ambulatory Care, 2012).  As health care 
services shift from inpatient settings to outpatient setting, access to RNs will be 
significantly less for the majority of the patient population (Bureau of Labor Statistics, 
2013a).   
Peri-menopause has been a focus in the literature since the mid-1990s, however 
prevention and screening for osteopenia or evaluating perimenopausal women for bone 
loss is lacking.  Bone loss is reported to be stable during pre-menopause, but accelerates 
significantly in late perimenopause (Finkelstein et al., 2008).  In the 5-7 year span of 
perimenopause and menopause, approximately, 12% of total bone mass is lost which is 
equal to one T-score (-1 SD) of measured bone density by DEXA which corresponds to a 
diagnosis of osteopenia (Armas & Recker, 2012). Most interventional studies focus on 
post-menopausal women, at that point in the life-span the proverbial “horse is out of the 
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barn”.  Menopausal transition biomarker research is needed to identify the 
perimenopausal women.  The best clinical setting to improve bone health awareness 
across the lifespan would be in the outpatient clinic setting for both generalist and 
advanced practice nurses to increase screening, patient education, and management.    
Research.  A collaboration and translation of technologies applicable to astronaut 
health may be useful in the general population.  Currently, the International Space Station 
uses NIR-LED to grow plants, but some day this technology may be applicable to bone 
health.  It has already been translated as a technology used in the general population for 
pain relief (Quantum Devices Incorporated, 2004) and used for wound healing in the 
military (Whelan et al., 2004).   
According to the National Institutes of Health, translational research can be 
defined as a two stage process; the application of innovative laboratory research into 
preclinical studies to design human clinical trials that results in the implementation of 
best practices into the community with objectives to achieve cost-effectiveness in 
prevention and treatment (National Institutes of Health, 2007).  Research is transferred 
from the laboratory’s bench (basic research) to the patient’s bedside (clinical research) 
then clinical study and trial findings transferred into the community and practice settings 
to improve health outcomes (Rubio et al., 2010).       
One example of translational research in collaboration with NASA was recently 
presented at the International Osteoporosis Foundation - International Society for Clinical 
Densitometry.  These researchers from Johnson Space Center, Wyle; aerospace 
contractor, Mercy Health, Cincinnati, and Lausanne University Switzerland investigated 
a new measurement for bone strength, trabecular bone score (TBS) of the lumbar spine in 
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long-duration spaceflight astronauts (Smith et al., 2014).  They calculated for changes in 
DEXA and TBS scores in three different bone loss countermeasure (intervention) groups. 
Changes in mineral content, cortical vs. trabecular bone, may suggest independent effects 
of bone loss according to group intervention.  These data support the continued need to 
investigate TBS as a significant measurement to evaluate bone architecture.    
Education.  Opportunities for nurses engaged in basic science research discovery 
are available.  The University Of Maryland School Of Nursing recently posted a nurse 
physiologist research scientist tenure track faculty position.  Further, access to 
laboratories for nurse physiologists can be found directly in the Schools of Nursing at 
Yale University and University of Pennsylvania.  However, it still remains difficult to 
find a good fit with a university that provides adequate support for basic science research 
without relying on external laboratory space for the nurse scientist.   
Most positions require at least one year of post-doctoral education (University of 
Maryland School of Nursing, 2014).  The Robert Wood Johnson Foundation supports a 
Nurse Faculty Scholar Award providing research funding to junior faculty creating the 
next generation of nurse leaders (Robert Wood Johnson Foundation, 2014).   
More regionally, Medical College of Wisconsin Center for Clinical and 
Translational Institute provides information regarding resources for specialized research 
laboratories at partner institutions; Blood Center of Wisconsin, Children’s Hospital of 
Wisconsin, Froedtert Hospital, Marquette University, Medical College of Wisconsin, 
Milwaukee School of Engineering, University of Wisconsin-Milwaukee and Zablocki 
VA Medical Center (Medical College of Wisconsin Center for Clinical and Translational 
Institute, 2014). These resources may allow a bench research nurse scientist network and 
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collaborate with those scientists with laboratory facilities if one is not available at their 
primary institution.  It is important that in becoming a basic science nurse scientist, a 
commitment is made not only by higher educational institutions to employ basic science 
nurse researchers but more importantly to foster relationships and mentor other doctoral 
nursing students.   
Implementing curriculum to prepare an Integrative Nurse Physiologist into the 
Nursing Doctorate of Philosophy should be considered.  Currently, there is not an 
academic pathway for this course of academic study and typically, post-doctoral study is 
required for employment in current nursing faculty positions.  It would be most 
advantageous to accommodate immediate employment upon completion of the PhD, thus, 
providing colleges of nursing an applicant pool of nurse physiologists. 
 The curriculum should complement the student’s program of research and allow 
for specialization.  For example, flexibility in course choice would be most beneficial to 
the student.  Some appropriate courses to include, but not limited to, are cell biology, 
clinical lab sciences, advanced anatomy and physiology, and chemistry.  Before 
implementing this academic pathway, resources such a laboratory facilities and research 
funding for bench research opportunities must be secured.  This may be established 
through College of Nursing endowment funding and field sites with bench research 
scientists. Nurse physiologists benefit the research community because their participation 
among multidisciplinary members provides perspectives regarding the human condition, 
and fosters creativity for research questions that involve multi disciplines.  They are the 
great collaborators, communicators, and teachers; and they tend to be the healthcare 
expert and caring agents among the team.  Many times their role is essential for bringing 
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the team together to together to discuss solutions to problems, and interpreting results 
then moving science forward.  
Future Research 
The main focus of this study was to test a biomedical device for effects in cell 
cultured osteoclasts. Much laser light treatment research has advanced, particularly in the 
field of dentistry.  In the past, the most common use for lasers was seen in surgical 
techniques to cut, coagulate, or ablate tissue.  The laser’s mechanism of action in this 
instance is to destroy tissue and provide precise surgical incisions. This is achieved by 
heating the tissue at a high irradiation intensity and energy density.  The use of low level 
laser treatment is the utilization of a low power laser or light emitting diode in the 
irradiance range of (1mW – 500MW) (Huang, 2009).   
  Recent search for NIR-LED treatment in combination with osteoporosis yielded 
no studies.  However, searching low level light treatment, a few new studies were found.  
As with any use of a bio-technology, beneficial or harmful effects may occur in different 
cell types. As stated biological aging related to human aging has been associated with 
cellular oxidative stress (OS) and mitochondrial dysfunction (Melov, 2000), and this may 
induce bone loss (Srinivasan & Avadhani, 2007).  Mitochondrial DNA (mtDNA) 
indicates that mutations of the mitochondrial genome are vulnerable to oxidative damage 
(Linnane et al., 1989) and may cause degenerative diseases and aging. NIR-LED light 
treatment has beneficial effects in reducing cellular oxidative stress, improving 
mitochondrial function and preventing premature cell apoptosis (Karu, 1999;  Desmet et 
al., 2006; Wong-Riley et al., 2001).  The following are updates to the NIR-LED 
literature. 
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As previously discussed, beneficial effects were found in improving wound 
healing (Eells et al., 2004; Whelan et al., 2003), bone regeneration (Pinheiro et al., 
2009), decreasing inflammation and pain, aiding in recovery of ischemic cardiac injury 
(Oron, 2006; Oron et al., 2001), and attenuating retinal/optic nerve degeneration (Eells et 
al., 2007; Eells et al, 2004; Eells et al., 2003; Liang et al., 2006).  Recent animal model 
research has demonstrated continued positive effects in bone repair activating osteogenic 
factors (Barbosa et al., 2013; Tim et al., 2014).  Of interest, bisphosphonates-related 
osteonecrosis of the jaw (BRONJ), a well-known adverse side effect of long-term use of 
bisphosphonates, is an area of bone exposed in the maxillofacial region that does not 
heal within two months (Khosla et al., 2007).  Use of  surgical laser-assited (low level 
laser treatment) in BRONJ patients aided bone healing positively compared to traditional 
medical treatment (Vescovi et al., 2012).  Further, NIR-LED treatment was used in two 
transgenic Alzheimer’s mouse animal models and found cerebral degeneration was 
reversed or alleviated (Purushothuman, Johnstone, Nandasena, Mitrofanis, & Stone, 
2014). Further, improvement in cognitive function in two traumatic brain injury patients 
improved with forehead and scalp NIR-LED light treatment (Naeser, Saltmarche, 
Krengel, Hamblin, & Knight, 2011).  Detrimental effects of NIR-LED treatment were 
found in a Meckel Syndrome animal model reporting that cystic kidneys did not improve 
with light therapy as a twofold increase in BUN was reported (Lim et al., 2011).  It 
remains unknown how NIR-LED light therapy affects the intricate physiological 
signaling between osteoblasts and osteoclasts, as well as what effects it may have on 
bone remodeling and absorption. 
202 
 
 
 
Continued Program of Research.  Provided once the experiment protocol 
produces trending reliable results and the most important independent variables are 
identified, three repeated experiments will be conducted to produce robust data 
appropriate to support or refute the hypothesis.  However, understanding more fully that 
aging impairs osteogenesis (bone remodeling) due to an imbalance or “uncoupling” of 
osteoclastic/osteoblast activity, interventions aimed at correcting this pathogenesis will 
further the science to provide knowledge in reaching the goal of developing an 
intervention that may restore physiological function, preserve or improve bone quality, 
improve bone mineralization with the hope of preventing bone fragility and fracture, and 
ultimately improve the bone architecture to withstand mechanical insult such as a fall.  
It is known that sex steroid deficiency (loss of estrogen) stimulates osteoblast and 
osteocyte apoptosis leading to fewer osteocytes in the bone matrix (Almeida & O'Brien, 
2013; Manolagas, 2010) because estrogen stimulates osteoprotegerin (OPG) production 
and is vital to the regulation of osteoclastogenesis.  As a result, menopausal transition and 
post-menopause, RANKL cytosol concentrations are greater than the OPG generation 
due to loss of estrogen (Tella, Gallagher, Tella, & Gallagher, 2013). Therefore, 
osteoclastogenesis is appropriately regulated by OPG, and osteoclastogenesis is increased 
due to higher concentration of RANKL.  Low level light treatment is known to have the 
above mentioned benefits to improve cellular oxidative stress, mitochondrial function, 
and improved gene transcription.  Further, transcription factor nuclear factor B (NF-κ-B), 
regulated by changes in cellular redox state is activated with low level light treatment 
producing protective and stimulatory gene products (Huang et al., 2011).  This is the 
same nuclear factor activated by the joining of the osteoblast RANKL and macrophage 
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RANK receptor.  There may be a link between light treatment and osteoclast formation.  
A future research question may be to explore if LLLT induces osteoclast formation via 
the activation macrophage nuclear factor B (NF-κ-B) in the absence of RANKL in cell 
culture.  
Discussion 
Given the opportunity to work collaboratively with NASA was a unique 
experience for a doctoral nursing scientist.  Participating with a bench-research scientific 
team, a nursing perspective was welcomed.   Traditionally the specialty of space nursing 
involves assisting flight surgeons in pre-flight preparation similarity to outpatient patient 
care.  Another role is the management and medical monitoring of specialized space-
related research, for example managing and monitoring subjects in bed-rest and sleep 
deprivation studies.  Nursing has multiple perspectives to bring to bench research teams.   
To summarize the major tenets of the considerable amount of available bone loss 
literature, the current incidence of osteoporosis and fractures remains high, and is soon to 
become a worldwide epidemic while many countries fail to consider this as a major 
health problem. It is evident that estimates of cost to treat osteoporotic-induced fractures 
are expected to at least double by 2040 placing a great societal financial burden to care 
for the anticipated 70 million older adults by 2030.  Access to quality and timely health 
care services may become difficult due to the shortage of healthcare providers, 
specifically, geriatric certified (Centers for Medicare & Medicaid Services, 2005; 
Hartford Center of Geriatric Nursing Excellence at the Arizona State University College 
of Nursing & Healthcare Innovation, 2008). Nurses have the most frequent patient 
contact, are trusted among many patient populations, and embrace the implementation 
204 
 
 
 
and improvement of evidence based practice.  Therefore, nursing has an opportunity to 
fill the foreseeable gaps in services by enhancing their knowledge base to efficiently 
identify and implement appropriate interventions for the prevention and treatment for 
osteoporosis across the life-span.  Skeletal health researchers have one common goal, 
which is to gain an in-depth understanding of how to prevent or reverse bone loss in order 
to prevent fractures and mortality, thus improving the quality life of older adults (Teng et 
al., 2009).  
Conclusions 
This pilot study accomplished two objectives.  First the development of a 
successful experiment protocol and second, concluding that NIR-LED affects 
osteoclastogenesis.  A challenge exists on how to effectively impact the identification and 
treatment of osteoporosis in order to prevent initial osteoporotic induced fractures.  
Osteoporosis and osteopenia are grossly underdiagnosed and usually are not assessed 
until a fracture occurs.  Fracture is a main causal factor for morbidity and mortality in the 
older adult population and the most common trigger point for osteoporosis identification 
and treatment; however, only modest results in improving osteoporosis management have 
been achieved through patient and clinician education, but nurse driven interventions 
have been found to be effective.  Further research is warranted to investigate fully the 
effects of NIR-LED light treatment and possible implications as an intervention to 
prevent or preserve bone health.    
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Figure 3 
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AEXP1381 Conditioned Medium Experiment on RAW264.7 Cells 
Goal: Follow Exp1377, to collect more CM for pit assay, also use the irradiated cells to 
repeat the replating exp, and possibly test different inhibitors 
 
I. Part A. Conditioned Medium Collection 
Day-1. Cell Plating (density of 7x10
4
 cells/mL)  
1. Cell Collection 
___ aspirate medium 
___ add 5mL pre-warmed medium to flask 
___ use a sterile cell scraper gently remove cells from flask 
___ transfer cell suspension into a sterile conical tube 
___ centrifuge at 800rpm for 5 min  
___ resuspend cells in 10mL medium 
___ use 1mL pipetman to break up clumps by pipetting up and down 
2. Hemocytometer Counting 
___ take 5uL of cell suspension, and mix with 45uL of trypan blue (dilution: 1/10, 
due to higher dilution if too concentrated.) 
___ load the chamber with 20uL diluted cells suspension 
___ count viable cells in 4 x 1mm
2
-squares with 10X objective under a 
microscope  
___ calculate the number of cells/mL 
Cell Density = D1 = (____/4)x10x10
4
= ____________cells/mL  
Total Number of Cells in 10mL cell suspension = 
(D1)*10=___________cells 
___ add another 10mL of medium to cell suspension, mix well 
3. Make _80_ mL cell stock with density of 7x104 cells/mL 
___ add __________  uL cell suspension 
___ mix with __________ mL α-MEM+10%FBS 
4. Plating in T-75 
___ pipet up and down several times to get an even suspension 
___ add 12mL of cell suspension to each T-75 
___ check under microscope  
___ incubate at 37
o
C  
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Day 0: Irradiation (this procedure will be carried by Ruth.)  
1. Irradiation step will be carried out by Ruth (0Gy and 2Gy) 
1. Immediately after IR, collect and replace with 12mL fresh medium. 
Centrifuge medium collected at 1000rpm for 10 min, then store at -80
o
C. 
 About _______ conditioned medium per flask was collected. 
2. Incubate flasks at 37oC. 
 
Day 3: Culture Medium Collection 
1. Prepare and label 6 x sterile and pyrogen-free centrifuge tubes 
2. Combine and transfer condition medium from flasks to centrifuge tubes  
3. Centrifuge tubes at 1000rpm for 10 minutes 
4. Collect supernatant and transfer to sterile, pyrogen-free tubes 
Store at -80
o
C  
  
Flask# (CM#) IR dose (Gy) ∆ medium after IR IR Time (min), Position 3, Rotate 
1, 2, 3 0Gy ∆ Sham IR 
4, 5, 6 2Gy ∆ 2.19 min 
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RAW 264.7 Culture Growth Medium Preparation: 
Manufacture HyClone procedure was followed (HyClone, 2003). 
1. Removed 500ml bottle of FBS from -80°C freezer and placed in 
refrigerator to thaw overnight.  Completed the thawing of serum the 
following day by placing serum in a 37°C water bath (Polysciences) 
with a water level higher than the serum level in the bottle. Mixed by 
inversion.  
2. Once serum was completely thawed, incubated for an additional 15 
min to allow serum to equilibrate with the 37°C bath.   
3. Raised the temperature setting of the bath to 56°C and continued 
heating the bath and serum until the bath reached 56°C (approximately 
35 minutes).  During this incubation period, mixed the serum by 
inversion every 10 min.   
4. Once bath reached 56°C, incubated serum for 30min mixing the serum 
bottle every 10 min.   
5. Removed serum from water bath and allowed to cool at room 
temperature for 30 min.  Reset water bath to the 37°C mark.   
6. Cleaned all surfaces in the cell culture hood, pipetman and conical 
tube holder with 70% ethanol.  Then cleaned external surfaces of ten 
50ml conical tubes and the 500ml bottle of FBS from the water bath 
with 70% ethanol (ETOH) to sterilize them to prevent contamination 
of cultured cells. Aliquoted 50ml of treated serum into ten 50ml 
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conical tubes (Fisher Scientific:  catalog number 0553860) and stored 
at 4°C or freeze at -20°C.   
7. After the FBS was heat inactivated and filtered (Fisher Catalog 
number:  0974028C), the FBS may be added to the growth culture 
medium (Fisher Scientific, 2010b). Removed one 50ml conical FSB 
(Fisher Scientific:  catalog number 0553860) from freezer and thawed 
in 37°C water bath (Polysciences).    
8. Cleaned external surfaces of the vial and hood with 70% ethanol 
(ETOH) to prevent contamination of cultured cells   
9.  Removed 500ml bottle of ά-MEM from the refrigerator and filtered 
through a 500ml filter Nalgene, 500/250ml capacity (surfactant-free 
cellulose acetate (SFCA) membrane 0.2um:  Fisher catalog number:  
0974028C)  followed by filtering 50ml of FBS (10% concentration). 
a4. RAW264.7 Cell Thawing:  The procedure for propagation of RAW 
264.7 cells was as follows:  
1. Prepared a water bath (Polysciences) to 37°C and pre-warmed ά-
MEM-10% FBS for approximately 15min in water bath.   
2. Thawed cells with a constant gentle agitation in the 37°C water bath.   
3. Cleaned all surfaces in the cell culture hood, pneumatic pipette-man 
(BrandTech Accu-Jet) and conical tube holder with 70% ethanol.  
Cleaned external surfaces of two 50 ml conical tubes (Fisher 
Scientific:  catalog number 0553860) to be used in the transfer of 
RAW 264.7 cells into cell culture dishes with 70% ethanol. Placed the 
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two conical tubes in the hood and labeled one tube “cell suspension” 
and the other “medium” with cryo marker (marker will not be removed 
if sprayed with 70% ethanol). Added 10ml of culture medium to 
“medium” conical tube.  
4. Under the sterile hood, flamed lid of vial of RAW 264.7 cells.  
Sterilized the lid prior to opening.  
5. Under the hood, gently transferred thawed cells to 50ml conical tube.  
6. Added warmed culture medium to “cell suspension” labeled conical 
tube in a drop-wise fashion such that 10ml is added over about 2 min 
then added the rest a little faster, gradually diluting cells and 
preservative.   
7. Centrifuged for 5 min at 100g (730 rpm Beckman GS-6KRl). 
8. Discarded the supernatant (medium above visible ring of centrifuged 
cells) and re-suspended the cells in 10 ml of fresh medium for culture.   
9. Aspirated cells with pipetman to break up cells and gently expelled 
them into three 10 cm tissue-culture treated Polystyrene petri dishes 
(Corning, Fisher Catalog number:  0877222) (Fisher Scientific, 2010a) 
in recommended cell suspension ratios 1:20, 1:10, 1:5 cell. 
10. Cell suspension Ratios: 
 Added culture medium and adjusted accordingly to ratio for 
a total of 10ml per culture dish 
 1:20  2ml cells/8ml = 20% concentration 
 1:10  1ml cells/9ml = 10% concentration 
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 1:5   0.5ml cells/9.5ml = 5% concentration 
  Cells are then ready for propagation (the multiplication and division of cells by 
natural reproduction) 
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Procedure for Cell Passaging 
 
The procedure to passage RAW 264.7 was as follows:  
1. Cleaned all surfaces in the cell culture hood, pneumatic pipette-man 
(BrandTech Accu-Jet) and conical tube holder with 70% ethanol.  
Then cleaned external surfaces of two 50 ml conical tubes (Fisher 
Scientific:  catalog number 0553860) to be used in the transfer of 
RAW 264.7 cells into cell culture dishes with 70% ethanol. Labeled 
one tube “cell suspension” and the other “medium” with cryo marker.  
2.  Removed 500ml bottle of ά-MEM-10% FBS from the refrigerator and 
cleaned with 70% ethanol and place in hood. Transferred 50ml of 
medium to the conical tube labeled “medium”.  Removed and placed 
in water bath. 
3. Prepared a water bath (Polysciences) to 37°C and pre-warmed ά-
MEM-10% FBS.  When warmed to 37°C (approximately 10 min), 
cleaned outside of conical tube with 70% ethanol prior to placing back 
in hood.   
4. While warming medium in water bath, gathered 10ml pipette tip (BD- 
catalog number 309604) and cell scraper (Falcon:  catalog number 
353085).  Placed by sterile technique two 10cm tissue-culture treated 
Polystyrene petri dishes (Corning, Fisher Catalog number:  0877222) 
(Fisher Scientific, 2010a) in the hood.   
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5. Labeled petri dishes with initials, date, the number of times cells have 
been passaged, name of cell line (RAW 267.4) and cell concentration 
suspension ratios of 1:10 and 1:5 cell with cryo marker.   
6. Took incubated petri dishes of RAW 264.7 cells from incubator and 
visualized under inverted microscope (inverted microscope, 10x 
magnification; Nikon Eclipse TS100).  Determined which cell culture 
dish had the highest cell confluence.  Saved other cell culture dish in 
reserve.   
7. Under hood, aspirated old culture medium from petri dish with suction 
and replaced with 10 ml fresh medium. 
8. Took cell scraper and gently whisked cells up off of the petri dish 
surface moving in a clockwise fashion. 
9. Aspirated 10ml from petri dish and placed in conical tube label “cell 
suspension”, Centrifuge for 5 min at 800rpm (Beckman GS-6KRl). 
10. While centrifuging, placed 9.5 ml and 9 ml of medium into petri dishes 
respectively. 
11. Took conical tube from centrifuge and discarded the supernatant and 
re-suspended with cells in 10ml of fresh medium.  Pipetted up and 
down in conical tube to break up cell clumps, then gently expelled 1ml 
of cell suspension into the labeled 1:10 petri dish and 0.5ml into the 
1:5 label petri dish.  
 Cell suspension Ratios: 
 
 1:10  1ml cells/9ml = 10% concentration 
  1:5   0.5ml cells/9.5ml = 5% concentration 
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Appendix D 
Cell Plating Procedure 
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Cell Plating Procedure 
The cell plating density was calculated by the following procedure: 
1. Calculate number of required experiment wells 
Control Plates:  5 wells per condition   Total Wells: 50 
4.5 J/cm
2
 Energy Density Control Plate     
Plate 1:   0-0-0 0-0-2.5 0-0-10 15 wells 
Plate 2:   0-0-0 0-0-25 0-0-50 10 wells 
 
45 J/cm
2
 Energy Density Control Plate     
Plate 1:   0-0-0 0-0-2.5 0-0-10 15 wells 
Plate 2:    0-0-25 0-0-50 10 wells 
 
Experimental Plates:  5 wells per condition  Total Wells:  50 
4.5 J/cm
2
 Energy Density Exp Plate     
Plate 1:   1-4.5-0 1-4.5-2.5 1-4.5-10 15 wells 
Plate 2:    1-4.5-25 1-4.5-50 10 wells 
 
45 J/cm
2
 Energy Density Exp Plate     
Plate 1:   1-45-0 1-45-2.5 1-45-10 15 wells 
Plate 2:    1-45-25 1-45-50 10 wells 
 
2. Total wells plated  
___      Controls:  50 wells 
___       Experimental:  50 wells 
___       Total 100 wells 
 
4.   Used 24 well plates @ 0.5 ml/well culture medium 
a. Equation: 
 
Total needed medium:    x     of wells * 0.5 ml =   y mls   
 100 wells * 0.5ml =50 mls [make 55 mls of cell 
stock (additional 5mls for reserve)]  
 
 
b. Cell plating density equation:   
 
4 x10
4 
cells   *   0.5 ml   = 2 x10
4   
cells/well
      
   1 ml                  well 
 
Day 0:  Cell Plating:  Density of 2 x 10
4 
cells/well   RAW264.7 cells were passaged 17 
times in ά-MEM-10%FBS 
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1.  Cleaned all surfaces in the cell culture hood, pneumatic pipette-man (BrandTech 
Accu-Jet) and conical tube holder with 70% ethanol.  Then cleaned external 
surfaces of three 50 ml conical tubes (Fisher Scientific:  catalog number 0553860) 
to be used in the transfer of RAW 264.7 cells into cell culture dishes with 70% 
ethanol. Labeled these three tubes “Cell Suspension”, “Plate Cell Suspension” and 
“Medium” with cryo marker. 
2.  Removed 500ml bottle of ά-MEM-10% FBS from the refrigerator and clean with 
70% ethanol and place in hood. Transfer 50ml of medium to the conical tube 
labeled “medium”.  Remove and place in water bath. 
3. Prepared a water bath (Polysciences) to 37°C and then pre-warmed ά-MEM-10% 
FBS.  When medium is warmed to 37°C (approximately 10 min), cleaned external 
surface with 70% ethanol prior to placing back in hood.   
 While warming medium in water bath, gathered 10ml 
pipette tip (BD- catalog number 309604) and cell scraper 
(Falcon:  catalog number 353085).  Placed by sterile 
technique two 10cm tissue-culture treated Polystyrene petri 
dishes (Corning, Fisher Catalog number:  0877222) (Fisher 
Scientific, 2010a) in the hood.   
 Used cryo marker, labeled petri dishes with initials, date, 
the number of times cells have been passaged, name of cell 
line (RAW 267.4) and cell concentration suspension ratios 
of 1:10 and 1:5 cells.   
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 Took incubating petri dishes of RAW 264.7 cells from 
incubator and visualized under inverted microscope 
(inverted microscope, 10x magnification; Nikon Eclipse 
TS100).  Decided which cell culture dish had the highest 
cell confluence.  Saved other cell culture dish in reserve.   
 Under hood, aspirated old culture medium from petri dishes 
with suction and replaced with 10 ml fresh medium. Took 
cell scraper and gently whisked cells up off of the petri dish 
surface moving in a clockwise fashion. 
 Aspirated 10ml from petri dish and placed in conical tube 
label “cell suspension”, Centrifuge for 5 min at 800rpm 
(Beckman GS-6KRl). 
 While centrifuging, placed 9.5 ml and 9 ml of medium into 
petri dishes respectively. 
 Took conical tube from centrifuge and discarded the 
supernatant and re-suspended with cells in 10ml of fresh 
medium.  Pipetted up and down in conical tube to break up 
cell clumps, then gently expelled 1ml of cell suspension 
into the labeled 1:10 petri dish and 0.5ml into the 1:5 label 
petri dish.  
 Cell suspension Ratios: 
 1:10  1ml cells/9ml = 10% concentration 
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  1:5   0.5ml cells/9.5ml = 5% 
concentration  
Save “Cell Suspension” conical to prepare plating cell suspension 
procedure. 
4. Hemocytometer Counting:   
 took 10uL of cell suspension, and mixed with 20ul of trypan blue 
(used to stain cells) (dilution:  1/10, go to higher dilution if too 
concentrated.) 
 
 loaded the hemocytometer chamber with  approximately 10uL 
diluted cell suspension  
 
 counted viable cells in 4 x 1mm2 squares with 10x objective under 
a microscope:  squares need to be > 50cells.  
 calculated the number of cells/ml 
 
 
 
Cell Density = (_ 214 _/4) =     53.5    *  10  (1/10 dilution) *10
4
 =  5.35 x 10
6
  
cells/ml    
 
 
5. Cell stock (Plating Cell suspension) 
Made _55_ ml cell stock with density of 4x10
4
 cells/ml 
 
 100 wells * 0.5ml = 53.5 mls [make 55 mls of cell stock] 
 
55ml x 4 x 10
4 
  = 2.2 x 10
6
 cells/ml 
      1ml
 
 
  
#cells in  
hemocytometer 
 
 
Dilution factor 
 
Cell plating density 
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2.2  x 10
6
 |   1ml 
     X        |   5.35 x 10
6
            
 
= .411 ml or 411ul 
 
 added  411ul cell suspension  
 mixed with  _54.5   ml ά-MEM+10% FBS in labeled “Plate cell 
suspension” conical  
 
 
6. Plated 25 wells in Control 24 well cell culture plates:   
 
Divided plates by experimental treatment groups according to the RANKL dose 
(0, 2.5, 10, 25 or 50 ng/ml), and the energy density (4.5 J/cm², 45 J/cm²) with respective 
negative controls.   
Plate 1:  (4.5 J/cm
2  
controls) 
1
st
 control plate:  15 wells 
[A2 – A6]:  0-0-0  
[B2 – B6]:  0-0-25 
[C2 – C6]:  0-0-50 
Plate 2:  (4.5 J/cm
2  
controls) 
2
nd
 control plate:  10 wells 
[A2 – A6]:  0-0-2.5  
[B2 – B6]:  0-0-10 
 
Plate 3:  (45 J/cm
2  
controls) 
1
st
 control plate:  15 wells 
[A2 – A6]:  0-0-0  
[B2 – B6]:  0-0-25 
[C2 – C6]:  0-0-50 
 
Plate 4:  (45 J/cm
2 
controls) 
2
nd
 control plate:  10 wells 
[A2 – A6]:  0-0-2.5  
[B2 – B6]:  0-0-10 
 
 
7. Plated in 25  wells of treatment 24 well cell culture plates:   
Plate 5:  (4.5 J/cm
2 
treatment plates) 
1
st
 treatment plate:  15wells 
[A2 – A6]: 1-4.5-0 
[B2 – B6]: 1-4.5-25 
Total 
amount of 
cell 
suspension 
needed     
 Cells/ml for hemocytometer 
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[C2 – C6]: 1-4.5-50 
 
 
Plate 6:  (4.5 J/cm
2 
treatment plates) 
2
nd
 treatment plate:  10 wells  
[A2 – A6]:  1-4.5-2.5 
[B2 – B6]:  1-4.5-10 
 
Plate 7:  (45 J/cm
2 
treatment plates) 
1
st
 treatment plate:  15wells 
[A2 – A6]: 1-45-0 
[B2 – B6]: 1-45-25 
[C2 – C6]: 1-4.5-50 
 
 
Plate 8:  (45 J/cm
2 
treatment plates) 
2
nd
 treatment plate:  10 wells  
[A2 – A6]:  1-45-2.5 
[B2 – B6]:  1-45-10 
 pipetted up and down several times for an even suspension  
 added 0.5ml cell suspension to each well   
o expelled cells gently alongside of well wall, and swirled plate 
for an even cell suspension 
 visualized cells under microscope to determine an even cell suspension 
 placed in incubator for 24hrs   
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Appendix E  
Receptor Activator of Nuclear Factor Ligand Induction (RANKL) 
Induction Procedure 
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- RANKL Induction Procedure 
A 20µl RANKL dilution was prepared to be added to each treatment well. 
20 wells @ 20µl of RANKL intermediate = 450µl of volume for each RANKL dose 
 
 
 
Each well contained 0.5ml of medium:  added 20µl of RANKL intermediate to 
each well. 
 
1.  Serial dilution:  began with highest RANKL dose:  50ng/ml 
 
50ng  x  0.5ml x    ____1______    =  1.25 x 10
3
 ng       
ml         20 x 10
-3 
 ml                 ml 
 
 
2.  Calculated final volume for 50ng/ml dose. 
  
  (100 x 10
3
ng)(____1_____)   =   0.788 ml = 788µl final volume (round to 800µl) 
                    ml               1.25 x 10
3 
ng/ml          
 
 
 
Calculated volume of RANKL from 10µl aliquot of RANKL stock needed for 
50ng/ml concentration. 
 
1250mg    x   0.788 ul   x  ____ 1_______     = 9.85 µl 
    ml                                 1.25 x 10
3 
ng/ml 
 
In order to simplify calculations refigured for using 10µl RANKL aliquot 
value since the RANKL stock was aliquoted into 10µl volumes. Serial Dilution 
for RANKL Intermediate Stock Concentration summarized below. 
 
Tube 
Number 
Dilution 
Factor 
Volume of 
Previous 
Stock/µl 
Add  
medium 
Volume/µl 
Beginning 
Tube 
Volume/µl 
Total final 
Volume/µl 
RANKL Intermediate 
Stock Concentration 
1:  50ng/ml 1:1 35ul 
RANKL  
 765 800  1.25 x 103 ng/ml 
2:  25ng/ml 1:2 800 338 338 765 0.63 x 103 ng/ml 
3:  10ng/ml 1:2.5 765 225 338 676 0.68 x 103 ng/ml 
4:  2.5ng/ml 1:4 676 113 337 563 0.31 x 103 ng/ml 
5:  0 ng/ml  0  0 450  450  
 
Number of 
treatment 
wells per 
RANKL 
Dose 
 
20ul RANKL Intermediate 
converted to ml  
wells per RANKL Dose 
 
Original Stock RANKL 
Concentration  
 
20ul RANKL 
Intermediate 50ng/ml 
concentration 
wells per RANKL Dose 
 
20ul RANKL 
Intermediate 50ng/ml 
concentration 
wells per RANKL Dose 
 
Original Stock RANKL 
Concentration  
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3. Cleaned all surfaces in the cell culture hood, pneumatic pipette-man 
(BrandTech Accu-Jet) and conical tube holder with 70% ethanol.  Prepared 
five 2ml cryotubes:  removed from sterile packaging and placed in hood.  
Labeled each tube with RANKL dose. Tube 1-5 labeled 50, 25, 10, 2.5, and 0 
ng/ml, respectively.  Then cleaned external surfaces of two 50 ml conical 
tubes (Fisher Scientific:  catalog number 0553860). Labeled both “medium”. 
4.  Removed 500ml bottle of ά-MEM-10% FBS from the refrigerator and 
cleaned with 70% ethanol and placed in hood. Transferred 50ml of medium to 
the conical tubes labeled “medium”.  Removed and placed in water bath. 
5. Prepared a water bath (Polysciences) to 37°C and pre-warmed ά-MEM-10% 
FBS.  When medium was warmed to 37°C (approximately 10 min), cleaned 
external surface of conical with 70% ethanol prior to placing back in the hood.   
6. While water bath is warming medium, removed 10µl aliquot of RANKL from 
the -70°C freezer. Slowly thawed 10µl aliquot of RANKL stock (1250ng/ml 
concentration) over ice for approximately 15 minutes.  Monitored closely 
because cytokines derogate rapidly with warmth.  When RANKL volume was 
visually mobile in the cryotube, i.e. thawed, centrifuged for 3 seconds to 
collect RANKL into one collected volume in the bottom of the cryotube.  The 
aliquot was now ready for dilution with culture medium. 
7.  Added 25µl of culture medium to the 10µl of RANKL stock, thus yielding 
35µl volume.  Mixed thoroughly with pipetman.   
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Changed pipette tips in-between mixing serial dilutions as to not alter the 
concentration of the RANKL dose.  Note all final volumes of RANKL 
intermediate are greater than 450µl needed for RANKL induction.  
8. Placed final volume amount in tubes 2-5.  Placed 765µl into tube 1 to begin 
dilution. 
9. Aspirated 35µl RANKL stock and added to tube 1 to create the RANKL 
intermediate. 
10. Aspirated 338µl RANKL intermediate from tube 1 and added to tube 2. 
11. Aspirated 225 RANKL intermediate from tube 2 and added to tube 3. 
12. Aspirated 113 RANKL intermediate from tube 3 and added to tube 4. 
13. Aspirated 20µl of RANKL intermediate from tube 2 and added to 
corresponding RANKL dose well.  Repeated until 20 wells have been filled. 
Repeated procedure for tubes 1, 4,  and 3. (Changed pipette tips when 
changing to the next RANKL concentration as not to alter the RANKL 
concentration.)  
14. When adding RANKL intermediate to each well  
 tilted culture plate towards self   
 did not touch sides of well or bottom of well to avoid disturbing 
cultured cells 
 gently pipetted up and down several times into the medium and 
swirled plate to get even mixing  
 visualized cells under microscope to determine if there was any 
disruption of plated cells 
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 placed in incubator for 24hrs   
 
RANKL Induction Plate Labeling 
 
 
 
 
 
 
 
 
  
Tube 1 :  50ng/ml 
Plate Number Energy Density J/cm
2   RANKL Dose ng/ml Number of Wells Well Number 
1 4.5 (controls) 50 5  [C2 – C6]:  0-0-50 
3 45 (controls) 50 5 [C2 – C6]: 0-0-50 
5 4.5 ( treatment)  50 5 [C2 – C6]: 1-4.5-50 
7 45 ( treatment)  50 5 [C2 – C6]: 1-45-50 
Tube 2:  25     
Plate Number Energy Density J/cm
2   RANKL Dose ng/ml Number of Wells Well Number 
1 4.5 (controls) 25 5  [B2 – B6]:  0-0-50 
3 45 (controls) 25 5 [B2 – B6]: 0-0-50 
5 4.5 ( treatment)  25 5 [B2 – B6]: 1-4.5-50 
7 45 ( treatment)  25 5 [B2 – B6]: 1-45-50 
Tube 3:  10ng/ml 
Plate Number            Energy Density J/cm
2   RANKL Dose ng/ml Number of Wells Well Number 
2 4.5 (controls) 10 5 [B2 – B6]:  0-0-10 
4 45 (controls) 10 5 [B2 – B6]:  0-0-10 
6 4.5 ( treatment)  10 5 [B2 – B6]: 1-4.5-10 
8 45 ( treatment)  10 5 [B2 – B6]: 1-45-10 
Tube 4:  2.5ng/ml 
Plate Number Energy Density J/cm
2   RANKL Dose ng/nl Number of Wells Well Number 
2  2.5 5 [A2 – A6]: 0-0-2.5 
4  2.5 5 [A2 – A6]: 1-4.5-2.5 
6  2.5 5 [A2 – A6]: 1-45-2.5 
8  2.5 5 [A2 – A6]:  0-0-2.5 
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Appendix F 
Tartrate-Resistant Acid Phosphatase Staining Protocol  
(TRAP)-Staining Protocol 
260 
 
 
 
TRAP Staining Protocol:   using SIGMA Acid Phosphatase Leukocyte Kit (prod #387) 
 
Solution not in kit, but required 
 Acetone 
 Formaldehyde, 37% (F1635 formaldehyde solution from SIGMA) 
1. Preparation of Solutions  
 Warm up dH2O to 37C ( 200ml)-  
 
A. Prepare fixation Solution:   (for cell cx only, use polypropylene or glass 
containers and pipettes)- keep at room temp- in glass beaker 
 Citrate solution:      25ml             18.75  12.5ml  8.3ml            6.25ml  
 Acetone:     65ml  48.75ml 32.5ml  21.6ml           16.25ml 
 37% Formaldehyde  8ml   6ml  4ml  2.6ml  2ml 
TOTAL    98ml  73.5ml  49ml  32.5ml  24.5ml   
   0.5 ml/well 
 
B. Prepare the Fast Garnet Solution:  use glass pipettes, Mix in 1.5ml centrifuge 
tube 
 Fast Garnet GBC 0.75ml  0.5ml  0.35ml 
 Sodium Nitrite Sol 0.75ml  0.5ml  0.35ml 
TOTAL  1.5ml  1ml  0.7ml 
  Mix gently inversion for 30sec   let stand for 2min 
 
C. Make the staining solution:  (using a glass beaker):  NEXT Experiment make up 
74.25 & 34.65 for 100 wells 
May mix in a polypropylene conical tube if amount is under 50ml. 
 
 dH20, 37C   67.5ml  45ml  31.5ml 
 Fast Garnet Sol  1.5ml  1ml  0.7ml 
o (From B) 
 Naphtol AS-BI phosphate 0.75ml  0.5ml  0.35ml 
 Acetate Sol   3.0ml  2.0ml  1.4ml 
 Tartrate Sol   1.5ml  1.0ml  0.7ml 
TOTAL   74.25ml 49.5ml  34.65ml 
 
D. Warm the Staining Solution in 37C water bath, protect from light. 
 
 
2. Staining 
 
A. Staining cell culture plates  
 Aspirate media 
 Wash the plate using PBS Ca+, Mg+ (2 times) 
 Add the fixation solution from (from above 1A), enough to cover the cells  
(e.g. 1ml per well for 12 well plates or 0.7ml per well for 24 well 
plates) 
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 wait for 30sec Rinse thoroughly with dH20 (3 times) 
Note:  Do not let sample dry out 
 Add the Staining Solution (from step 1C), enough to cover the cells (same 
as fixation sol)              
 Incubate in 37C (protected from light) for 10min  but check q 5 min 
 Rinse thoroughly with dH20 (3times) 
Air dry and evaluate with microscope – store plates protected from light 
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Appendix G  
Cell Counting Classification Tool   
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Example/source E1384 NIR #3 RAW Cells 090713  
TRAP Stain Counting Rules:  Lisa Anderson-Antle 
Rule Est. 
 
Counted 
RUQ and LLQ Established 10/20/09 
 
Use 10x Magnification on cell cx 
room microscope. 
 
Entire well counted:  Divided into 
4ths.  Counted OC that touched the 
arrowed margins 
Cells must be: 
First—TRAP+ 
Then—Have 3+ nuclei 
8/8/2009  
e1385_NIR #4 Plate 1-4b  
 e1385_NIR #4 Plate 1-5b 0-0-25  
These are nuclei. Found in cell clump,  
if defined cell margins and 3 nuclei 
but did not count. 
8/8/2009 
 e1385_NIR #4 Plate 1-4b 0-0-25  
 e1385_NIR #4 Plate 1-4b 
 e1385_NIR #4 Plate 1-5c 0-0-25   
Pale purple; counted numerous Lg OC 
throughout all plates, decision to count  
 
 
 
 
Counted 
 
 
 
 
 
 
 
 
Counted dark purple 
 
 
 
 
 
Deep Purple-pink; counted 
 
 
 
8/8/2009 
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 e1385_NIR #4 Plate 1-4c 0-0-25  m 
 e1385_NIR #4 Plate 1-4b 0-0-25  
 e1385_NIR #4 Plate 1-5b 0-0-25   
 
 
 
 
 
 
Counted OC with processes  
 
 
 
 
 
 
 
 
 
Dark Pink; counted 
 
 
 
 
 
 
 
 
OC under cell clump; counted 
 e1385_NIR #4 Plate 1-4b 0-0-25  
 
Clear cytoplasm, no distinct pink or 
purple around nuclei—this is not 
TRAP+  Did not count 
8/8/2009  
e1385_NIR #4 Plate 1-4b 0-0-25  
 
 
 
 
 
 
 
Did not count  
clumps on side walls not counted 
 
Scattered TRAP+ areas; not counted 
 
Stained Cell clump:  did not count 
8/8/2009 
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E1385 NIR #4: TRAP Stain-OC Counting Rules 
 24 well plates:  8 plates; 36 wells.  2 wells per plate; wells 3b & 4b 
control plates [3a – 3e] [4a – 4e] [5a – 5e] 
 
 
 
  
 e1385_NIR #4 Plate 1-4b 0-0-25  
 
 
Fusing not defined boarders; not 
counted 
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Tables  
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Table 1.   
     Cell Plate Labeling Example: 5 wells per Condition Labeled by Number of Light Treatments – Energy 
Density - RANKL Dose 
Plate Number Row 1 Row 2 Row 3 Number of Wells Used 
 
        4.5 J/cm
2
 Energy Density Control Plate 
 
Plate 1   
 
0-0-0             0-0-2.5              0-0-10 15 wells 
 
Plate 2  
 
0-0-0 0-0-25 0-0-50 10 wells 
 
     45 J/cm
2
 Energy Density Control Plate 
Plate 1   0-0-0 0-0-2.5 0-0-10 15 wells 
Plate 2 * 0-0-25 0-0-50 10 wells 
 
4.5 J/cm2 Energy Density Experimental Plate 
Plate 1 1-4.5-0 1-4.5-2.5 1-4.5-10 15 wells 
Plate 2 * 1-4.5-25 1-4.5-50 10 wells 
 
45 J/cm
2
 Energy Density Experimental Plate 
Plate 1:   1-45-0 1-45-2.5 1-45-10 15 wells 
Plate 2:   * 1-45-25 1-45-50 10 wells 
* Well not utilized 
 
Table 2. 
      Serial Dilution for RANKL Intermediate Stock Concentration 
Tube 
 
Number 
Dilution  
 
Factor 
Volume of  
 
Previous 
 
Stock/µl 
Add  
 
Medium 
 
 Volume/µl  
Beginning  
 
Tube 
 
Volume/µl 
Total 
Final 
Volume/µl 
RANKL  
 
Intermediate Stock 
 
Concentration 
 
1:  50ng/ml 
 
1:1 
 
35ul 
 
 RANKL 
  
  
765 
 
800  
 
1.25 x 10
3 
ng/ml 
2:  25ng/ml 
 
1:2 800 338 338 765 0.63 x 10
3 
ng/ml 
3:  10ng/ml 
 
1:2.5 765 225 338 676 0.68 x 10
3 
ng/ml 
4:  2.5ng/ml 
 
1:4 676 113 337 563 0.31 x 10
3 
ng/ml 
5:  0 ng/ml  0  0 450  450  
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Table 3 
 Summary of Experiment Variables by Experiment Number 
Experiment  
Number 
Number of 
Light  
Treatments 
 
WARP™ 10 
Light  
Source 
Energy  
Density  J/cm
2
 RANKL Dose ng/ml 
  
 
4.5 
 
45 0 25 50 
 
e1380 
 
 
 
1 
 
 
* 
 
* 
 
* 
 
* 
 
* 
 
* 
 
4 
 
 
* 
 
* 
 
* 
 
* 
 
* 
 
* 
 
e1383 
 
 
1 
 
* 
 
* 
 
* 
 
* 
 
* 
 
* 
 
4 
 
* 
 
* 
 
* 
 
* 
 
* 
 
* 
 
e1384 
 
1 
 
* 
 
* 
 
* 
 
* 
 
* 
 
* 
 
e1385 
 
1 
 
* 
 
* 
 
* 
 
* 
 
* 
 
* 
* Variable utilized in the experiment 
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             NASA Ames Research Center:  Bone and Signaling Laboratory 
                                              Mentor: Ruth Globus, PhD 
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Summer 2008     
 NASA Science & Technology Institute:  United Negro College 
Fund-Special Programs 
NASA Ames Research Center:  Psychophysiology Laboratory 
Mentor; Patricia Cowings PhD 
 
SKETCH OF WORK HISTORY (FULL LIST AVAILABLE UPON REQUEST)  
ACADEMIC RESEARCH 
 
2009: Summer & Fall, NASA Ames Research Center 
Doctoral Research Assistant             
     Responsibilities:  Completed supervised independent research 
 
2008:  Summer, NASA Ames Research Center 
Research Assistant-Medical Monitor  
                 Responsibilities:  Human Sleep Deprivation Study; medical monitoring 
 
2007 – 2008    University of Wisconsin-Milwaukee:  College of Health Sciences 
Research Assistant 
Responsibilities: Multi-disciplinary team participation; in vivo development and      
experimentation  
 
2006-2007   University of Wisconsin-Milwaukee:  College of Nursing, Milwaukee, WI 
Clinical Assistant Professor 
Project Director:  RO1 NIH randomized interventional study  
Responsibilities: 
o Implementation ,  budget accountability, management & supervision  
o Database validity/reliability and statistical interpretation 
o Validity of instrumentation and data collection 
 
2004-2005   University of Wisconsin-Milwaukee: College of Nursing, Milwaukee, WI 
Research Coordinator 
   Responsibilities:  Implementing and coordinating a multi-grant/research site 
study 
 
ACADEMIC HIGHER EDUCATION 
 
2010-2012 George Williams College of Aurora University 
Adjunct Faculty 
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2005-2006   Columbia/St Mary’s Health System College of Nursing, Milwaukee, WI  
             Assistant Professor  
2003 Fall      Southwest Missouri State University Department of Nursing, Springfield, MO  
Clinical Supervisor 
2001-2003    Southwest Baptist University:   Department of Nursing, Springfield, MO 
        Adjunct Faculty 
1997-1998   Lester E. Cox Heath Systems:  College of Nursing, Springfield, MO 
         Assistant Professor of Nursing    
 
ADVANCED PRACTICE NURSING 
  
2007 – 2008   In Your Home Internal Medicine & Geriatrics SC, Milwaukee, WI                                                                  
        Gerontological Advance Practice Nurse 
 
2004-2005    Evercare Wisconsin:  United Health Group, Milwaukee, WI         
        Nurse Practitioner  
 
2000-2003     Gerontological Consulting Services, Springfield, MO                                                                              
     Gerontological Advanced Practice Nurse  
                  
1996-1997       Lester E. Cox Health Systems, Springfield, MO                                                                                 
     Gerontological Clinical Nurse Specialist 
 
FIELDS OF INTEREST   
 
 Space Biomedical Countermeasures; Skeletal and Bone Health-Translational 
Medicine 
 Bio-Gerontological Preventive Aging Research:  Photobiomodulation 
 Population Health Research:  Gerontological Community/Home Care & 
Institutional Based Long-Term Care  
PROFESSIONAL ORGANIZATIONS   
 
 The American Society for Bone and Mineral Research   
 American Nurses Association 
 Sigma Theta Tau International Nursing Honor Society 
 Wisconsin Nurse Association 
 American Medical Directors Association 
 Midwest Nursing Research Society: 
 Missouri Nurses Association:  Board member (select years) 1992- 2003 
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 Missouri League of Nursing 
 National Conference of Gerontological Nurse Practitioners 
 The American Geriatric Society 
 The Gerontological Society of America   
 Student Nurses Association:  President 1990-1991    
PUBLICATIONS  
Marek, K. D., & Antle, L. L. (2008) Medication management of the community-dwelling 
older adult. In R. Hughes (Ed.), Advances in Patient Safety & Quality – An Evidence-based 
Handbook for Nurses. Rockville, MD: Agency for Healthcare Research and Quality. 
 
Antle, L. A. (2004). Advanced practice nurse controlled substance authority. The Missouri 
Nurse, 1, 11-12, 25. 
 
Antle, L. A. (1995). Defining the Role of Advanced Practice Nursing:  Clinical Nurse Specialists' and 
Nurse Practitioners' Perceptions of Their Roles. Unpublished Masters Thesis, St. Louis, 
MO, St. Louis University. 
CONFERENCE PRESENTATIONS   
Anderson-Antle, L. L., & Globus, R. (2011, October 3-7). Effects of Photobiomodulation and 
Osteoclast Formation in Vitro:  a Pilot Study. Paper Presented at the 62nd International 
Astronautical Congress: African Astronaissance, Cape Town, South Africa.  
Submitted.    
 
Anderson-Antle, L. L., Cowings, P., Toscano, W., Orasanu, J., & DeRoshia, C. W. (2009, 
October 12 – 16). Consequences of sleep deprivation on performance and mood states. Paper 
presented at the 60th International Astronautical Congress:  Space for Sustainable 
Peace and Progress, Daejeon Republic of Korea.    
 
Anderson-Antle, L. L., & Globus, R. (2010). Near Infrared Laser Emitting Diode 
Photobiomodulation and Osteoclast Formation In Vitro. Poster presented at the 34th 
Midwest Nursing Research Society:  “Nursing Research:  Bench to Bedside”. Kansas City, 
Missouri. 
 
Anderson-Antle, L. L., Globus, R. (2009). Near Infrared Laser Emitting Diode Photobiomodulation 
and Osteoclast Formation In Vitro, Poster Presentation at the Ames’ 70th Anniversary 
Celebration. NASA Ames Research Center, Moffett Field, California. 
 
Anderson-Antle, L. L., Cowings, P., and Toscano, W. (2008).  Consequences of Sleep Deprivation 
on Performance & Mood States, Poster Presentation at the NLSI Lunar Science 
Conference.  NASA Ames Conference Center, Moffett Field, California. 
 
Anderson-Antle, L. L., Bauer, D., Gopalakrishnan, S., Lark, D.S., Sandoval, C., Eells, J. T., 
and Snyder, A.C. (2008). Streptozotocin-Induced Diabetic Animal Model Recapitulates Many 
Features of Frailty in Older Adults with Diabetes. Poster Presentation Experimental 
Biology 2008, “Today’s Research:  Tomorrow’s Health”. San Diego, California.   
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Marek, K. D., Antle, L. L. (2006). Pharmacy Screen Results and Consumer Satisfaction of a Home 
Care Medication Management Program, Paper Presentation at the 30th Annual Midwest 
Nursing Research Society Research Conference “Linking Research and Practice:  A 
Roadmap for the Future”, Milwaukee, Wisconsin.  
 
Antle. L. L. (May, 2005).  Clinical Outcomes of Aging in Place:   Karen Dorman Marek PhD, MBA, 
RN, FAAN, Paper Presentation at the 7th Annual Southeastern Wisconsin Nursing 
Research Conference “Building Bridges to Research Based Practice”. Pewaukee, Wisconsin. 
 
Antle, L. (2001). Role of the Advanced Practice Nurse in Long Term Care. Paper presented at the 
Southwest Missouri Geriatric Symposium, Springfield, Missouri. 
 
Antle, L. (1995). Defining the Role of Advanced Practice Nursing:  Clinical Nurse Specialists’ and Nurse 
Practitioners’ Perceptions of Their Roles. Paper presented at the Missouri Nurses 
Association “Coming together in Advanced Practice”. Columbia, Missouri. 
 
 
 
LICENSES AND CERTIFICATIONS   
 
Registered Nurse:  Wisconsin 
Registered Nurse:  California inactive 
Registered Nurse:  Missouri inactive 
Advanced Practice Nurse:  Missouri inactive 
Advanced Practice Nurse Prescriber:  Wisconsin 
Gerontological Clinical Nurse Specialist:  American Nurse’s Credentialing Center 
 
 
 
